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ABSTRACT  
The saccharopine pathway is considered the main route for lysine catabolism in higher eukaryotes. 
In this pathway, the enzyme aminoadipate-semialdehyde synthase (AASS) catalyzes the oxidation 
of lysine into aminoadipic semialdehyde (AASA). The latter is immediately oxidized to 
aminoadipic acid (AAA) by aminoadipic semialdehyde dehydrogenase (AASADH). In humans, 
mutations affecting AASS activity lead to hyperlysinemia, a benign inborn error of metabolism. In 
contrast, mutations affecting AASADH activity cause pyridoxine dependent epilepsy (PDE), in 
which the accumulation of AASA and its cyclic form piperideine-6-carboxylate (P6C) are 
considered the main pathogenic drivers of this disease as it depletes pyridoxal 5′-phosphate (PLP) 
by formation of Knoevenagel condensation products. Although there exist another lysine catabolic 
route known as  the pipecolate pathway, we hypothesize that the elevated plasma and urine levels 
of AASA/P6C observed in PDE patients arises predominantly from the saccharopine pathway. In 
the work comprising this thesis, a series of experiments were carried out employing diverse 
bilological models to study lysine catabolism to AAA. In addition, a new quantitative LC-MS/MS 
method was developed, which allowed the analysis of lysine catabolism products in mouse plasma 
and tissues. The quantification of lysine metabolites and the tracking of N15-labelled lysine suggest 
that AASS is the main enzyme of lysine degradation. We suggest that the primary source of 
pathogenic accumulation of AASA/P6C is the liver and the kidney, since they present high levels 
of AASS activity. In addition, we demonstrate that the pipecolate pathway plays only a minor role 
in the overall figure of lysine oxidation to AAA. The idea of the predominant role of the 
sacharopine pathway in lysine degradation was reinforced by studies performed in bacteria and 
plants and also from the observation that a significant proportion of the circulating pipecolate is 
actually produced from the saccharopine pathway. Taken together these results may support the 
hypothesis that targeting AASS inhibition or AASS down-regulation at transcription level would 
reduce the toxic levels of AASA/P6C and this may result in a better outcome for PDE. We then 
knocked-down AASS in HEK293T cells and observed that this does not imply in any detrimental 
phenotype. Then we used primary skin fibroblasts from PDE patients and observed that these cells 
display reduced viability in the presence of high lysine levels when compared to skin fibroblasts 
derived from normal children. As proof-of-concept, we recovered the normal cell survival in the 
presence of high lysine levels by knocking-down AASS expression in skin fibroblasts obtained 
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from PDE patients, which suggest that inhibition of AASS prevents accumulation of AASA/P6C 
and thus improves cell performance. This may potentially be a new method to treat PDE. In order 
to understand the biochemistry and structural biology of human AASS as a tool for the design of 
an enzyme inhibitor, we expressed, purified and obtained the crystallographic structure by X-ray 
diffraction at 2.6 Å of the saccharopine dehydrogenase (SDH) domain of human AASS. The solved 
structure consists on a homodimer bound to the cofactor NAD+. Structure-based drug design 
approaches are being used to design potential ligands that may act as competitive inhibitors to 
saccharopine binding site. 
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RESUMO 
A via da sacaropina é considerada a principal rota para o catabolismo de lisina em mamíferos, na 
qual a enzima Aminoadipato Semialdeído Sintase (AASS) catalisa a oxidação da lisina ao 
aminoadipato semialdeído (AASA). Este é imediatamente oxidado a ácido aminoadípico (AAA) 
por ação da enzima Aminoadipato Semialdeído Desidrogenase (AASADH, codificada pelo gene 
aldh7a1). Em humanos, mutações no gene AASS são a causa da hiperlisinemia, um erro inato do 
metabolismo, porém benigno. Por outro lado, mutações no gene Aldh7a1 causam Epilepsia 
Dependente de Piridoxina (PDE), na qual o acúmulo de AASA e sua forma cíclica, Piperideine-6 
Carboxilato (P6C), são consideradas as principais causas desta doença. Estes compostos causam 
depleção de Piridoxal-5’ fosfato (PLP) do organismo por meio da formação de produtos de 
condensação com o composto P6C. Apesar de existir uma rota alternativa de degradação de lisina 
(conhecida como via do pipecolato), hipotetizamos que os níveis elevados de AASA/P6C 
observados no plasma e urina de pacientes com PDE decorrem, principalmente, da atividade da via 
da sacaropina, especificamente da enzima AASS. Durante o presente trabalho de doutorado, 
desenvolvemos um novo método quantitativo de espectrometria de massas (LC-MS/MS) que 
permitiu a analise dos metabólitos da degradação de lisina em plasma e tecidos de camundongos. 
Como resultado da quantificação de metabólitos e também experimentos de rastreio de 15N 
(usando-se injeção de lisina marcada no nitrogênio α ou ε) sugerimos a enzima AASS como a 
principal enzima de degradação de lisina do organismo. Desta forma, esta enzima seria a 
responsável pela síntese da maior parte do AASA/P6C acumulado em pacientes de PDE e, sendo 
que esta enzima é principalmente hepática e renal, sugerimos estes órgãos como os principais sítios 
de produção destes compostos tóxicos. Adicionalmente, a ideia de que a via do pipecolato possui 
apenas um papel minoritário no metabolismo geral de lisina é também suportada por esses 
experimentos, onde cerca da metade deste composto circulante provavelmente se origina da via da 
sacaropina. Este efeito também foi observado e discutido por nós em outros modelos biológicos 
como bactéria (Ruegeria pomeroyi) e plantas (Zea mays). Sugerimos, portanto, que a escolha da 
AASS como alvo terapêutico para desenvolvimento de inibidores seja uma nova alternativa para 
tratamento de PDE, pois seria observada redução dos níveis tóxicos de AASA/P6C. Observamos 
que o uso de shRNA para realizar knockdown da expressão do gene aass em células HEK293T 
não resultou em nenhum fenótipo detrimental e também não causou indução dos genes da via do 
pipecolato. Ao estudarmos células primárias de cinco distintos pacientes de PDE (modelo de 
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fibroblastos de pele) observamos que estas células possuem maior sensibilidade à presença de 
Lisina ao meio de cultura se comparadas à células normais. Como prova de conceito observamos 
que o knockdown da expressão de aass usando shRNA restaura a sobrevivência das células PDE 
na presença de altos níveis de lisina. Isso pode sugerir o uso de ASO (Anti-sense Oligonucleotides) 
ou inibidores da atividade da AASS para tratamento da PDE. Para promover melhor entendimento 
da bioquímica e biologia estrutural deste novo alvo terapêutico, expressamos, purificamos e 
obtivemos com sucesso a estrutura cristalográfica do domínio Sacaropina Desidrogenase (SDH) 
da enzima AASS humana. Propriedades cinéticas e bioquímicas da enzima foram estudadas, bem 
como foram realizados ensaios de screening de ligantes por desnaturação térmica e ensaios de 
atividade. Foram feitas várias rodadas de desenho computacional de inibidores baseados na 
estrutura do sítio ativo com o intuito de usar esta tecnologia para desenhar compostos que atuem 
competindo com a sacaropina pelo sítio ativo.  
 xiv 
 
ABBREVIATIONS  
AAA   Aminoadipic Acid 
AASA   α-aminoadipic-δ-semialdehyde 
AASADH  Aminoadipic semialdehyde dehydrogenase enzyme 
AASS   Aminoadipic semialdehyde synthase (or aminoadipate semialdehyde synthase) 
AB    Alamar Blue 
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AmpR   Ampicillin resistance gene 
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BB    Binding Buffer 
BCA    Bicinchoninic acid 
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INTRODUCTION 
 
Lysine catabolism via the saccharopine pathway in distinct biological models and 
relation to pyridoxine dependent epilepsy (PDE) in humans 
The saccharopine pathway is considered the main route for the irreversible 
degradation of lysine (Lys) in higher eukaryotes. It has an essential role in regulating 
intracellular lysine levels, nitrogen homeostasis, and the conversion of lysine into ketone 
bodies. The two initial steps of this pathway involve lysine ketoglutarate reductase (LKR) 
condensing lysine and α-ketoglutaric acid to form saccharopine, and saccharopine 
dehydrogenase (SDH) subsequently hydrolysing saccharopine into glutamic acid and α-
aminoadipic-δ-semialdehyde (AASA) (Fig. 1) (Arruda, et al., 2000). Animals and plants 
possess a bifunctional polypeptide called aminoadipic semialdehyde synthase (AASS), 
encoded by the gene aass or lkrsdh respectively, containing both LKR and SDH domains 
(Markovitz, et al., 1984 ) (Gonçalves-Butruile, et al., 1996) (Papes, et al., 1999). In contrast, 
fungi encode distinct genes for LKR and SDH enzymes and the pathway is used for lysine 
biosynthesis (Bhattacharjee, 1992). Plants and bacteria synthesize lysine by the 
dihydrodipicolinate branch of the aspartate pathway (Azevedo, et al., 1997). We have 
recently shown that the saccharopine pathway also exists in bacteria and that it is used for 
Lys degradation, similar to what is observed in plants and animals (Serrano, et al., 2012) 
(Neshich, et al., 2013).  
The bacterial genes lkr and sdh are often organized contiguously in operons, 
generating two separate polypeptides. The AASA produced from the reactions catalysed by 
LKR and SDH is then oxidized to α-aminoadipic acid by aminoadipic semialdehyde 
dehydrogenase (AASADH) (Fig. 1), also encoded by the orthologous mammalian gene 
Aldh7a1. Although all eukaryotes contain the saccharopine pathway, only 27 of the 1,479 
prokaryotic species analysed presented this pathway (Neshich, et al., 2013). Interestingly, 
prokaryotes have at least four pathways for the conversion of lysine to AASA (see Figure 1 
from Chapter 1), with the lysine dehydrogenase (LysDH) pathway being the most frequently 
observed in these organisms (Neshich, et al., 2013). In the seawater model bacteria, Ruegeria 
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pomeroyi (formerly Silicibacter pomeroyi), both the saccharopine and the LysDH pathways 
are present, with LysDH 200-fold more expressed (mRNA levels) relative to the 
saccharopine pathway in the presence of lysine. Both the lysdh-aasadh and the lkr-sdh 
operons were induced upon salt stress. The association with salt and osmotic stresses may be 
related to the production of the compatible solute pipecolate as a secondary metabolite and 
also for the detoxification of aldehydes by the enzyme AASADH. The description of LYS-
to-AASA catabolic pathways in prokaryotes, the studies using R. pomeroyi, the expression 
of LysDH and AASADH in Escherichia coli, and the possible connection with osmotic stress 
resistance are all described in detail in Chapter 1 of this thesis in the form of an article 
published in the ISME Journal (Neshich, et al., 2013). The biochemistry and structural 
biology of the newly described enzyme, LysDH from R. pomeroyi, were also studied as part 
of our effort to characterize lysine degradation in Prokaryotes. This enzyme was expressed, 
purified, and crystalized with its tridimensional structure solved by X-ray diffraction at 1.8 
Å. The 3D structure of LysDH consist of an hexamer (a dimer of trimers) with one active site 
per monomer. This study is not described in the current thesis but will soon be finished and 
submitted for publication in the Journal of Biological Chemistry (JBC). 
In addition, a R. pomeroyi double knockout (KO) for lysdh and aasadh genes was 
generated. This KO lost the growth advantage observed in lysine supplemented medium for 
the wild type bacteria, which confirms the importance of such genes for lysine degradation. 
The KO also had reduced growth in the presence of salt stress. The lysine catabolic 
metabolites formed in the first steps of the Lys-to-AAA pathways were determined by mass 
spectrometry. An accumulation of saccharopine was not observed in the WT bacterium, 
indicating the LysDH as the preferential pathway. However, an absence of LysDH and 
AASADH in the double KO led to an accumulation of saccharopine, favouring the 
saccharopine pathway for lysine degradation. The absence of functional AASADH in the 
double KO lead to an over-accumulation of the secondary metabolite pipecolate. These 
results add further insight into the role of lysine degradation in stress response pathways in 
R. pomeroyi, as described in detail in Chapter 2 in the article submitted to FEBS Letters 
(Pena, et al., Submitted 1).  
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Figure 1: Schematic representation of the two mammalian lysine degradation pathways. The 
first (left), believed to operate mostly in brain, uses L-pipecolic acid as an intermediate and 
begins with the oxidative deamination of the alpha nitrogen of lysine. The second (right) 
occurs preferentially in other organs, mainly liver and kidney, and proceeds via the 
deamination of the epsilon nitrogen of lysine by condensing with α-ketoglutarate to form 
saccharopine intermediate. The enzyme AASS possess two domains: Lysine Ketoglutarate 
Reductase (LKR) and Saccharopine Dehydrogenase (SDH), that act independently as two 
separate enzymes catalysing the first two steps for the saccharopine pathway. AASA 
dehydrogenase activity is absent in PDE patients.  
 4 
 
As previously mentioned, AASADH is common to all prokaryotic and eukaryotic 
lysine-to-AASA catabolic pathways. This enzyme is also known as antiquitin (antique 
nature) due to the highly conserved amino acid sequence among taxa (Fong, et al., 2006). 
AASADH has been described to be associated with the cellular response to oxidative stress 
due to its ability to oxidize several toxic aldehydes (Brocker, et al., 2011). The 
overexpression of the ALDH7A1 gene, that encodes AASADH, protects human cell lines 
from salt and oxidative stresses (Brocker, et al., 2010) (Brocker, et al., 2011). In plants, 
AASADH enzyme has also been associated with salt and drought stress (Guerrero, et al., 
1990) (Buchanan, et al., 2005) (Fong, et al., 2006) (Rodrigues, et al., 2006). There are 
presently only few studies conducting knockdown assays for the AASS gene and no studies 
performing its overexpression in mammalian models. However, several works were 
performed on plants and it has been suggested that AASS is connected with salt, osmotic, 
and oxidative stress resistances (for a detailed review, please refer to Arruda and Neshich, 
2012, Attachment 1). In addition, it is well established that AASS activity is under post-
translational regulation in plants, in which LKR activity was shown to be stimulated by 
excess cellular Lys, via an intracellular signaling cascade involving Ca2+ and protein 
phosphorylation (Karchi, et al., 1995) (Arruda, et al., 2000). In mammals it is not clear if 
AASS phosphorylation occurs but in fish it has been show that diet mediates changes in either 
AASS mRNA levels or LKR activity, the latter being suggested to be due to post-translational 
modifications (Higgins A, 2005). LKR activity was described to be upregulated by Glucagon 
and downregulated by insulin (Shinno, et al., 1980). Papes et al. (1999) have also 
demonstrated that LKR activity increased about 52% in mice starved 1-2 days, which may 
account in the role of lysine degradation in the production of ketone bodies. 
Mutations in humans that reduce or even abolish LKR and/or SDH activity cause 
familial hyperlysinemia and/or saccharopinuria, respectively (Markovitz, et al., 1984 ) 
(Houten, et al., 2013) (OMIM 238700). These autosomal recessive inborn errors of 
metabolism represent a benign, non-pathogenic metabolic variant (Houten, et al., 2013). 
About 50% of probands are reported to be asymptomatic and it has been suggested that 
accumulation of Lysine does not represent a causal relation to neurological symptoms 
observed in some individuals that have mutations in AASS. Recent works performed a 
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revision of syntomatic patients and it was concluded that there was no definitive common 
phenotype, except for the increased serum lysine (Houten, et al., 2013). The authors conclude 
that the hyperlysinemia in these individuals can not be considered the cause for the 
pathogenic effects observed, given the broad range of clinical features and consanguinity in 
several families, which may account for other gene disfunctions yet to be discovered. In some 
of the cases displaying severe neurological effects it was observed additional gene deletion 
of PTPRZ1, contiguous to AASS gene, which may be the cause of the observed pathogenic 
phenotype (Houten, et al., 2013).  
Although mutations in AASS are apparently benign,  mutations in the ALDH7A1 gene 
that reduce or abolish the activity of AASADH cause pyridoxine dependent epilepsy (PDE, 
OMIM 266100) (Mills, et al., 2006). Hunt et al. (1954) first characterized PDE as a rare 
genetic disease with autosomal recessive inheritance where patients present recurrent 
seizures in the prenatal, neonatal, and/or postnatal periods. All patients display clear 
accumulation of AASA and P6C in plasma, urine and CSF, and these compounds are 
considered the main biochemical markers of the disease and are considered as diagnostic 
markers (Stockler, et al., 2011). Pipecolic acid is considered a secondary biomarker, however 
some patients display normal levels (Stockler, et al., 2011). Recently it was discovered that 
abolished activity of AASADH in PDE patients cause the toxic accumulation of AASA and 
its cyclic form piperideine-6-carboxylate (P6C). Only few epidemiologic studies of PDE 
have been conducted, suggesting incidences varying among 1:20.000 in Germany (Ebinger, 
et al., 1999), 1:100.000 in the northern part of the United Kingdom (Baxter, et al., 1996), 
1:396.000 in the Netherlands (Been, et al., 2005). More than 80 ALDH7A1 sequence 
alterations have been documented and the common Glu399Gln pathogenic variant is 
responsible for approximately 30% of the mutated alleles. The accumulated AASA/P6C is 
suggested to react with Pyridoxal 5’-Phosphate (PLP) by a Knoevanegel condensation 
(Figure 2), thereby depleting it from the organism (Mills, et al., 2006). A comparable 
chemical inactivation of PLP occurs through accumulation of Piperideine 5-Carboxylate 
(P5C) in hyperprolinemia type 2 and in isoniazid induced vitamin B6 deficiency (Stockler, 
et al., 2011). PDE symptoms do not respond to traditional anti-epileptic drugs, such as 
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Phenobarbital, but are only alleviated by the administration of high, diary doses of pyridoxine 
(e.g. 30mg/kg/day, oral). 
PLP is the active form of vitamin B6 (pyridoxine), and its synthesis from pyridoxine 
occurs mainly in the liver by the action of the enzymes pyridoxal kinase and pyridoxamine 
phosphate oxidase (PNPO) (Mills, et al., 2011). Although its synthesis is mainly hepatic, its 
concentration in the brain is usually about 100-fold higher than in the blood. Given that PLP 
is an essential cofactor for more than a hundred of enzymes, its deficiency in the brain impairs 
the synthesis of important substances, notably neurotransmitters such as GABA, which may 
contribute to the occurrence of the seizures (Mills, et al., 2006). In induced vitamin B6 
deficiency in rats several biochemical and morphological abnormalities were observed, 
which include decreased dendritic arborisation, reduced number of myelinated axons, 
epileptiform seizures and movement disorders (Sharma, et al., 1994). The reduced seizure 
threshold and delayed neuronal recovery are related to significantly reduced brain regional 
GABA and elevated glutamate concentrations in the pyridoxine deficient rats (Sharma, et al., 
1994). Although attempts have been made to measure cerebral GABA in PDE patients, the 
results were inconclusive. Low levels of pyridoxal-phosphate were measured in the frontal 
and occipital cortex post mortem in one patient (Lott, et al., 1978). Other genetic diseases 
display vitamin B6 responsive epilepsies exist and support the hypothesis that the absence of 
PLP (either regional in the brain or systemic) is strongly associated with seizure occurrence. 
These diseases include PNPO deficiency, Hypophosphatasia (TNSALP deficiency), Familial 
Hyperphosphatasia (PIGV deficiency) and Hyperprolinemia type 2 (P5CD deficiency) 
(Stockler, et al., 2011).  
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Figure 2: Proposed Knoevanagel condensation reaction between PLP and P6C as 
suggested by (Mills, et al., 2006). P6C causes depletion of PLP by forming two inactive 
complexes (Complex A and B) which are probably eliminated in urine. 
Although pyridoxine treatment is effective to reduce seizure occurrence, many 
patients present delayed neurodevelopment and neuronal death (Baxter, 2001). 
Consequently, treatments with pyridoxines are not effective to ensure the normal 
neurodevelopment, despite its effectiveness in reducing seizures, (Pérez, et al., 2013). 
Perhaps the accumulation of AASA and/or P6C in the cerebrospinal fluid (CSF) of PDE 
patients contributes to this phenotype, among other abnormalities, since these compounds 
are highly reactive and may bind molecules other than PLP. These observations may 
evidence that adjuvant therapies are required. One emerging approach is lysine restricted 
diet, that resulted in improved biochemical and neurodevelopmental outcome (van 
Karnebeek, et al., 2012). However a recent study demonstrated that although lysine 
restriction can reduce (but not normalize) AASA levels, the patients can develop serotonin 
deficiency as a side effect of the diet (Mercimek-Mahmutoglu, et al., 2014). L-arginine 
(ARG), a competitor of lysine transport, supplementation in the diet has arisen as another 
alternative therapeutically-based intervention. It has been shown that this diet approach can 
partially reduce AASA levels, similar to that observed for lysine restriction diet (Mercimek-
Mahmutoglu, et al., 2014). Both strategies have improved neuropsychological assessments 
although only partial; this fact plus the onerous nature of restriction diet in children make it 
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clear that alternative more efficacious therapeutic approaches are needed to ensure alleviation 
of the symptoms and also a better quality of life for the patients.  
Given that the accumulation of AASA and/or P6C is the primary source of 
pathogenesis for PDE, and that mutations in AASS gene are considered to be mainly benign 
(Houten, et al., 2013), the present study postulates that the inhibition of AASS activity could 
be an effective therapy for PDE. Thus, a substrate reduction therapy (SRT) could be applied 
to reduce AASA/P6C levels by attenuating its synthesis. Also to consider is the formation of 
pipecolate and glutamate through the saccharopine pathway (Baumeister, et al., 1994), since 
AASS inhibition could reduce the accumulation of these compounds, thus promoting an 
amelioration of symptoms. Were a new inhibitor to be created and potently inhibit AASS 
(affecting either its transcription/post-translational activations or directly influencing the 
LKR or SDH activities), the patient would be predicted to have reduced AASA and P6C in 
the blood, urine and CSF. Thus, high daily doses of pyridoxine would not be required, as 
healthy circulating levels of pyridoxine would be achieved in the absence of P6C 
accumulation. Furthermore, this treatment would not only normalize PLP levels but prevent 
the toxic accumulation of AASA/P6C, potentially benefiting patients. 
The relative contributions of the saccharopine and pipecolate pathways for lysine 
degradation 
Demonstrating AASS as a target for PDE treatment would require testing the 
hypothesis that this enzyme is significantly responsible for AASA/P6C production. There are 
two pathways for lysine degradation in humans: the saccharopine and the pipecolate 
pathways (Fig. 1). Both pathways converge at the synthesis of AASA and its equilibrium 
form P6C, which are substrates for the enzyme AASADH. The final product of both 
pathways is aminoadipic acid (AAA), a non-toxic metabolite (Fig 1). Although there is a 
general consensus that the saccharopine pathway plays a major role in overall lysine 
metabolism, especially in liver and kidney (Higashino, et al., 1971) (Blemings, et al., 1994) 
(Papes, et al., 2001), recent reports have suggested that this pathway is hardly present in the 
brain and that the pipecolate pathway is probably preferred in cerebral tissues (Hallen, et al., 
2013) (Sauer, et al., 2011) (Posset, et al., 2015). Literature is contradictory in this point, with 
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a recent article showing that AASS enzyme is active in the brain (Rzem, et al., 2015), with 
low but significant activity levels. The experiment from Rzem et al (2015) showing activity 
of LKR and SDH in mouse cerebral tissues was performed after 24 hours of starvation, which 
is a condition known to induce activation of AASS enzyme (Papes, et al., 2001). In fact, in 
mammals, both Aldh7a1 and Aass have low expression in brain and are mostly expressed in 
liver and in kidney (Figure 3), which are expected to be the organs in which lysine 
degradation mainly takes place (Papes, et al., 1999).  
Individuals with mutations in LKR and/or SDH encoding gene (AASS) display 
hyperlysinemia and/or saccharopinuria (Markovitz, et al., 1984 ) (Houten, et al., 2013). If the 
pipecolic pathway plays an important role in lysine degradation, one would expect that these 
patients would not accumulate lysine, as it could favour pipecolate pathway in the absence 
of AASS activity. However, lysine accumulates at 4-13 fold higher levels in plasma for 
hyperlysinemic individuals (Houten, et al., 2013)). The relative contribution of each pathway 
remains uncertain, and more experiments should be performed to address this issue. Most of 
the data showing low saccharopine levels in the brain (Sauer, et al., 2011) or no activity of 
AASS in cerebral tissues were determined in low lysine diet, without lysine supplementation, 
or conducted several hours after injecting lysine in mice. Were the kinetics of saccharopine 
pathway rapid and dependent on lysine levels, perhaps the lysine degradation rate would 
saturate within the first few hours after lysine injection. In this case, low levels of 
saccharopine pathway metabolites and enzymatic activities would be expected several hours 
post lysine injection. Furthermore, were the enzymes activated (e.g. by phosphorylation) in 
the presence of lysine, no active enzymes would be expected in low lysine diet, so the absence 
of activity in brain in these conditions would be plausible. Here, low levels of saccharopine 
pathway metabolites and enzyme activities would be expected several hours post lysine 
injection. 
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Figure 3: mRNA expression levels of Aass (A), Aldh7a1 (B) and Aadat (C) in mouse tissues 
obtained from NCBI GEO database (GDS3142). 
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The first challenge faced in addressing these questions was to establish a mass 
spectrometry method to detect the lysine degradation metabolites saccharopine (SAC), 
pipecolic acid (PIP), aminoadipate semialdehyde (AASA), its cyclic form piperideine-6 
carboxylate (P6C), aminoadipic acid (AAA), glutamate (GLU), and the targeted metabolite 
pyridoxal-5-phosphate (PLP). Currently, the methods reported in the literature normally 
require three distinct analytical approaches to detect these analytes: GC-MS for PIP, LC-
MS/MS without derivatization for P6C detection and LC-MS/MS with derivatization for 
AASA, SAC and AAA. Referring to experiments in bacteria using LC-MS/MS in which free 
PIP was detected (Neshich, et al., 2013), a method was established to detect and quantify all 
these analytes in a single run without additional derivatization and any complex sample 
preparation. A single LC-MS/MS method was developed that allowed the simultaneous 
detection of the relevant metabolites for lysine catabolism with high sensitivity, precision 
and accuracy. This method is the main topic of Chapter 3 presented as the article submitted 
to Metabolomics (Pena, et al., Submitted 2). This method was used to perform a time-course 
of lysine degradation metabolites in mouse blood, in which lysine degradation peaked in the 
first hours post-injection (Pena, et al., Submitted 2). The experiments are discussed in 
Chapter 3. 
Subsequently, the relative contribution of liver, kidney, and brain was tested for lysine 
degradation by developing a quantitative method to access the concentrations of 
saccharopine, pipecolic acid, aminoadipic acid and glutamic acid by LC-MS/MS in tissues 
collected two hours after lysine injection. Furthermore, mice were injected with N15-lysine 
differentially labelled at alpha (α) or epsilon (ε) nitrogen to further identify whether the 
pipecolate or the saccharopine pathway was preferred for lysine degradation in the whole 
organism as assessed in blood and in a tissue-based analysis. From this analysis, it was 
possible to observe that the saccharopine pathway was likely the preferred producer of 
AASA/P6C and AAA. These results are described in the Chapter 4 and may implicate AASS 
as a potential target for PDE therapeutic research. Were a small molecule to target and inhibit 
LKR or SDH domains of AASS enzyme, it could potentially reduce the toxic accumulation 
of AASA/P6C observed in PDE and thus prevent seizure occurrences. 
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AASS as a novel target for PDE 
In this study, a lentiviral system was used to deliver shRNA targeting AASS to 
promote knockdown of its mRNA levels. HEK293T cells were used to optimize this 
technique; the knockdown (KD) cells presented no detrimental phenotype (in terms of 
survival in the presence of stresses, accumulation of ROS, changes in mitochondrial 
dynamics or cell cycle) compared to controls. This was expected given that hyperlysinemia 
caused by absence of AASS activity is a benign condition (Houten, et al., 2013). In addition, 
transcriptome analysis revealed that the pipecolate pathway is not induced upon AASS KD, 
which is also in agreement with the findings pertaining to hyperlysinemia, as lysine 
accumulates rather than being fully catabolized by pipecolate pathway.  
Thus, a proof-of-concept experiment was designed to establish whether the KD of 
AASS could somehow rescue the phenotype in PDE cells. It has been suggested that the use 
of real patient samples as disease models is critical for an accurate understanding of the 
pathophysiology and can be considered a model for preclinical target validation (Edwards, 
et al., 2015). For this purpose, five different PDE patient-derived skin fibroblast cell lines 
were obtained in collaboration with the Care4Rare project at the Children’s Hospital of 
Eastern Ontario (CHEO) and the University of Ottawa. As a result of the work conducted 
within the scope of a 3-month internship at CHEO, survival in the presence of high lysine 
levels was identified as a distinctive phenotype between PDE and control skin cells. While 
the IC50 for control cells in the presence of lysine is ~80 mM, PDE cells tend to be more 
sensitive to this amino acid, displaying an IC50 of ~40 mM. Therefore, most of the observed 
PDE cells died in high levels of lysine after 24 hours of exposition. This increased lysine 
sensitivity observed in PDE cells is probably due to accumulation of AASA/P6C. By using 
the same lentiviral delivery system for shRNA-AASS, it was possible to obtain AASS KD 
for the PDE and control skin fibroblast cells. The AASS KD in PDE cells restored viability 
in the presence of high levels of lysine, therefore being sufficient to revert the lysine 
sensitivity phenotype. This will be described in chapter 4. 
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The biochemistry and structural biology of human AASS as tools for drug discovery 
against PDE 
To create a potential PDE therapy targeting the aass gene, it is important to fully 
understand the physical-chemical properties of the enzyme it encodes. The availability of a 
3D structure of a potential target can accelerate the process of drug discovery either by 
rational design or by the implementation of protocols for in vitro and in silico ligand 
screening (Borshell, et al., 2011). Using the 3D structure of the potential target, it is also 
possible to identify inhibitors by using structure-based drug design techniques. During a six 
month internship at the Structural Genomics Consortium (SGC), University of Oxford, the 
3D crystal structure of the SDH domain of human AASS was solved at 2.6 Å resolution. 
Additionally, the purified recombinant protein will be useful in developing high throughput 
assays for testing possible ligands either by thermal shift or activity assays. Taking 
inspiration from the structure of saccharopine and the properties of its binding site obtained 
from the SDH 3D structure, several potential ligand probes were already designed as a part 
of this research initiative. The probes were selected for chemical synthesis based on their 
performance during simulation against the active site by molecular docking. Future research 
initiatives include developing potent inhibitors of SDH activity and testing in PDE patient 
cell cultures to obtain proof-of-concept for a new PDE therapy. Currently, two of the 
synthesized compounds that displayed similar binding properties to saccharopine in silico 
and in vitro act as weak inhibitors (Ki in miliMolar range). This process is described in detail 
in Chapter 4. 
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 OBJECTIVES 
The main objective of the present project was to study the biology of lysine degradation in 
several biological models, with emphasis on describing the biochemistry, molecular biology 
and genetic characteristics of the genes/enzymes involved in the conversion of Lysine to 
Aminoadipic Acid. The last goal that emerged while developing the current project was to 
study lysine degradation specifically to understand more about Pyridoxine Dependent 
Epilepsy (PDE) and suggest AASS as a new target for a substrate reduction therapy for PDE. 
Specific objectives while studying Lys-to-AAA catabolism in Prokaryotes (Chapters 1 and 
2): 
1) Use bioinformatics to study the occurrence, taxonomic distribution and genomic 
features of the Lys-to-AAA pathways in Prokaryotes (Chapter 1); 
2) Study lysine degradation using a marine bacteria as a model and explore the possible 
connection with stress response (Chapter 1 and 2); 
3) Generate a KO model in bacteria for LysDH and AASADH and observe its 
characteristics and metabolic content (Chapter 2); 
Specific objectives while studying Lys-to-AAA catabolism in mammals (Chapters 3 and 4): 
1) Detect and quantify the relevant metabolites for the first steps of lysine degradation 
(SAC, AASA/P6C, AAA, PIP and GLU) in plasma and tissues (Chapter 3). 
2) Address the possibility that AASS can be suggested as a potential target for PDE, by 
answering the following biological questions (Chapter 4): 
1. Which pathway (saccharopine versus pipecolate) is responsible for AASA/P6C 
accumulation in PDE patients? 
2. Is the saccharopine pathway responsible for the production of aminoadipic acid 
in the liver and in the brain? 
3. Which tissues are responsible for the pathogenic accumulation of P6C? 
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4. Can we inhibit AASS in cellular models? What is the implication for cell 
physiology/metabolism?  
5. Will the pipecolate pathway be upregulated when AASS is inhibited in a cellular 
model? 
6. Do cells derived from PDE patients display any differential phenotype 
compared to control cells? Can these cells be used as model to study PDE? 
7. Can a detrimental phenotype in PDE cells be reversed while inhibiting AASS?  
8. What are the structural determinants for AASS enzyme? Can we design 
inhibitors based on their substrates?  
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RESULTS 
Chapter 1 - “Genome-wide analysis of lysine catabolism in bacteria reveals 
new connections with osmotic stress resistance” 
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1.1 Abstract 
Lysine is catabolized via the saccharopine pathway in plants and mammals. In this 
pathway, lysine is converted to α-aminoadipic-δ-semialdehyde (AASA) by lysine-
ketoglutarate reductase/saccharopine dehydrogenase (LKR/SDH); thereafter, AASA is 
converted to aminoadipic acid (AAA) by α-aminoadipic-δ-semialdehyde dehydrogenase 
(AASADH). Here, we investigate the occurrence, genomic organization and functional role 
of lysine catabolic pathways among prokaryotes. Surprisingly, only 27 species of the 1,479 
analyzed contain the lkr and sdh genes, while 323 species contain aasadh orthologs. A sdh-
related gene located contiguously to an aasadh gene was identified in 159 organisms. This 
gene, annotated as lysine dehydrogenase (lysdh), encodes LYSDH an enzyme that directly 
converts lysine to AASA. Pipecolate oxidase (PiPOx) and lysine-6-aminotransferase (LAT), 
that converts lysine to AASA, were also found associated to aasadh. Interestingly, most of 
the lysdh-aasadh-containing organisms live in stressful environments. To test the role of the 
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lysine-to-AASA pathways in the bacterial stress response, we subjected S. pomeroyi to salt 
stress. lkr, sdh, lysdh and aasadh were upregulated under the salt stress conditions. In 
addition, lysine-supplemented culture medium increased the growth rate of S. pomeroyi 
under high salt conditions and induced high-level expression of the lysdh-aasadh operon. 
Finally, transformation of Escherichia coli with the S. pomeroyi lysdh-aasadh operon 
resulted in increased salt tolerance. The transfected E. coli accumulated high levels of the 
compatible solute pipecolate, which may account for the salt resistance. These findings 
suggest that the lysine-to-AASA pathways identified in this work may have a broad 
evolutionary importance in osmotic stress resistance. 
Keywords: lysine catabolism/osmoprotection/prokaryote/stress resistance  
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1.2 Introduction 
The saccharopine pathway is the main irreversible pathway for lysine catabolism in 
higher eukaryotes. It plays an essential role in homeostasis and the regulation of cellular 
lysine levels (Papes et al., 1999; Deleu et al., 1999). The two initial steps of this pathway are 
catalyzed by lysine-ketoglutarate reductase (LKR), which condenses lysine and α-
ketoglutarate into saccharopine, and saccharopine dehydrogenase (SDH), which hydrolyses 
saccharopine into α-aminoadipic-δ-semialdehyde (AASA) and glutamic acid (Figure 1) 
(Arruda et al., 2000). AASA is then hydrolyzed to aminoadipic acid (AAA) by α-
aminoadipic-δ-semialdehyde dehydrogenase (AASADH) (Arruda et al., 2000). In plants and 
animals, these genes are induced in response to osmotic and oxidative stresses (Guerrero et 
al., 1990; Stroeher et al., 1995; Deleu et al., 1999; Buchanan et al., 2005; Kirch et al., 2005; 
Rodrigues et al., 2006; Brocker et al., 2010) but the mechanism by which the enzymes protect 
against stress remains to be elucidated. 
 Recently, we identified LKR and SDH in the marine bacterium Silicibacter pomeroyi 
(Serrano et al., 2012). An interesting aspect of the LKR- and SDH-encoding genes in S. 
pomeroyi is their co-localization in an operon together with the gene encoding glutathione-
S-transferase (GST) (Serrano et al., 2012). GST, is an important enzyme associated with 
cellular detoxification, xenobiotics clearance and protection against chemical and oxidative 
stresses (Veal et al., 2002; Gratão et al., 2005; Allocati et al., 2009). This genomic 
organization suggests a possible connection between stress responses and the saccharopine 
pathway.  
 In this work, we investigate the occurrence and organization of the genes encoding 
LKR, SDH and AASADH in the sequenced genomes of prokaryotic organisms. We 
examined the breadth of distribution of the saccharopine pathway and the organization of the 
genes encoding these its enzymes within the prokaryotic genomes. Surprisingly, we 
discovered that prokaryotic organisms use other lysine catabolic enzymes rather than 
saccharopine pathway to convert lysine to AASA. These other enzymes have its encoding 
genes frequently organized in operons. One of these operons, lysdh-aasadh, contains the gene 
encoding lysine dehydrogenase (LYSDH), an enzyme that directly transforms lysine into 
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AASA. The role of this operon in the salt stress response was investigated in S. pomeroyi. 
Furthermore, we expressed this operon in Escherichia coli to assay the involvement of 
LYSDH along with AASADH in protection against high salt stress. We suggest a role for the 
lysine-to-AASA pathways in the stress response of prokaryotes that live in stressful 
environments. 
 
Figure 1: The four pathways used by prokaryotes to catabolize lysine to AASA. In green, 
lysine is converted to AASA via the saccharopine pathway. The two-step reaction involves 
lysine-ketoglutarate reductase, which condenses lysine and α-ketoglutarate into 
saccharopine, and SDH, which hydrolyzes saccharopine into AASA and glutamate. In red, 
lysine is directly converted into AASA by LAT, which catalyzes the transamination of α-
ketoglutarate, yielding AASA and glutamate. In blue, lysine is also directly converted into 
AASA by LysDH, which catalyzes the oxidative deamination of lysine. In gray, a multi-step 
reaction starts with the conversion of L-lysine to D-lysine by a racemase. D-lysine is then 
deaminated by an aminotransferase to form Δ1-piperidine-2-carboxylate, which is then 
converted to pipecolate by Δ1-piperidine-2-carboxylate reductase. Pipecolate is finally 
oxidized to AASA by pipecolate oxidase. All four pathways use AASADH (brown) to convert 
AASA to aminoadipate. P6C, glutamate and AAA can be used as substrates for several 
cellular pathways, leading to the production, for example, of pipecolate and proline (pink) 
by P5CR (dark pink). 
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1.3. Materials and methods 
1.3.1. Bioinformatics 
The prokaryotes genome sequences were retrieved from the NCBI Microbial 
Genomes database (ftp://ftp.ncbi.nlm.nih.gov/genomes/Bacteria) as of October 2011. We 
retrieved 2,712 completely sequenced genomes and plasmids corresponding to 1,362 bacteria 
and 116 Archaea. The nucleotide sequences encoding LKR, SDH and AASADH from S. 
pomeroyi, yeast, human, mouse and plants were used as true positive queries. Nucleotide 
sequences encoding other enzymes that share conserved domains with the enzymes of the 
saccharopine pathway were used as true negative queries. 
 The query nucleotide sequences were tBLASTn (Altschul et al., 1997) against 
prokaryotic genomes using a 10-10 e-value cut-off. The NCBI taxonomy database was used 
to cross information through the “GI” and “TaxID” associated with each organism group. 
The “best hit” obtained in the tBLASTn search was mapped to the corresponding full-length 
protein sequence using BLASTx. To avoid misinterpretation of the BLAST results, the 
bidirectional best hit function was used to select true positives. All the data were parsed into 
MySQL tables and, using SQL queries, crossed with data containing the organism 
information. The information contained in the “.gff” file was used to determine the distance 
between genes, orientation and genomic organization.  
 The phylogenetic analysis was performed using ClustalW for the multiple sequence 
alignments and MEGA 5 (Tamura et al., 2011) for the creation of phylogenetic trees, using 
the Neighbor-joining method with 1000 bootstrap replicates. 
1.3.2. Bacterial strain and culture conditions 
Silicibacter pomeroyi DSS-3 were obtained from the American Type Culture 
Collection (ATCC) (www.atcc.org). The bacteria were plated on solid Difco Marine Broth 
2216 (MB) containing 0.8% agar and grown for 2 days at 30°C. Individual colonies were 
inoculated in half-strength MB containing 5 g/L sucrose and grown in a rotatory shaker at 
200 rpm at 30°C for 36 hours. Liquid cultures were obtained by inoculating 2 ml of 12.5% 
MB containing various concentrations of NaCl with 100 μL of the primary cultures. 
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1.3.3. RNA expression analysis 
Total RNA was isolated from bacterial cultures using the Illustra RNAspin Mini 
Isolation Kit (GE). The RNA quality and integrity was verified by gel electrophoresis. First 
strand cDNA was synthesized from 1 µg total RNA using the RevertAid H Minus First Strand 
cDNA Synthesis Kit (Fermentas). Real-time PCR was conducted using defined primers 
(Table S1) and the SYBR GREEN PCR master mix (Applied Biosystems). The PCR 
amplification was performed in triplicate. 
1.3.4. Construction of vectors for LYSDH, AASADH and LYSDH/AASADH and expression in E. 
coli BL21 DE3 
The lysdh and aasadh gene sequences (separately or together as an operon unit) were 
amplified from the S. pomeroyi genomic DNA using the following forward primers: 
ggtcagccatgggcatgcgctggaacatttgtgt (lysdh) ggtcagccatgggcatgaaagatatcgtcatgac (aasadh), 
which contain NcoI restriction site, and reverse primers: ggagttgctcagctcaagcggccttgttttggg 
(lysdh) ggctacgctcagctcagatgtcgaacttcaccc (aasadh), which contain BlpI restriction site. The 
amplified fragments were cloned into pET28a (Novagen) that had been double-digested with 
NcoI and BlpI. The restriction endonucleases and the T4 DNA ligase were obtained from 
New England Biolabs. The pET28a-lysdh, pet28a-aasadh and pET28a-lysdh-aasadh 
constructs and the empty vector were transformed into the BL21 (DE3) pRIL E. coli strain 
(Novagen, USA). The positive colonies were verified by PCR, digestion and sequencing. 
To induce recombinant protein expression the four clones were independently grown 
in LB medium containing 50 μM isopropyl β-D-1-thiogalactopyranoside (IPTG) (inducer) or 
5 mM D-glucose (repressor). RNA and protein were extracted using the NucleoSpin® 
RNA/Protein kit (Macherey-Nagel, Germany). cDNA was synthesized and Real Time-PCR 
was performed for the LYSDH and AASADH transcripts. Protein extraction and 
quantification was performed as described (Karlsson et al., 1994). Expression of the LYSDH 
and AASADH proteins was verified by SDS-PAGE. 
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1.3.5. Stress treatment of E. coli transfected with the expression vectors 
E. coli lines harboring the four constructs were grown overnight in 2.5 mL LB 
containing 50 μM kanamycin in a rotatory shaker at 250 rpm and 37°C. Fifty microliters of 
each pre-inoculum was used to inoculate 1.2 mL LB with or without 400 mM NaCl and either 
50 μM IPTG or 5 mM D-glucose. The effect of lysine was analyzed under the same 
conditions with or without 5 mM L-lysine. 
1.3.6. Solutes extraction 
E. coli transfected with empty pET28a or the recombinant plasmids were grown in 
triplicate for 8 hours in LB medium containing 50 μM kanamycin and 50 μM IPTG. Bacteria 
was pelleted by centrifugation and washed three times with glucose-tris-EDTA (GTE) buffer 
to avoid contamination of cell extracts with culture medium metabolites. The pellet was 
frozen in liquid nitrogen, and the cells were disrupted by freezing and thawing three times. 
The solutes were extracted with 80% ethanol (Gouesbet et al., 1992).  For S. pomeroyi, 
bacterial cultures were pelleted after 24 hours growth in 12.5% MB containing 400 mM NaCl 
in the presence of 0, 5, 10 and 20 mM lysine or pipecolate. The ethanol extract was 
evaporated to dryness, and the dry residue was dissolved in deionized water. 
1.3.7. Pipecolate determination 
The samples were analyzed in an Acquity UPLC coupled to a TQD triple quadrupole 
mass spectrometer (Micromass-Waters, Manchester, UK). Five μL of each sample was 
injected into a Waters Acquity C18-BEH (2.1 x 50 mm, 1.7 µm) column at 30°C. The column 
was eluted using a 0 to 10% acetonitrile gradient in 50 mM ammonium acetate pH 6.5 at a 
flow rate of 0.15 mL.min-1. Electrospray ionization in the positive ion mode was performed 
under the following parameters: ion source temperature 150°C, desolvation temperature 
300°C, capillary 3.0 kV and cone 50 V. The MS/MS spectra of the detected peaks were 
obtained using collision-induced dissociation (CID) with a collision energy of 15 V. Pure L-
pipecolic acid (Sigma, USA) was used as standard. The retention time and fragmentation 
pattern were used to identify L-pipecolic acid in the bacterial samples. 
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1.4. Results 
1.4.1. Identification lysine catabolic enzymes linked to AASA synthesis in prokaryotes 
tBLASTn searches using the LKR, SDH and AASADH nucleotide sequences against 
2,712 nucleotide sequence files comprising chromosomal and plasmidial genome sequences  
corresponding to 1,478 microbe organisms identified orthologs for both the lkr and sdh genes 
in a restricted set of 27 organisms (Table 1). 
 We found a large number of SDH-related sequences, harboring around 40% amino 
acid similarity to the first two thirds of the SDH amino acid sequence, that were contiguously 
located to an aasadh gene. BLASTp searches against the protein database (PDB) identified 
a partial 3D structure for the N-terminal portion of the enzyme encoded by the SDH-related 
sequence from S. pomeroyi (PDB code: 3IC5). We used PyMol (Delano, 2002) to structurally 
align this N-terminal structure with the fungal SDH structure (PDB 2Q99), but this resulted 
in a non-valid alignment (Figure S1 A). A valid and low-RMSD alignment was obtained with 
an archaea LYSDH enzyme (PDB 3ABI) (Yoneda et al., 2010) (Figure S1 B). We also found 
a LYSDH in Agrobacterium tumefaciens (Misono et al., 1982) whose amino acid sequence 
is 70% similar to the amino acid sequences of the SDH-related sequences found in S. 
pomeroyi. Thus, we annotated these sdh-related genes as lysdh (Table 1). LYSDH directly 
converts lysine into AASA in a single-step reaction using NAD(P)+ as a cofactor (Misono et 
al., 1982; Yoneda et al., 2010) (Figure 1). We found lysdh homologues in 159 bacterial 
species, and the gene was co-localized in an operon with the aasadh gene in 36 of them 
(Table S2). Interestingly, 29 of these 36 organisms live or are able to live in highly saline, 
drought, heavy metal and oxidative stress environments (Table S2).  
 We then searched for other genes that frequently co-localize with aasadh as this gene 
was found in a large number of organisms. We identified the genes encoding lysine-6-
aminotransferase (LAT) and pipecolate oxidase (PIPOX) co-localized with aasadh. Similar 
to LYSDH, LAT catalyzes the direct conversion of lysine to AASA using α-ketoglutarate as 
the lysine ε-amino group aceptor for the production of glutamate and AASA (Fujii et al., 
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2000) (Figure 1). This enzyme was identified in 56 prokaryotic organisms, in 35 of which it 
was located in an operon with the aasadh gene (Table S3). Twenty nine of these 35 organisms 
live or are able to live in stressing environments. PIPOX catalyzes the final reaction step of 
a pathway, described in the Pseudomonas genus, which starts with the isomerization of L-
lysine to D-lysine by a racemase. Then, D-lysine is deaminated by D-lysine aminotransferase 
to form Δ1-piperidine-2-carboxylate, which is used by Δ1-piperidine-2-carboxylate reductase 
(Pip2C) to form L-pipecolate. The pipecolate is then oxidized to AASA by PIPOX (Revelles 
et al., 2005) (Figure 1). PIP2C, PIPOX and AASADH were found in 25 organisms, and genes 
similar to Pseudomonas PIPOX were found in 61 organisms, 48 of which showed co-
localization of pipox and aasadh in operons (Table S4). This could be a phylogenetically 
distinct feature of alpha- and gamma-proteobacteria (Table S4). 
 Thus, in a large number of prokaryotes, LKR/SDH, LYSDH, LAT and PIPOX are 
alternative pathways for the production of AASA from lysine. All the four pathways have 
AASADH as a common enzyme to convert AASA to AAA (Figure 1). The most abundant 
and widely distributed lysine catabolic enzymes found in this work for prokaryotes are the 
LYSDH and LAT pathways (Table 1).  
Table 1: Distribution of enzymes of the Lysine-to-AASA catabolic pathways among 
prokaryotes 
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1.4.2. Lysine catabolism genes are linked to stress response genes in operons  
Lkr, sdh, lysdh, lat and aasadh co-localize in operons in the genomes of diverse 
prokaryotes (Figure S2). Interestingly, phylogenetically distant taxa conserve similar operon 
configurations. Additionally, genes encoding transcription factors involved in the regulation 
of amino acid metabolism, such as asnC, are frequently located adjacent to lysdh or lat. It is 
likely that these operons allow the co-expression of functionally related genes in response to 
a range of stress conditions.  
 The lkr-sdh configuration was found in the genomes of nine organisms (four 
actinobacteria, four α-proteobacteria and one γ-proteobacteria) (Table S5). Five of these 
bacteria are considered moderately halophilic (from the Silicibacter, Roseobacter, 
Roseovarius and Salinispora genera), one is a psychrophilic and piezophilic deep-sea 
bacterium (Shewanella genus) and the remaining three are actinobacteria found in dry soil 
(Table S5). The lysdh-aasadh configuration was found in 36 organisms, 22 of which are 
proteobacteria (two α-, seven β-, and 12 γ-), 11 firmicutes, 2 bacteroidetes and one putative 
nitrospira bacterium (Table S2). Twenty-nine of these 36 species live in stress environments 
(Table S2). The lat-aasadh configuration was found in 35 organisms: 32 actinobacteria, 2 
bacteroidetes and 1 δ-proteobacteria (Table S3). Interestingly, there are also some cases of 
single gene (i.e. aasadh gene in Rhodococcus jostii RHA1 and Rhodococcus opacus B4) or 
operon duplication, in Mycobacterium bovis. In several Mycobacterium, the lat gene is 
localized in an operon with asnc and the sigma factor sigf (Figure S2 B), which is known to 
be essential for survival in conditions of heat shock, pH and oxidative stress (Gebhard et al., 
2008). The gene encoding AsnC is upregulated by starvation and plays a significant role 
during the persistent/latent phase of mycobacterial infection (Betts et al., 2002). The sigf-
asnc-lat configuration was found in 18 of the 22 Mycobacteria that have completely 
sequenced genomes (Table S3). Other actinomycetes that contain the LAT pathway produce 
pipecolate to serve as a substrate for antibiotic synthesis. In Streptomyces, for example, the 
LAT enzyme is considered to be the first step in the -lactamic biosynthetic pathway (such 
as in cephamycin production) (Alexander et al., 2007). There is no evidence that the LAT 
pathway is involved in abiotic stress responses in these organisms. 
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  Lateral gene transfer may explain the presence of lysine-to-AASA pathways in 
distantly related taxa. Because all four pathways have AASADH in common, we used this 
enzyme to analyze the phylogenetic relationships among these organisms. We built a tree 
using the RNA polymerase subunit α (rpoA), a gene commonly used for phylogenetic 
analysis (Zeigler, 2003), to trace the phylogenetic relationships among bacteria containing 
LKR, SDH, LYSDH, LAT or PIPOX. Next, we created a phylogenetic tree using AASADH 
for the same organisms. The phylogenetic tree constructed with RpoA is consistent with the 
taxonomy established for bacteria (Figure 2A), but the phylogenic relationships among the 
AASADH sequences are not congruent with the taxonomic results from the topology of the 
rpoA tree (Figure 2B). This result suggests that the lysine-to-AASA pathways may have been 
acquired via lateral gene transfer. Interestingly, some phyla, such as bacteroidetes, contain 
organisms that have genes for the LYSDH, LAT or saccharopine pathway, suggesting that 
gene transfer may have occurred several times. Taken together, these observations suggest 
that the lysine-to-AASA pathways have been widely spread among bacteria living in 
different ecosystems, and the prevalence of these genes among bacteria living in stressful 
environments points to a potential role in adaptive advantage.  
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Figure 2: Phylogenetic tree based on the maximum likelihood method. (a) RpoA and (b) 
AASADH amino-acid sequences from organisms that contain LKR and SDH (●), LYSDH (●), 
LAT (●) and PipOX (●). The shadowed boxes indicate bacterial phyla: (gray) Bacteroidetes; 
(blue) Firmicutes; (yellow) Actinobacteria; (pink) Nitrospirae; (red) Proteobacteria. 
 Another interesting finding is that S. pomeroyi, Silicibacter sp. TM1040 and 
Kangiella koreensis, all moderately halophytic seawater bacteria (Lima et al., 2009), have 
both the saccharopine and LYSDH pathways. Other species, such as the soil and sea 
bacterium Pedobacter heparinus, bacteria from genus Rhodococcus and the extremely 
halophytic bacteria Salinibacter ruber, contain both LYSDH and LAT. Some Rhodococcus 
species have more than one copy of the aasadh gene. Coincidently, all of these organisms 
live or are able to live in stressful environments. Salinibacter species are among the most 
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halophilic bacteria known. S. ruber, for example, cannot grow in salt concentrations below 
15% and is very successful at colonizing saltern ponds (Anton et al., 2002). 
 S. pomeroyi has two lysine-to-AASA pathways. The lkr and sdh genes co-localize 
with GST and the glycolysis gene encoding phosphoglycerate mutase (PGM). The lysdh gene 
co-localizes with aasadh, the transcriptional regulator asnc and the oxidative stress 
associated gene encoding quinone oxidoreductase (QOR) (Figure 3). To probe the 
functionality of the operons pgm-gst-lkr-sdh and qor-asnc-lysdh-aasadh, they were amplified 
from cDNA synthesized from total RNA isolated from S. pomeroyi grown in MB medium. 
Primers designed to amplify individual as well as concatenate genes produced amplicons, 
supporting the hypothesis that these genes are produced as polycistronic mRNA. This 
evidence supports the idea that the genes encoding lysine catabolic enzymes are functionally 
linked in operons together with stress responsive genes (Figure S3).  
 
Figure 3: Genomic organization of the genes comprising the lkr-sdh and lysdh-aasadh 
operons in S. pomeroyi. The (+) signal preceding the numbers 1, 2 and 3 indicates the 
transcribed frame. SPO followed by 4 digits indicates the NCBI gene identifier. The genes of 
the LKR/SDH operon encodes: PGM, phosphoglycerate mutase; GST, glutathione-S-
transferase; LKR, lysine-ketoglutarate reductase; HP, hypothetical protein; SDH, 
saccharopine dehydrogenase. The genes for the lysdh-aasadh operon encodes: QOR, 
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quinone oxidorreductase, AsnC, AsnC transcriptional regulator family; LysDH, lysine 
dehydrogenase, AASADH, α-aminoadipic-δ-semialdehyde dehydrogenase. 
 
1.4.3. Lysine catabolism genes are upregulated in high salt conditions in a lysine-
dependent manner 
To verify whether the lkr, sdh, lysdh and aasadh genes are induced by salt stress, S. 
pomeroyi was grown in 12.5% MB medium supplemented with increasing concentrations of 
NaCl in the presence or absence of lysine (Figure 4). The addition of 5 mM lysine to the MB 
medium in the absence of salt had no significant effect on the bacterial growth rate (Figure 
4A), but addition of the amino acid to MB medium containing 100, 200 or 400 mM NaCl 
significantly increased the bacterial growth rate and extended the exponential growth phase. 
(Figure 4B-D). These results suggest that S. pomeroyi can use lysine to adapt to high salt 
environments. 
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Figure 4: Effect of lysine supplementation on the S. pomeroyi growth rate in high salt 
medium. Bacterial cultures were grown for 36 hr in 12.5% MB medium containing the 
indicated salt concentrations: A, no salt; B, 100 mM NaCl, C, 200 mM NaCl, D, 400 mM 
NaCl, in the presence or absence of 5 mM lysine. Growth curves were analyzed for statistic 
significance based on comparison of log phases slopes using covariance analysis. A, not 
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significant (p = 0.43); B, significant (p=0.008); C, significant (p=0.0007). D, significant 
(p=0.0008). E, relative mRNA levels in bacterial cells sampled at 24 hours of growth for the 
genes lysdh, aasadh, lkr, sdh and p5cr. The relative expression was calculated using the delta 
Ct method based on the expression of glyceraldehyde 3-phosphate dehydrogenase as 
endogenous control. Relative mRNA was compared using T-test. One and two asterisk 
represents significant difference at p <0.05 and p<0.1, respectively.  
 We then asked whether the lkr-sdh and lysdh-aasadh operons are induced in S. 
pomeroyi grown under salt stress. Samples were collected from S. pomeroyi grown for 24 hr 
in MB medium containing 400 mM NaCl in the presence or absence of 5 mM lysine. In 
addition, we verified the expression of the p5cr gene, which encodes the enzyme δ1-
pyrroline-5-carboxylate reductase (P5CR). P5CR uses δ1-piperideine-6-carboxylate (P6C), 
the cyclic form of AASA, as a substrate to produce pipecolate (Fujii et al., 2002; Eduard and 
Jakobs, 2010). P5CR also catalyzes the formation of L-proline using δ1-pyrroline-5-
carboxylate (P5C) as a substrate (Peisach and Strecker, 1962). The expression analyses 
revealed that both the lkr-sdh and lysdh-aasadh operons are induced by lysine and salt stress, 
but the lysdh-aasadh pathway is 100-fold more responsive to lysine than the lkr-sdh pathway, 
indicating that the lysdh-aasadh pathway is preferentially expressed under lysine 
supplementation (Figures 4E and S4). Interestingly, the p5cr gene is also upregulated by high 
salt, but only in a lysine-dependent manner (Figure 4E). The upregulation of the p5cr gene 
might indicate that lysine and salt can trigger pipecolate production under salt stress. 
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Figure 5: Effects of pipecolate, lysine, glucose or histidine on the S. pomeroyi growth rate 
in high salt medium. Bacterial cultures were grown in 12.5% MB medium containing 400 
mM NaCl supplemented with: A, 0, 5, 10 or 20 mM pipecolate;  B, 0, 5, 10 or 20 mM lysine; 
C, 5 mM glucose or 5 mM lysine; D, 5 mM glucose was replaced by 5 mM histidine. 
 If pipecolate itself acts as an osmoprotectant or if it is used as a substrate to produce 
other osmoprotectants, the addition of this amino acid to the salt stress medium might 
improve adaptation to saline environments. The addition of 5, 10 or 20 mM pipecolate to 
12.5% MB medium containing 400 mM NaCl improved the growth of S. pomeroyi  (Figure 
5A) at a rate similar to that observed for lysine supplementation (Figure 5B). The amount of 
pipecolate inside the bacterial cells was determined by mass spectrometry. We could not 
detect pipecolate accumulation in the bacteria grown in 5 mM pipecolate or 5 mM lysine, but 
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it accumulated at high levels inside the bacterial cells at high concentrations of pipecolate 
(10 and 20 mM). 
 To address the question of whether lysine is simply being used as a carbon source for 
bacterial growth, S. pomeroyi was grown in 12.5% MB medium supplemented with high salt 
and either glucose or lysine (Figure 5). The bacteria grew more densely with lysine than with 
glucose in the high salt medium (Figure 5C). We also assayed whether the addition of other 
positively charged amino acids to the high salt MB medium provided the same growth 
advantages as lysine. When histidine was added to the high salt MB medium, the bacteria did 
not grow as densely as they did with the lysine supplementation (Figure 5D). 
1.4.4. Expression of lysdh-aasadh operon in E. coli increases high salt tolerance 
The S. pomeroyi lysdh and aasadh genes were cloned into pET28a under the control 
of the lac promoter and transformed into BL21 DE3 pRIL. The two genes were cloned both 
individually and together. Individual E. coli lines harboring the empty pET28a plasmid or 
one of the three recombinant plasmids had similar growth rates in LB medium without high 
salt (Figure S5 A). When induced with 50 μM IPTG, the E. coli expressing lysdh, aasadh or 
lysdh-aasadh grew similarly to without IPTG induction but those transformed with the empty 
pET28a plasmid had a significantly reduced growth rate (Figure S5 B). The higher growth 
rate observed in the E. coli harboring the lysdh, aasadh or lysdh-aasadh genes may indicate 
that these genes alleviate the stress caused by IPTG (Yee and Blanch, 1993). The E. coli 
strains harboring the lysdh, aasadh or lysdh-aasadh constructs correctly expressed the 
recombinant 40 kDa LYSDH protein and/or the recombinant 52 kDa AASADH protein when 
induced with 50 μM IPTG (Figure 6A). Under high salt conditions, the three strains harboring 
the recombinant constructs showed increased growth rates compared to the control strain 
harboring the empty pET28a plasmid (Figure 6B). The addition of 5 mM lysine to the high 
salt medium further increased the growth rate of the E. coli strains harboring the recombinant 
lysdh and lysdh-aasadh constructs as compared with the strain harboring the empty pET28a 
plasmid or that containing aasadh (Figure 6C). The LB medium used in this assay has lysine 
originated from hydrolyzed tryptone and yeast extract. This lysine-containing medium may 
help the strains grow in high salt for the first 10 hr. After this period, the medium 
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supplemented with additional lysine maintained the high growth rate of the strain harboring 
the lysdh construct compared with the strains harboring the other constructs or the empty 
pET28a plasmid (Figure 6C). 
 
Figure 6: Effect of salt stress on the growth rate of E. coli BL21 DE3 harboring constructs 
expressing the lysdh-aasadh operon components. A, SDS-PAGE of proteins extracted from 
bacterial cells grown for 8 hr in non-induced and IPTG-induced cultures. Lanes 1, 2, 3 and 
4 correspond to the protein extracts of bacterial cells harboring the pET28a empty plasmid, 
lysdh-aasadh, lysdh and aasadh, respectively, grown in non-induced LB medium. Lanes 5, 6, 
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7 and 8 correspond to the protein extracts of bacterial cells harboring the pET28a empty 
plasmid, lysdh-aasadh, lysdh, and aasadh, respectively, grown in LB medium conatining 50 
μM IPTG. B, Growth rates of E. coli harboring the pET28a empty plasmid, lysdh-aasadh, 
lysdh, and aasadh constructs in high-salt LB medium containing 50 μM IPTG. C, Growth 
rates of E. coli harboring the the pET28a empty plasmid, lysdh-aasadh, lysdh, and aasadh 
constructs in high-salt LB medium conatining 50 μM IPTG in the presence or absence 5 mM 
lysine. D-G, Pipecolate accumulation in extracts of bacterial cells from experiment 
represented in C.  Elution pattern of cellular solutes from E. coli harboring: D, empty 
pET28a plasmid; E, lysdh-aasadh construct; F, aasadh construct; G, lysdh cosntruct. In D-
G the peaks for m/z 129 were found, with the expected retention time for L-pipecolic acid 
(1.32 minutes) for lysdh-aasadh and lysdh constructs but not for the aasadh construct or the 
empty pET28a. 
 Samples of the E. coli harboring one of the recombinant constructs or the empty 
pET28a plasmid grown in high salt medium were analyzed for pipecolate accumulation. The 
pipecolate standard peaked at m/z = 130.2, corresponding to C6H11NO2. The base peak was 
at m/z ~ 84 (Figure S 5 C). Nearly identical peak patterns were found for bacteria harboring 
lysdh and lysdh-aasadh, confirming the presence of pipecolate in the samples (Figure S5 D). 
The strains harboring the aasadh-only construct or the empty pET28a plasmid did not show 
any pipecolate accumulation (Figures 6 D and F). The bacteria harboring the lysdh-only or 
the lysdh-aasadh construct accumulated pipecolate to approximately 611 and 32,9 nmol/mg 
protein, respectively (Figure 6 E and G). The accumulation of high amounts of pipecolate 
indicate that the lysine-to-AASA pathway derives compatible solutes, which can improve 
bacterial performance under salt stress, and suggests that LYSDH may play a major role in 
salt stress tolerance. 
1.5. Discussion 
The saccharopine pathway is involved in the regulation of lysine levels and the stress 
response in plants and animals (Arruda and Neshich, 2012). In this pathway, LKR and SDH 
catalyze, in two reaction steps, the conversion of lysine to AASA and the formation of 
glutamate. AASA is a toxic semialdehyde, and AASADH, the third enzyme of the pathway, 
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may keep the AASA concentration at very low levels by converting it to AAA (Figure 1). 
The cyclic isomer of AASA, P6C, can be used as a P5CR substrate to produce pipecolate 
(Fujii et al., 2002; Eduard and Jakobs, 2010), a physiological osmoprotectant (Moulin, et 
al., 2006) (Figure 1). The saccharopine pathway was recently found in the seawater bacteria 
S. pomeroyi (Serrano et al., 2012). Interestingly, the S. pomeroyi genes encoding LKR and 
SDH are localized in an operon together with GST, suggesting that this pathway has a 
significant role in the stress responses of diverse organisms. 
 The LKR and SDH proteins were found in only a few bacterial species, while 
AASADH was identified in a much larger number of organisms (Table 1). The existence of 
other enzymatic pathways that produce AASA from lysine (Figure 1) indicates that this lysine 
catabolic derivative is an important metabolite that is used by bacteria for growth and 
adaptation to stressing environments. This view is supported by the fact that lysdh, lat and 
pipox genes are located in operons together with aasadh in diverse organisms (Figure S2). 
LYSDH and LAT occur more frequently and are distributed among distantly related 
organisms, including archaea. There is no apparent clade specificity for each pathway, 
although most of the LYSDH-containing organisms belong to the proteobacteria phylum and 
the majority of the LAT-containing organisms are actinobacteria. Nearly all phyla 
represented has LYSDH-containing organisms (Table 1), and phylogenetic analyses suggest 
that horizontal gene transfer may have contributed these pathways to spread to distinct taxa, 
perhaps as a consequence of environment pressure. In the four lysine-to-AASA pathways 
identified, the genes are frequently organized in the form of lkr-sdh, lysdh-aasadh, lat-aasadh 
and pipox-aasadh operons that also comprise genes encoding oxidative stress enzymes. This 
suggests a connection among lysine catabolism and stress adaptation. 
 The LYSDH and LAT pathways are more widely distributed among prokaryotes than 
the LKR-SDH and PIPOx-AASADH pathways. We hypothesize that the LYSDH and LAT 
pathways produce the osmoprotectant pipecolate more efficiently than the other two 
pathways. The rapid production of pipecolate from P6C quickly relieves osmotic stress 
allowing for rapid adaptation of the bacteria in stressful environments. For example, 
pipecolate accumulates at high levels and protects against osmotic stress in Corynebacterium 
ammoniagenes (Gouesbet et al., 1992) and has been described as a genuine osmoprotectant 
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for E. coli grown in high salt (Gouesbet et al., 1994). Pipecolate was also shown to 
accumulate in rapeseed leaf tissues subjected to osmotic stress (Moulin, et al., 2006) and in 
halophytic and sand dune plants subjected to permanent water stress (Goas et al., 1975; 
Jefferies et al., 1979). Furthermore, pipecolate co-accumulates with proline in water-stressed 
soybeans (Fukutoku et al., 1981). Proline could also be a derivative of the LAT and 
saccharopine pathways, as it can be synthesized from the glutamate formed in the first 
transamination step (Figure 1). In plants, glutamate is a substrate for proline synthesis; the 
enzyme P5C synthetase converts it to P5C, which is reduced to proline by P5CR (Delauney 
et al., 1993), the same enzyme that converts P6C to pipecolate (Fujii et al., 2002; Eduard and 
Jakobs, 2010). Thus, in the presence of AASA and glutamate, the protective osmolytes 
pipecolate and proline could be formed.  Another possibility is that these pathways 
produce AASA, which may act as a signaling molecule. In yeast for example, AASA 
modulates the transcription factor Lys14, which regulates the transcription of LYS genes 
(Feller et al., 1994). 
 In S. pomeroyi, the LYSDH pathway is preferentially expressed, as compared to the 
saccharopine pathway, upon salt stress and mainly lysine induction (Figure 4). It is possibile 
that this bacterium is adapted to be able to rapidly degrade lysine when it is available as a 
source of carbon and nitrogen. It has been suggested that S. pomeroyi is equipped to take 
advantage of transient occurrences of high-nutrient niches within a bulk low nutrient 
environment (Moran, et al., 2004) and LysDH might play an important role in this matter. 
The fact that the gene encoding P5CR is also upregulated in high salt medium in a lysine-
dependent manner (Figure 4) corroborates with the notion that lysine may fuel pipecolate and 
its derivatives in bacteria submitted to stressful conditions. In plants, the lysine derived from 
osmo-induced proteolysis increases under stress and stimulate the LKR/SDH expression 
channeling lysine to AASA, which can be used to form either Acetyl-CoA or pipecolate 
(Moulin, et al., 2000) (Moulin, et al., 2006). The accumulation of pipecolate reached 
remarkable concentrations in the E. coli expressing lysdh alone and, to a lesser extent, in the 
bacteria expressing both lysdh and aasadh, but not in the bacteria expressing aasadh alone. 
These results indicate that pipecolate is accumulating rather than being metabolized in the E. 
coli harboring lysdh and, thus, potentially acting as a genuine osmoprotectant. Bacteria 
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containing lysdh-aasadh showed a reduced accumulation of pipecolate due to the conversion 
of AASA to AAA by AASADH (Figure 6E). Although no pipecolate accumulation was 
observed in E. coli expressing aasadh alone, these bacteria performed better in high salt 
medium than the E. coli harboring the empty pET28a plasmid. This suggests that salinity, in 
addition to its specific ionic and osmotic stress, may increase oxidative stress and the 
accumulation of toxic aldehydes that can be degraded by AASADH. This physiological 
AASADH function has already been demonstrated in plants and animals (Rodrigues et al., 
2006; Brocker et al., 2010), but in the case of the lysine-to-AASA pathways, as demonstrated 
in the experiments with S. pomeroyi, the co-localization of lysdh and aasadh in an operon 
places the two genes within the same regulon and suggests that AASADH plays a role in 
maintaining AASA at very low levels while its cyclic isomer P6C is used by P5CR to produce 
pipecolate (Figure 4E). Thus, the lysine-to-AASA pathways could be used to alleviate high 
stress by producing compatible solutes and preventing the accumulation of toxic aldehydes. 
In addition, AASADH could play a role in oxidizing aldehyde precursors to produce other 
compatible solutes, such as the conversion of betaine aldehyde to the osmoprotectant betaine 
(Brocker et al., 2010).  
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1.8. Supporting Information 
 
Figure S1 Annotation of S. pomeroyi LYSDH through structural alignment. A, Views of the 
structural alignment of S. pomeroyi putative LYSDH N-terminal (red, PDB code 3IC5, 
fragment representing the first 118 residues of this enzyme) with the fungi SDH structure 
(green, PDB code: 2Q99), with RMSD = 3.5. B, Correspondent views of Structural alignment 
of the N-terminal of S. pomeroyi putative LYSDH with the LYSDH from Archaea (blue, 
PDB code 3ABI), with RMSD = 2.3. 
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Figure S2 - Genomic organization of the operons containing the genes of the lysine 
catabolism pathways in selected prokaryote genomes. Frequent patterns are also shown on 
the right of the panels of each pathway. A, The saccharopine pathway in α-proteobacteria 
contains the genes pgm, gst, lkr, hp and sdh. In γ-proteobacteria only lkr and sdh is found. In 
actinobacteria, there are examples of lkr and sdh alone and located adjacently with other 
genes such as acdh (acyl-CoA dehydrogenase), lkr, sdh, limox (L-lysine 6-monooxygenase) 
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and fadox (a FAD dependent oxidoreductase). B, The LAT pathway in Actinobacteria was 
found frequently placed with asnc gene which encodes an transcription factor associated to 
aminoacid metabolism regulation. In Mycobacterium, lat gene was found placed with the 
stress sigma factor SigF. C, The LYSDH pathway in distinct proteobacteria class occurred 
with lysdh and aasadh adjacently placed to asnc. D, The last genes of D-Lysine pathway 
were found placed in the pipox-aasadh configuration in Pseudomonas. Taylorella 
asinigenitalis MCE3 has, additionally, the gene nhac which encodes for a Na+/H+ antiporter 
(NhaC) and the gene ocd which encodes Ornithine Cyclodeaminase. Rhizobium species have 
genes for AsnC and LysR transcriptional regulators located adjacently to pipox-aasadh 
operon. 
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Figure S3 - Probing the operon structure of the saccharopine and LYSDH pathways in S. 
pomeroyi. A, cDNA prepared from RNA extracted from bacteria growing control MB 
medium was used as template to amplify the single or the concatenated genes comprising the 
two operons. Lane 1 represents the 1kb plus DNA ladder, lanes 2, 3, 4 and 5 represent the 
amplification of qor-asnc-lysdh-aasadh operon using primer pairs 6, 7, 8 and 9 (from 
supplemental table 6), respectively. Lanes 6, 7 and 8 represent amplification of pgm-gst-lkr-
hp-sdh operon using primer pairs 10, 11 and 12, respectively. The expected amplicons sizes 
are shown above each visible band. B, Schematic representation of genes comprising the two 
operons in S. pomeroyi DSS3. 
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Figure S4 - Relative mRNA expression of the genes comprising the lysdh and saccharopine 
operons of S. pomeroyii growing in MB medium containing increasing concentrations of 
NaCl in the presence or absence of 5 mM lysine. The relative mRNA values were calculated 
relative to expression in the correspondent medium non-supplemented with lysine. lysdh, 
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aasadh, p5cr, lkr and sdh relative mRNA from bacteria grown in 2.5% MB medium without 
NaCl (A), 200 mM NaCl (B), 400 mM NaCl (C) and 800 mM NaCl (D). 
 
Figure S5 Effect of IPTG on the growth rate of E. coli BL21 DE3. Bacteria harboring the 
pET28a empty plasmid or the constructs lysdh-aasadh, lysdh or aasadh were grown in LB 
medium without NaCl supplementation. A, MB medium supplemented with 5 mM glucose 
in the absence of IPTG induction. B, MB medium supplemented with 50µM IPTG. UPLC-
MS/MS spectra of (C) pipecolic acid standard and (D) corresponding chromatographic peak 
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collected from bacterial sample. Both spectra present the same fragmentation pattern, 
confirming the identity of the analyte. 
Supplemental tables can be accessed online by clicking on each table name or by visiting 
the following ISME Journal link:  
http://www.nature.com/ismej/journal/v7/n12/suppinfo/ismej2013123s1.html?url=/isme
j/journal/v7/n12/abs/ismej2013123a.html 
 
Table S1 - Oligonucleotides used as primers in the in the Real Time PCR for operon 
validation and relative expression analysis. 
Table  S2 - Prokaryote organisms that contain the lysdh and aasadh genes in their genomes 
in an operon configuration. Organisms marked with ˣwere found to live or be able to live in 
extreme environments. The NCBI code for LYSDH and AASADH protein sequences are 
shown. 
Table S3 - Prokaryote organisms that contain the lat and aasadh genes in their genomes in 
operon configuration. Organisms marked with x were found to live or be able to live in 
extreme environments. a indicates duplicate operon. The NCBI code for LAT and AASADH 
protein sequences are shown. 
Table S4 - Prokaryote organisms that contain pipox and aasadh genes in their genomes in 
operon configurations. Organisms marked with ˣ were found to live or be able to live in 
extreme environments. b represents organisms that also have Pip2C similar sequences. The 
NCBI code for PIPOX and AASADH protein sequences are shown. 
Table S5 - Prokaryote organisms that contain the lkr and sdh genesin their genomes in operon 
configuration. Organisms marked with ˣ were found to live or be able to live in extreme 
environments. 
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2.1. Abstract 
Lysine catabolism to aminoadipate-semialdehyde in prokaryotes occurs through four 
different pathways, which converge to the use of aminoadipate-semialdehyde dehydrogenase 
(aasadh) to aminoadipate. The proteobacteria R. pomeroyi possesses the saccharopine and 
lysine dehydrogenase (lysdh) pathways for lysine catabolism. Here we generated a lysdh and 
aasadh double knockout (KO) in R. pomeroyi. The double KO showed reduced growth under 
salt stress and in lysine supplemented medium when compared with wild type (WT). It also 
had an over-accumulation of saccharopine, indicating a shift of lysine degradation towards 
the saccharopine pathway. Finally, absence of a functional AASADH enzyme in the double 
KO led to an over-accumulation of the side molecule pipecolate. These results add further 
insights into lysine degradation and stress response pathways in R. pomeroyi. 
 
Keywords: Lysine catabolism, stress response, pipecolic acid,  
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2.2. Introduction 
 Ruegeria pomeroyi DSS-3 (formerly Silicibacter pomeroyi DSS-3) is a heterotrophic 
alpha-proteobacterium, considered to be an important model organism for the study of 
ecology, biochemistry and physiology of marine microorganisms (Moran et al., 2004). R. 
pomeroyi is a member of the marine Roseobacter clade, which comprise around 10-20% of 
coastal and oceanic bacteria (González, 1997) and are found frequently in association with 
phytoplankton, macroalgae and marine animals (Luo & Moran, 2014). Recent findings 
suggest that the availability of substrates including amino acids derived from phytoplankton 
bloom control the abundance and activities of heterotrophs such as Roseobacters (Teeling et 
al., 2012). This group of organisms is exclusively marine or hypersaline with some species 
displaying salt requirement for growth (Buchan et al., 2005). Several Roseobacter members, 
such as those from the Ruegeria genus, are able to degrade dimethylsulfoniopropionate 
(DMSP) and thus participate in the sulphur cycle (Buchan et al., 2005). 
 R. pomeroyi DSS-3 has also been used for studying lysine catabolism during bacterial 
adaptation to osmotic stress (Serrano et al., 2012; Neshich et al., 2013). These bacteria 
possess two of the four lysine catabolic pathways described in prokaryotes having in common 
the formation of aminoadipate-semialdehyde (AASA) (Neshich et al., 2013). R. pomeroyi 
DSS-3 contains the saccharopine pathway, which converts lysine into AASA in a two step 
reaction catalysed by the enzymes lysine-ketoglutaratereductase (LKR) and saccharopine 
dehydrogenase (SDH) as well as the lysine dehydrogenase (LysDH) pathway that converts 
lysine directly into AASA (Fig.1). In both pathways, AASA is further oxidized to 
aminoadipic acid (AAA) by the enzyme aminoadipate-semialdehyde dehydrogenase 
(AASADH). These pathways can be used to degrade lysine as source of nitrogen and carbon 
but can also be used to produce pipecolic acid, a compatible solute that can act as an 
osmoprotectant for microbes living in the naturally high salt marine environment (Gouesbet 
et al., 1994; Neshich et al., 2013). Pipecolic acid is synthesized from piperideine-6-
carboxylate (P6C), the cyclic form of AASA, by the enzyme, δ1-pyrroline-5-carboxylate 
reductase (P5CR) (Struys & Jakobs, 2010) (Fig. 1). The genes lysdh (SPO0234) and aasadh 
(SPO0235) are located in an operon separate from lkr (SP03307) and sdh (SP03309), which 
are located together with genes encoding enzymes involved in the oxidative stress response 
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(Serrano et al., 2012). The LysDH pathway is the predominant route of lysine catabolism in 
R. pomeroyi as transcript levels produced by the lysdh gene are over 200-fold higher than 
those from the lkr and sdh genes when bacteria are grown in MB medium supplemented with 
5mM lysine (Neshich et al., 2013). Both the lysdh-aasadh and lkr-sdh operons are 
upregulated when the bacterium is submitted to salt stress (Neshich et al., 2013), which 
provides a means of study this pathway in R. Pomeroyi.  
 
Figure 1: Representation of lysine catabolic pathways of R. pomeroyi. The saccharopine 
pathway is shown in green, and involves a two-step reaction catalysed by lysine-
ketoglutarate reductase (LKR), which condenses lysine with α-ketoglutarate into 
saccharopine, and saccharopine dehydrogenase (SDH), which hydrolyzes saccharopine into 
α-amininoadipic-δ-semialdehyde (AASA) and glutamate. The LysDH pathway is shown in 
blue and consists of oxidative deamination of lysine to produce AASA. Both pathways use α-
amininoadipic-δ-semialdehyde dehydrogenase (AASADH) (brown) to convert AASA to 
aminoadipate (AAA). AASA or its cyclic form piperideine-6-carboxylate (P6C), glutamate 
and AAA can be used as substrates for several cellular pathways, leading to production of 
for example, pipecolate and proline through δ1-pyrroline-5-carboxylate reductase (P5CR) 
and acetyl-CoA. 
 
 In this work, we tested if the absence of functional AASADH in R. Pomeroyi would 
lead to a re-adaptation of the lysine degradation pathway and block production of 
aminoadipic acid. To answer this question, we produced a double knockout (KO) of the R. 
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Pomeroyi lysdh-aasadh genes by homologous recombination. The KO bacteria were then 
analyzed for accumulation of metabolites of lysine catabolism and bacterial growth 
performance in MB medium supplemented with lysine under salt stress conditions. The 
results are discussed in the context of a useful methodology for investigation of lysine 
metabolism and the stress response in R. Pomeroyi. 
2.3. Materials and methods 
2.3.1. Chemicals and reagents 
 The restriction endonucleases and T4 DNA ligase were obtained from New England 
Biolabs (Ipswich, MA, USA). Formic acid was obtained from Sigma–Aldrich (São Paulo, 
Brazil). Acetonitrile (ACN) was purchased from J.T. Baker (São Paulo, Brazil). All solvents 
used were HPLC grade and water was obtained from a Milli-Q purification system 
(Millipore; São Paulo, Brazil. All chemicals and reagents were of the highest purity and were 
stored at appropriate temperatures and conditions. 
2.3.2. Bacterial strain and culture conditions 
 Ruegeria pomeroyi DSS-3 was obtained from the American Type Culture Collection 
(www.atcc.org). Bacteria were plated onto solid Difco Marine Broth (MB) 2216 containing 
0.8% agar and grown for 2 days at 30°C. Individual colonies were inoculated in half-strength 
MB and grown on a rotatory shaker at 200 rpm for 36 hours at 30°C. Growth curves were 
obtained by inoculating 100 μL of the primary cultures in 2 mL 12.5% MB containing various 
concentrations of NaCl and/or lysine and by measuring the optical density at 620 nm 
(OD620) in a spectrophotometer. 
2.3.3. Knockout construct targeting the lysdh-aasadh operon 
 A genomic DNA fragment spanning the genes lysdh and aasadh was amplified by 
polymerase chain reaction (PCR) from R. pomeroyi DSS-3 genomic DNA using the primers: 
5′-ggtcagccatgggcatgcgctggaacatttgtgt-3′ (lysdh, SPO0234), which contained a NcoI 
restriction site and 5′-ggctacaagctttcagatgtcgaacttcaccc-3′ (aasadh, SPO0235), containing a 
HindIII restriction site. The amplified fragment was digested with NcoI and HindIII 
restriction enzymes and inserted into the NcoI-HindIII cloning site of the pBAD/Myc-His 
vector (Invitrogen; Groningen, NL) to create the plasmid pBAD-lysdh-aasadh. The 
kanamycin resistance (kanR) cassette was amplified from the pET28a (Novagen; Darmstadt, 
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Germany) vector using the primers 5′-gtacagcagctgaaaccaccgctggtagcggt-3′ and 5′-
gtaggccagctgttagaaaaactcatcgagca-3′, both containing PvuII restriction sites. Restriction 
digestion analysis showed that the PvuII enzyme cut twice inside the lysdh-aasadh amplicon 
releasing a fragment of 533 base pairs (bp). The PvuII site was chosen, as it is not present in 
other sequences of the pBAD backbone or kanR cassette. This resulted in two arms of 
homologous recombination, one of 860 bp located at the 5’ end of lysdh and another of 1,200 
bp located at the 3’ end of the aasadh gene. The 1,050 bp kanR cassete was amplified by 
PCR, digested with PvuII and ligated between the PvuII sites of pBAD-lysdh-aasadh, 
generating the plasmid pBAD-KO-lysdh-aasadh containing kanamycin and ampicilin 
resistance markers (Fig. 2A). When pBAD-KO-lysdh-aasadh is introduced in the R. 
pomeroyi genome, homologous recombination can lead to transfer of the kanR cassette into 
the bacterial chromosome disrupting both the lysdh and aasadh genes (Fig. 2B and 2C). 
2.3.4. Production of R. Pomeroyi electrocompetent cells 
 R. Pomeroyi DSS-3 electrocompetent cells were produced according to a procedure 
adapted from Sebastian & Ammerman (2009) and Green & Sambrook (2012. Primary 
cultures (100 μL) were inoculated into 50 mL of half strength MB media and grown in a 
rotatory shaker at 200 rpm at a temperature of 30°C until the OD 620 reached approximately 
0.6. The bacterial cultures were then chilled on ice for 20 minutes and centrifuged at 4,000 x 
g for 10 minutes at 4ºC. The supernatants were removed and 40 mL of ice-cold 10% glycerol 
(v/v) added. The bacterial suspensions were vortexed and then centrifuged for 6 minutes at 
4,000 x g at 4ºC. The glycerol suspension and centrifugation steps were repeated twice. After 
the last centrifugation step, the supernatants were removed and the pellets re-suspended in 
200 μL ice-cold 10% glycerol (v/v) and aliquots of 40 μL were stored at -80ºC. 
2.3.5. Transformation of R. pomeroyi by electroporation 
 A 1 μL aliquot containing 100 ηg DNA of the pBAD-KO-lysdh-aasadh plasmid was 
added to 40 μL glycerol suspension of electrocompetent bacteria and incubated on ice for 5 
minutes. The suspension was then transferred to an electroporation cuvette and 
electroporated by applying a single pulse of 25μF at 200Ω using a GenePulser (BioRad 
Laboratories; Richmond, CA, USA). Independent experiments were carried out to identify 
optimal conditions for bacterial transformation by varying voltages at 12, 16, 20 and 25 
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kV/cm. Immediately after electroporation, the bacterial suspension was diluted with 2 mL of 
half-strength MB and incubated overnight with rotation at 200 rpm and a temperature of 
30ºC. The electroporated bacterial suspension (100μL) was plated onto solid half-strength 
MB containing 50 μg/mL kanamycin. Colonies formed after 2 days of incubation were 
picked and grown in 2mL of half-strength MB containing 50 ug/mL of kanamycin or 
ampicilin. Colonies which grew in MB medium containing kanamycin and not ampicilin 
were selected. These colonies had the kanR cassette successfully integrated into the 
bacterium genome while the plasmid pBAD-KO-lysdh-aasadh containing the ampicillin 
resistance cassette was eliminated. 
2.3.6. Confirmation of lysdh-aasadh KO 
 Genomic DNA was extracted from positive colonies and used for PCR amplification 
of the lysdh-aasadh region. The PCR amplification should produce amplicons of 2,600 bp 
and 3,100 bp for WT and KO strains, respectively. Another primer pair was used to amplify 
the region flanking the kanR cassette insertion, which should produce amplicons of 1,150 bp 
for the WT and 1,600 bp for the KO forms of R. pomeroyi. The KO was also checked for 
production of the AASADH protein by immunoblot analysis using the ALDH7A1 (506-520) 
antibody (SIGMA) raised against the human homolog of AASADH. 
2.3.7. Immunoblot analysis 
 Total proteins were extracted from 10 mL of WT and KO cultures grown in half 
strength MB to an OD620 of approximately 0.6. Cells were pelleted by centrifugation, 
suspended in ice-cold extraction buffer (25 mM sodium phosphate pH 7.4, 1 mM DTT, 1 
mM EDTA and 5 mMbenzamidine) and sonicated for 3 minutes with a 10 second on off 
cycle at 30% potency. The extracts were centrifuged at 20,000 x g for 10 minutes and the 
supernatants collected. Protein extracts were quantified using the Bradford assay and 60 μg 
of WT and KO proteins were separated by electrophoresis on 12% sodium dodecyl sulphate 
polyacrylamide (SDS-PAGE) gels. The proteins were transferred electrophoretically to 
Hybond C membranes (GE Healthcare; Pittsburgh, PA, USA) using a cell transfer Semi-Dry 
Trans Blot SD (Bio-Rad). The membranes were blocked overnight with a 5% solution of 
low-fat milk in TBS-T (50 mΜTris-HCl, 137 mΜ NaCl, 2.7 mΜ KCl, 0.1% Tween 20, pH 
7.6). The membranes were then rinsed with 20 mL TBS-T and incubated for 2 hours at 8°C 
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with the respective AASADH antibodies diluted 1:1000 in TBS-T. Following this, the 
membranes were washed 3 times for 5 minutes with 20 mL TBS-T and then incubated for 2 
hours at 8°C with ALDH7A1 antibody diluted 1:5,000 in TBS-T. The membranes were 
washed 3 times for 5 minutes, developed with Super Signal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Waltham, MA, USA) and immunoreactive protein bands were 
imaged using Kodak BioMax MR film. The same procedure was performed with pre-immune 
serum to verify antibody specificity. 
2.3.8. Osmotic stress treatment and metabolite extraction 
 Overnight WT and KO cultures (100 μL) were inoculated into 2 mL of MB medium 
containing 200 to 800 mM NaCl. In another experiment, 100 μL of the WT or KO overnight 
cultures were inoculated into 2 mL of 25% MB medium containing 200 mM NaCl plus or 
minus 5 mM lysine. The growth rates for WT and KO bacterial lines were measured by 
following the OD620. 
 For metabolite extraction, WT and KO bacterial lines were grown for 20 hours in 
25% MB plus or minus 5 mM lysine. Bacterial cultures were centrifuged at 4,000 x g for 5 
minutes and the pellets washed twice with GTE buffer (50 mM glucose, 25 mM Tris-HCl, 
10 mM EDTA, pH 8.0). Methanol (100 μL) and chloroform (50 μL) were added to the pellets 
and the samples were vortexed vigorously. Cells were then lysed by three cycles of 3 minutes 
freezing on dry ice followed by 40 seconds thawing at 37ºC. Then, 75 μL chloroform and 75 
μL ddH2O were added and the lysates vortexed and centrifuged at 25,000 x g at 4ºC for 20 
minutes. The supernatants containing the polar metabolites were collected and diluted 5x 
with double deionized (dd) H2O containing 0.1% formic acid and used for metabolite 
analysis. 
2.3.9. Analysis of lysine catabolism metabolites by tandem liquid chromatography mass 
spectrometry (LC-MS/MS) 
 The chromatographic system consisted of an Agilent 1260 series HPLC with a binary 
gradient pump. For the analytical separation, a Phenomenex Luna PFP (2) 4.6 x 250.0 mm 
column with 5.0 µm particles (Alchrom; São Paulo, Brazil) was used. A 10 μL aliquot of 
metabolite extract was injected into the column and analytes were eluted at a flow rate of 0.8 
mL/min at 30οC with solvent (0.1% formic acid in ddH2O and solvent B, (100% Acetonitrile, 
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ACN). The A/B solvent gradient started with 2% solvent B for 1.3 minutes, followed by a 
linear increase to 60% solvent B for 6 minutes, then an increase to 100% B in 1 minute and 
maintenance at this concentration for an additional 2 minutes, followed by a return to the 
initial conditions. 
 The analytes were measured using an ABSciex 5,500 Qtrap mass spectrometer 
coupled with a TurboV source (Concord; Ontario, Canada). Analytes were detected using an 
electrospray ionization in the positive ion mode set at 5.5 kV with a curtain gas of 30 psi, 
collision gas of 9 psi, temperature of 650οC, nebulizer gas of 70 psi and desolvation gas of 
70 psi.  For instrument tuning, the analytes were diluted with water containing 0.1% formic 
acid and methanol (1:1, v/v) to a final 50 ng/mL concentration. The analytes were directly 
infused into the ion source using a Harvard syringe at a flow rate of 10 µL/min. Multiple 
Reaction Monitoring (MRM) tuning was carried out to optimize fragmentation conditions 
and identify the best precursor/product transitions for detection (Supplemental Table 1). Both 
instrument and ionization source were optimized via automatic settings available in the 
software Analyst version 1.6.2. The heights of the detected peaks were analysed using the 
algorithm MQ4 from the software MultiQuant 3.0. Peak height values of the analytes were 
normalized using those of internal standards added to the extracts at a concentration of 20 
ng/mL and these were normalized to the OD620 of the bacterial suspension used for 
metabolite extraction. Fold changes in metabolite levels for the KO were estimated using the 
WT value of 1.0 in the absence of lysine. Intra- and inter-day precision values were evaluated 
at low, median and high levels (18.8, 37.5 and 75 ng/mL, respectively) of the standard 
samples. Five replicates in each level were run. One-way ANOVA (Excel 2010) was used to 
determine method precision. 
2.3.10. Alignment and clustering of aldehyde dehydrogenase amino acid sequences 
 The amino acid sequences of R. pomeroyi DSS-3, human and seabrem Arabidopsis 
thaliana and Streptomyces clavuligerus AASADHs (NCBI Gene Identifiers: 56695157, 
118138656, 15221042, 3328165, 188036012) were used as queries in blastp searches against 
the annotated protein sequences of R. Pomeroyi DSS-3 using an e-value of 1e-05. The blast 
search returned 21 distinct hits that were aligned and clustered to the query sequences using 
MEGA 6 (Tamura et al., 2013). 
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2.4. Results 
2.4.1. Generation of R. pomeroyi DSS-3 double KO for lysdh and aasadh 
 R. pomeroyi DSS-3 was successfully transformed with the pBAD-KO-lysdh-aasadh 
plasmid (Fig. 2A) using an electroporation procedure adapted from the methodology 
described by Sebastian et al. (2009) and Green et al. (2012). The efficiency of transformation 
was positively correlated with the pulse strength and a maximum number of transformed 
colonies was achieved at 25 kV/cm (Supplemental Fig. S1). For routine transformation, we 
used 20 kV/cm. Individual colonies appeared after 2 days grown at 30oC on agar plates 
containing MB plus 50 μg/L kanamycin. For validation of the double KO, genomic DNA 
was extracted from kanamycin resistant colonies and used as template for PCR amplification 
of a DNA fragment spanning the lysdh-aasadh region. The primers used for cloning the genes 
produced amplicons of 2,600 bp for WT and 3,100bp for the double KO (Fig. 3A and B). 
PCR amplification using the primers flanking the kanR insertion cassette produced 
amplicons of 1,150 bp for WT and 1,600 bp for the double KO (Fig. 3C). To further validate 
KO of the aasadh gene, protein extracts prepared from WT and KO bacteria were separated 
on 12% SDS-PAGE gels and immunoblotted with the anti-human ALDH7A1 antibody. A 
55 kDa band corresponding to the AASADH protein was detected only in extracts prepared 
from the WT colonies (Fig. 3D). Thus, analysis of genomic DNA and protein expression 
confirmed that homologous recombination introduced the kanR cassette in the R. pomeroyi 
DSS-3 genome, leading to disruption of both lysdh and aasadh genes (Figs.2 and 3). 
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Figure 2: Strategy to produce a knockout (KO) for the lysdh-aasadh operon in R. pomeroyi. 
(A) The KO plasmid pBAD-KO-LysDH-AASADH shows the kanamycin resistant (kanR) 
cassette for disruption of the contiguous lysd-aasadh coding regions. (B) Circular 
chromosome representation of R. Pomeroyi DSS-3 showing the genomic location of lkr, sdh, 
lysdh and aasadh genes as shown in Neshich et al., 2013. (C) Predicted structure of the 
circular chromosome of the R. pomeroyi double KO. 
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Figure 3: Validation of R. pomeroyi lysdh-aasad double KO. (A) Fragments illustrated as 
PCR1 and PCR2 were amplified from WT and putative KO genomic DNAs. (B) For PCR1, 
the expected fragments of 1.1 Kb and 1.6 Kb are shown for the WT and KO, respectively. (C) 
For PCR2, the expected amplicons of 2.6 Kb and 3.1 Kb are shown for the WT and KO, 
respectively. (D). For both PCR1 and PCR2, the plasmids pBAD-LysDH-AASADH and 
pBAD-KO-LysDH-AASADH were included as controls. (D) WT and KO bacterial protein 
extracts were subjected to immunoblot analysis with human AASADH antibodies to confirm 
the absence of AASAD in the double KO. 
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2.4.2. The double KO for lysdh and aasadh genes reduces bacterial growth performance 
under salt stress 
 Growth of the R. pomeroyi DSS-3 lines in 12.5%MB showed that the WT performed 
better than the KO line in the presence of increasing NaCl concentrations (Fig. 4). However, 
when medium was supplemented with 5 mM lysine, the WT exhibited increased growth 
compared with the KO line (Fig. 5A). In the presence of 5 mM lysine, WT bacteria displayed 
an extended growth exponential phase and achieved a higher plateau as compared with the 
growth in the absence of lysine, whereas the KO line showed no lysine response (Fig. 5A). 
The beneficial effect of lysine on the WT line growth rate can be attributed to the presence 
of functional LysDH and AASADH enzymes, since the growth rate of the KO line did not 
differ in the presence or absence of 5 mM lysine and remained similar to that seen in the WT 
line grown in the absence of lysine (Fig. 5A). This is consistent with our previous results on 
the role of lysine catabolism on growth performance of R. pomeroyi DSS-3 (Neshich et al., 
2013). 
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Figure 4: R. pomeroyi WT and double KO growth curves in MB medium containing 
increasing (A to D) NaCl concentrations. 
 
2.4.3. Metabolite analysis indicates a switch to the saccharopine pathway in the lysdh and 
aasadh double KO 
 We tested whether KO bacteria grown in the presence of 5 mM lysine activates the 
saccharopine pathway, the less active lysine catabolic pathway in R. pomeroyi DSS-33 
(Neshich et al., 2013). WT and KO bacterial lines were grown in 12.5% MB for 20 hours in 
the presence or absence of 5 mM lysine and cells were then pelleted and used for preparation 
of metabolite extracts for LC-MS/MS analysis. This showed that supplementation with 5mM 
lysine resulted in an 11-fold increase in accumulation of intracellular saccharopine in the KO 
bacteria, compared to growth in the absence of lysine. Saccharopine was observed at only 
low levels in WT bacteria grown in the presence of lysine (Fig. 5B). 
 AASA, the lysine oxidation product, exists in spontaneous equilibrium with its cyclic 
form P6C (Mills et al., 2006) (Fig. 1). P6C can be used as substrate to synthesize pipecolic 
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acid (PIP) in a reaction catalyzed by the enzyme pyrroline-5-carboxylic reductase (P5CR) 
(Struys & Jakobs, 2010) (Fig. 1). The metabolite analysis carried out here showed that the 
P6C levels were markedly low, with a signal close to noise signal in all treatments (data not 
shown). The levels of PIP in WT bacteria grown with or without lysine, and in KO bacteria 
grown without lysine, were also low but in the presence of 5 mM lysine, KO showed a 17-
fold increase in PIP accumulation compared with KO bacteria grown in the absence of lysine 
(Fig. 5C). We then tested whether the absence of a functional AASADH enzyme in double 
KO bacteria would prevent synthesis of AAA from the AASA produced through the 
saccharopine pathway (Fig. 1). Surprisingly, a peak with MRM transitions of 162→98 and 
162→55, which had the same mass and retention time of the AAA standard, was observed in 
KO bacteria grown in MB medium supplemented with 5 mM lysine and this was 
approximately 2-fold higher compared to KO bacteria grown in the absence of lysine (Fig. 
5D).  
 Glutamic acid (Glu) is produced from saccharopine hydrolysis through catalysis by 
SDH (Fig. 1). The levels of Glu in KO bacteria grown in the presence of lysine were similar 
to that of WT grown without lysine (Fig. 5E). However, Glu levels were significantly lower 
in the WT grown in the presence of lysine and in KO bacteria grown in absence of the amino 
acid (Fig. 5E). Analysis of the levels of pyridoxal-5-phosphate (PLP) in the WT and KO 
showed that this was 3-fold lower in KO bacteria grown in the presence of 5 mM lysine, 
compared to growing these bacteria without lysine (Fig. 5F). PLP levels were also reduced 
in the WT grown in the presence of lysine but this effect was not as pronounced as that 
observed in KO bacteria (Fig. 5F). 
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Figure 5: Effect of lysine on WT and KO R. Pomeroyi and quantitation of metabolites. (A) 
WT and KO bacteria were grown in 12.5% MB containing 200 mM NaCl with or without 
5mM L-lysine. (B) The intracellular metabolite content was profiled by LC-MS/MS, targeting 
(B) saccharopine, (C) L-pipecolic acid, (D) L-2-aminoadipic acid, (E) L-glutamic acid and 
(F) pyridoxal-5-phosphate (F). Asterisks indicate statistically significant differences 
(p<0.05) based on T-test of KO when compared with WT or incubation in MB without lysine. 
2.5. Discussion 
 In this work we describe a methodology for genomic knockout in R. Pomeroyi DSS-
3 as a model to study lysine catabolism. Metabolites of lysine play a significant role in 
osmotic stress adaptation in R. pomeroyi (Neshich et al., 2013). KO of the lysdh and aasadh 
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genes led to the loss of growth advantage when these bacteria were incubated in MB medium 
supplemented with lysine, which reinforces the importance of lysine catabolism in R. 
pomeroyi growth. The finding of low levels of saccharopine in WT bacterium grown in MB 
medium supplemented with lysine further supports the hypothesis that LysDH is the 
preferred pathway for lysine catabolism in R. pomeroyi as this enzyme directly converts 
lysine to AASA (Neshich et al., 2013). In the absence of the preferred LysDH pathway, 
bacteria can quickly adapt and switch to use of the saccharopine pathway for lysine 
degradation, as shown by accumulation of high levels of saccharopine in the KO bacteria. 
However, the switch to the saccharopine pathway did not benefit bacterial growth 
performance in lysine supplemented MB media (Fig. 5B). Taken together, these findings 
suggest that the growth advantage of WT bacterium in MB medium supplemented with lysine 
could be due to the detoxification role of AASADH and also production of acetyl-CoA at the 
final stage of the degradation process. 
 The use of a KO for lysdh gene provides evidence for functional LysDH and 
saccharopine pathways in R. pomeroyi. In the absence of LysDH and AASADH, and in the 
presence of 5 mM lysine, there was an over accumulation of saccharopine and PIP as the 
result of LKR, SDH and P5CR activities. The over accumulation of PIP observed in the KO 
bacteria was most likely a result of the absence of AASADH enzyme and the consequent 
accumulation of AASA, and its cyclic form P6C, that served as substrates for P5CR. 
 It has been suggested that AASADH is the sole enzyme that converts AASA/P6C to 
AAA in animals (Mills, et al., 2006). However, the current finding that KO bacteria grown 
in the presence of lysine showed a small but significant increase of AAA compared to 
bacteria grown in the absence of lysine suggests that there might be other aldehyde 
dehydrogenases in R. pomeroyi capable of using AASA as a low affinity/alternative substrate 
to produce AAA. Therefore, we attempted to identify other aldehyde dehydrogenase 
candidates that could fulfill this role by performing a Blastp search using AASADH amino 
acid sequences as driver. This revealed that the R. pomeroyi genome encodes 21 aldehyde 
dehydrogenases, although clustering analysis placed only the product of the SPO0235 gene 
in the AASADH group with high confidence (Supplemental Fig. S2). The closest sequence 
to AASADHs was SPO3191 but this had only 31% identity to SPO0235 and was lacking 
residues important for AASA/P6C recognition, such as Glu-120 (Brocker, et al., 2010). 
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Therefore, further studies are required in R. pomeroyi in order to identify an aldehyde 
dehydrogenase capable of using AASA as substrate. 
 Another interesting finding was the 4-fold reduction in the levels of PLP in the KO 
bacteria grown in the presence of lysine as compared to the WT. Low PLP levels in humans 
are associated with pyridoxine dependent epilepsy (PDE) (Stockler, et al., 2011). PDE is 
caused by mutations in aldh7a1 gene that encodes the human AASADH. PDE patients have 
an accumulation of high levels of AASA/P6C in body fluids. The accumulated P6C can react 
with PLP possibly causing its depletion (Mills et al., 2006). In the KO bacteria, accumulation 
of AASA/P6C to high levels may result in their reaction with PLP and this may account for 
the reduced PLP levels observed in this mutant when grown in the presence of lysine. Taken 
together, the current findings indicate that the R. pomeroyi lysdh-aasadh double gene 
knockout may be a useful model for further studies of lysine degradation and stress responses. 
This may also help understanding diseases associated with lysine degradation pathways in 
human.  
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2.8. Supporting Information  
Supplemental Table 1: MS/MS conditions for analytes and internal standards used for 
Multiple Reaction Monitoring (MRM). Q1, precursor ion; Q3, fragment product ion; DP, 
dispersion potential; CE, collision energy; CXP, collision cell exit potential. 
 
 
 
Analyte Abbreviation Q1 Q3 DP CE CXP 
L-Glutamine Gln 147.1 130 41 13 8 
L-2-Aminoadipic acid  AAA 
162 98 46 21 14 
162 55 46 35 8 
DL-2-Aminoadipic-d3 acid  d3-AAA 165 101 56 21 16 
DL-Pipecolic-d9 acid d9-PIP 139.1 93.1 71 23 12 
∆-1-Piperideine-6-
carboxylate 
P6C 128 
82 101 17 10 
55 101 27 8 
L-Pipecolic Acid PIP 130 
84.1 51 21 12 
56 51 39 8 
Pyridoxal 5'-phosphate PLP 248.1 
150 66 21 10 
67 66 41 10 
L-Saccharopine SAC 277.1 
84 71 29 14 
1130 71 21 14 
L-Aspartic acid-13C4 C13-ASP 138 76 56 19 10 
L-Glutamic Acid GLU 
148 84.1 61 19 14 
148 56 61 37 8 
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Supplementary Figure 1: The higher the field strength, more colonies are efficiently 
transformed. 
 
Supplementary Figure 2: Neighbor-Joining tree created using the protein sequences of 
known AASADHs from R. pomeroyi DSS-3 (NCBI Gene Identifiers: 56695157, shown in 
blue), human, seabrem, Arabidopsis thaliana and Streptomyces clavuligerus (NCBI Gene 
Identifiers: 118138656, 15221042, 3328165 and 188036012) aligned to the 21 aldehyde 
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dehydeogenases found in the genome of R. pomeroyi. The branch of the tree that clusters 
together the AASADHs has a high bootstrap value of 99. The next closely related aldehyde 
dehydrogenase (SPO3191) is grouped with a low bootstrap value (38). 
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Chapter 3 - “Simultaneous detection of lysine metabolites by a single LC-
MS/MS method: monitoring the dynamics of lysine degradation in mouse 
plasma” 
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Eberlin2, Paulo Arruda1 
1Centro de Biologia Molecular e Engenharia Genética, Universidade Estadual de Campinas 
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3.1. Abstract 
Detection and quantification of lysine degradation metabolites in plasma is important for the 
diagnosis and follow-up of diseases such as pyridoxine dependent epilepsy (PDE). The main 
metabolites involved in the disease are related to the first steps of lysine oxidation, either 
through the saccharopine or the pipecolate pathways. Currently there are three different 
analytical methods used to assess the content of these metabolites in urine and plasma but 
they require different sample preparations and analytical equipment. Here, we describe a 
single protocol that calls for a simple sample preparation and uses liquid chromatography 
tandem mass spectrometry (LC-MS/MS) that allows simultaneous detection and 
quantification of underivatized L-saccharopine, L-aminoadipic acid, L-pipecolic acid, 
piperideine-6-carboxylate, L-glutamic acid, L-glutamine and free pyridoxal-5-phosphate in 
plasma samples. The levels obtained in the time zero point zero are consistent with basal 
levels seen in metabolome databases for mammalian plasma. To evaluate the robustness of 
the method we analyzed the degradation time course after intraperitoneal injection of 20 mg 
of L-lysine in C57BL/6/J mice. We observed that lysine was degraded through the 
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saccharopine pathway within the first 2 hours. This was seen as an increase in the levels of 
the metabolites saccharopine, aminoadipic acid and pipecolic acid by 3-, 24- and 3.4-fold, 
respectively, compared to initial levels. These metabolites returned to basal levels after 4-6 
hours. In conclusion, we have developed a novel LC-MS/MS approach which allows 
simultaneous analysis of lysine degradation metabolites without the need for derivatization. 
Finally, we suggest that future experiments investigating lysine metabolites should adopt the 
use of similar shorter time points to increase sensitivity of detection.  
 
 
Keywords: Lysine catabolism, Saccharopine, Amino acid, Mass spectrometry, Lysine 
metabolism 
 
3.2 Introduction 
Lysine oxidation in mammals is essential for regulating the free levels of this amino 
acid, for balance of nitrogen and conversion to ketone bodies. The saccharopine pathway is 
considered the main route for irreversible degradation of lysine in higher eukaryotes 
(Blemings et al. 1994). The first step of this pathway is catalysed by lysine-ketoglutarate 
reductase (LKR), which condenses lysine and α-ketoglutaric acid to form saccharopine 
(SAC) (Arruda et al. 2000). The next step is catalyzed by saccharopine dehydrogenase 
(SDH), which hydrolyses saccharopine into glutamic acid (GLU) and α-aminoadipic-δ-
semialdehyde (AASA) (Fig. 1). In animals and plants, the activities of LKR and SDH belong 
to distinct domains of a bifunctional polypeptide called aminoadipic semialdehyde synthase 
(AASS) that is encoded by the gene aass (Markovitz et al. 1984; Gonçalves-Butruile et al. 
1996; Papes et al. 1999). An additional pathway for lysine degradation exists in humans, the 
pipecolate pathways (Fig. 1) (Chang 1978; Hallen et al. 2013). The saccharopine and 
pipecolate pathways differ in the way lysine is oxidized and which nitrogen group is removed 
to form to AASA. In the pipecolate pathway lysine degradation occurs via α-deamination 
whereas in the saccharopine pathway the reaction involves an ε-deamination. In both cases 
lysine is deaminated and oxidized to produce AASA, which spontaneously cyclizes into 
piperideine-6-carboxylate (P6C). Both of these molecules function as substrates for the 
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enzyme aminoadipic semialdehyde dehydrogenase (AASADH), in a rapid reaction which 
gives rise to aminoadipic acid (AAA) (Fig 1). 
Metabolites derived from lysine oxidation have important implications in the 
pathophysiology of specific diseases such as pyridoxine dependent epilepsy (PDE). PDE is 
caused by a mutation in the aldh7a1 gene that abolishes the AASADH activity and patients 
accumulate high levels of AASA/ P6C and PIP (Mills et al. 2006). Although there is a general 
consensus that the saccharopine pathway plays a major role in lysine catabolism, especially 
in liver and kidney (Higashino et al. 1971; Blemings et al. 1994; Papes, et al., 2001), recent 
reports have suggested that this pathway is virtually absent in the brain (Sauer et al. 2011; 
Hallen et al. 2013; Posset et al. 2015). Instead, the pipecolate pathway may be predominant 
in cerebral tissues, suggesting that this could be the target of choice for development of new 
therapeutic interventions (Sauer et al. 2011; Hallen et al. 2013; Posset et al. 2015). Literature 
is contradictory in this point, with a recent article showing that AASS enzyme is active in the 
brain (Rzem, et al., 2015), with low but significant activity levels. The experiment from Rzem 
et al (2015) showing activity of LKR and SDH in mouse cerebral tissues was performed after 
24 hours of starvation, which is a condition known to induce activation of AASS enzyme. 
One point to consider is that  most of the experiments that suggested absense of saccharopine 
or AASS activity in cerebral tissues were performed in mice without lysine supplementation 
and/or after several hours following intraperitonial lysine injection (Sauer et al. 2011; Posset 
et al. 2015). If the kinetics of the saccharopine pathway are rapid and dependent on lysine 
levels and/or post-translational activation of LKR domain as has been hypothesized 
elsewhere (Carson et al. 1968), it is possible that AASS activity and therefore lysine 
degradation reaches a maximum over a shorter time interval following lysine injection/diet. 
The main tools that have been used to evaluate lysine degradation at the metabolome 
level are based on mass spectrometric platforms. Currently, the methods described which are 
capable of detecting and quantifying the relevant lysine metabolites are based on multiple 
sample processing protocols and several distinct equipments. Typically, pipecolic acid (PIP) 
is measured by gas chromatography mass spectrometry (GC-MS) following derivatization of 
the amine group with methyl chloroformate, acidic ethyl acetate extraction and further 
derivatization of the carboxyl group to produce the pentafluorobenzyl ester (Kok et al. 1987). 
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SAC, AASA and AAA are usually derivatized with fluorenylmethyloxycarbonyl (FMOC) 
chloride and analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS) 
performed in a triple quadrupole mass spectrometer (Mills, et al. 2006; Sadilkova et al. 2009). 
Alternatively, P6C can be detected and quantified without derivatization before LC-MS/MS 
analysis (Struys et al. 2012). Since AASA is in spontaneous equilibrium with P6C, the 
diagnostic power of measuring either one or the other is comparable (Struys et al. 2012). 
Here, we propose a new LC-MS/MS approach capable of detecting and quantifying all of 
these metabolites in a single method without derivatization. It was our primary interest to 
validate the method using a lysine-injected mouse model by monitoring the time course of 
lysine-derived metabolite levels in peripheral blood. 
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Figure 1 -Schematic representation of the lysine degradation pathways described for 
mammals. Lysine can be degraded via two pathways: one with L-pipecolic acid as an 
intermediate that is believed to operate mostly in brain starts with oxidative deamination of 
the alpha nitrogen of lysine. The other pathway that has been demonstrated in other organs 
proceeds via deamination of the epsilon nitrogen of lysine by condensation with a-
ketoglutarate to form saccharopine as an intermediate. The enzyme AASS possess two 
domains, LKR and SDH, which act independently as two separate enzymes catalysing the 
first two steps for the saccharopine pathway. AASADH activity is absent in PDE patients. 
GCDH activity is absent in glutaric aciduria type 1 patients. 
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3.3. Materials and Methods 
3.3.1 Chemicals and reagents 
Acetonitrile (ACN) was purchased from J.T. Baker (São Paulo, Brazil). Formic acid 
was obtained from Sigma-Aldrich (São Paulo, Brazil). All solvents used were high 
performance liquid chromatography (HPLC) grade. Mili-Q water was obtained from a Milli-
Q purification system (Millipore, São Paulo, Brazil). All chemicals and reagents were of the 
highest purity and stored at appropriate temperatures and conditions. The standards 
compounds AAA, SAC, PIP, GLU, L-aspartic acid (ASP), L-glutamine (GLN) and 
pyridoxal-5-phosphate (PLP) were obtained from Sigma-Aldrich (St Louis, MO, USA). 
AASA/P6C was prepared from allysine ethylene acetal as described (Mills, et al., 2006). The 
internal standards used were the deuterated compounds d3-aminoadipic acid and d9-
pipecolic acid, purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada) and 13C4-ASP 
was purchased from Sigma-Aldrich (St Louis, USA). Stock solutions of 1 mg/mL were 
prepared for each standard according to manufacturers' instructions. Standard solutions were 
stored at -80o. 
3.3.2 Analysis of lysine degradation metabolites by LC-MS/MS 
3.3.2.1 High-performance liquid chromatography (HPLC) 
The chromatographic system consisted of an Agilent 1260 series HPLC with a binary 
gradient pump. For the analytical separation, a Phenomenex Luna PFP (2) 4.6 x 250.0 mm 
column with 5.0 µm particles (Alchrom, São Paulo, Brazil) was used. Extracts (10 µL) were 
injected into the column and the analytes eluted at a flow rate of 0.8 mL/minute at 30οC with 
solvent A (0.1% formic acid in ddH2O) and solvent B (100% acetonitrile, ACN). The solvent 
gradient started with 2% solvent B (98% solvent A) for 1.3 minutes, followed by a linear 
increase to 60% B for 7 minutes, then to 100% B in 1 minute and maintained at this 
concentration for an additional 2 minutes followed by return to the initial conditions. The 
total run time was 15 minutes. 
3.3.2.2 Mass spectrometry 
The analytes were quantified using an ABSciex 5500 Qtrap mass spectrometer 
coupled with TurboV source (Concord, Ontario, Canada). Analytes were detected using an 
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electrospray ionization detector in positive ion mode set at ion spray voltage of 5.5 kV, 
curtain gas of 30 psi, collision gas of 9 eV, temperature of 650οC, nebulizer gas of 70 psi and 
desolvation gas of 70 psi. For instrument tuning, the analytes were diluted with water 
containing 0.1% formic acid and acetonitrile (1:1, v/v) to a final concentration of 50 ng/mL. 
Analytes were directly infused into the ion source using a Harvard syringe at a flow rate of 
10 µL/minute. Multiple reaction monitoring (MRM) tuning was carried out to optimize 
fragmentation conditions and identify the best precursor/product transitions for quantitation 
and confirmation (Supplemental Table 1). To increase sensitivity, scheduled MRM was used 
with the source parameters tuned using flow injection analysis. Both instrument and source 
were optimized via the automatic program, available in the software Analyst version 1.6.2. 
The areas of the detected peaks were integrated using the algorithm MQ4 from the software 
MultiQuant 3.0.1. The peak areas of the analytes were normalized using those of the 
corresponding internal standards (added to extracts at final working concentrations of 20 
ng/mL). 
3.3.2.3 Analytical curves 
 Calibration curves of each lysine catabolism metabolite were prepared by serial 
dilutions of stock solutions to achieve the following final concentrations: 300, 150, 75, 37.5, 
18.75, 9.38, 4.69, 2.34 and 1.17 ng/mL (corresponding to ~2μM to ~7mM) and 20 ng/mL of 
each internal standard (as above). An artificial plasma solution (Vella et al. 2012) containing 
10% bovine serum albumin (BSA) was use as a surrogate matrix and this was processed as 
the plasma extraction protocol by diluting three times in ACN, vigorously vortexing and 
centrifuging at 20,000 x g for 15 minutes at 4°C. This ACN extract was diluted 10 times in 
ddH2O containing 0.1% formic acid and spiked in with serial dilutions of all analytes of 
interest. 
3.3.3 Animals and sampling 
Five week old C57BL/6/J female mice were obtained from the Multidisciplinary 
Center for Biological Investigation on Laboratory Animal Sciences (CEMIB) of the 
University of Campinas. Experiments were approved by the Ethics Committee of UNICAMP 
under the protocol number 3625-1. Animals were fasted overnight and then injected 
intraperitoneally (IP) with 20 mg of lysine diluted in phosphate buffered saline (PBS) or with 
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a solution of 10 mg of pyridoxine hydrochloride in PBS or PBS only as control. Five animals 
were used per experimental group. For the time-course experiment, approximately 50 μL of 
peripheral blood was collected by retro-orbital bleeding into EDTA containing tubes. 
3.3.4 Metabolite extraction from mouse plasma 
Blood was centrifuged at 1,500 g for 10 minutes and a fixed volume of 20 μL of 
plasma was sampled for metabolite extraction. Proteins were precipitated and metabolites 
extracted using ACN (2:3) as described in the section 3.3.2.3. The supernatants containing 
the polar metabolites were collected and used either immediately for LC-MS/MS or stored 
at -80°C prior to analysis. 
3.3.5 Method validation 
The LC-MS/MS method was validated according to food and drug administration 
(FDA) protocols as discussed below. 
3.3.5.1 Linearity 
Calibrations were performed using standards prepared as described in Section 3.3.1 
and 3.3.2.3. Six analytical curves were used to obtain the linear equation (y = mx + c) as well 
as the coefficient of determination (R2). 
3.3.5.2 Detection and quantification limits 
The limit of detection (LOD) and of quantification (LOQ) were defined as the 
minimum concentration where the signal was at least 3 times and 10 times greater than the 
average background noise at the retention time of each analyte, respectively. 
3.3.5.3 Precision and reproducibility 
The intra- and inter-day precisions were evaluated at low, median and high levels. 
Five replicates were run at each level. Assay reproducibility was accessed by analyzing three 
data points in the nanomolar range (18.8, 37.5 and 75 ng/mL) (see Table S2) in triplicate on 
two different days. The relative standard deviation (% RSD) was calculated at each point. 
3.3.5.4 Run stability  
 Stability at the run time was determined by injecting three concentrations in triplicate, 
directly after sample preparation and after a 12 hour overnight experiment. The samples were 
kept at 10ο C in the auto-sampler. 
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3.4. Results and Discussions 
3.4.1 LC-MS/MS method development and validation 
The LC method was developed so as to be capable of retaining all polar analytes on 
the column without the need of derivatization. Good retention and separation was obtained 
using the PFP(2) Luna column, composed of pentaflourophenyl groups that can interact with 
aromatic and polar amino acids. GLN was included to optimize the chromatographic 
separation in the hope to avoid interference with the GLU signal. ACN was chosen as the 
solvent that gave best selectivity and peak shapes (Fig. 2). The use of stable isotope-labelled 
metabolites as internal standards for PIP and AAA was meant to correct any drift in 
instrument performance and ion suppression effects. 
Figure 2: Chromatrograms showing the detection of all the analytes at 37 ng/ml.  
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The method was validated by analyzing calibration standards in sextuplicate for each 
unlabeled molecule to determine linear dynamic range, R2, retention time, LOD, and LOQ 
(Table 1). LODs ranged from to 0.3 to 3.7 ng/mL and LOQs ranged from 0.9 to 9.0 ng/mL 
for GLU and PLP, respectively. We found high R2 values for all curves (> 0.99, Supplemental 
Fig. 1) showing excellent correlation between signal intensity and actual analyte 
concentrations. These analytical curves were used to estimate the concentration of each 
analyte in plasma extracts. Table 2 shows the repeatability and intermediate precision 
(%RSD), and accuracy for all analytes studied. The lowest %RSD value was 2.6% for PIP 
(medium concentration) and the highest %RSD was 15.1% for GLN (low concentrations). 
Percent RSD values are in accordance with the accepted values (Boulanger et al. 2005). 
Accuracy varied from 99.3% for P6C (low concentration) to 104.5% for PLP (low 
concentration). These data show that the LC-MS/MS method is capable of delivering high 
confidence results. Statistical analysis using one-way ANOVA showed that there were no 
significant differences between days in which experiments were performed. Molecules were 
stable for 12 hours in the auto-sampler at 10°C. 
 
Table 1:  LC-MS/MS method validation parameters 
Metabolite 
Linear 
dynamic range 
(ng mL-1) 
Linear equation R2 
Retenti
on time 
(min) 
LOD         
(ng mL-1) 
LOQ            
(ng mL-1) 
L-Aminoadipic acid 1.17 - 300 y= 0.09111x + 0.01669 0.995 2.4 0.3 1.0 
L-saccharopine 9.3 -300 y= 0.02147x + 0.00424 0.995 2.1 2.1 7.0 
L-Pipecolic acid 1.17- 300 y= 0.03658x + 0.00081 0.999 2.9 0.3 1.0 
L-Glutamic acid 1.17-300 y= 0.07887x + 0.05449 0.995 2.2 0.3 0.9 
L-Glutamine 1.17-300 y= 0.06593x + 0.01567 0.991 2.1 0.4 1.1 
Pyridoxal phosphate 9.3-300 y= 0.00107x + 0.00200 0.996 4.8 3.7 9.0 
Piperideine-6-
carboxylic acid 
1.17- 300 y= 0.02032x + 0.00532 0.998 2.4 0.8 2.5 
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Table 2: Method performance as measured in two consecutive days with three different 
concentrations of metabolites (Low, Medium and High). The results were obtained using 
MultiQuant 3.0.1 software (ABSciex). 
Metabolite 
 %RSD (n=10)  Accuracy (n=10) 
 Low 
 
Medium 
 
High 
 
 Low Medium High 
L-Amino adipic acid  11.7 12.4 10.5  99.9 99.9 100.0 
L-saccharopine  13.1 12.7 12.3  99.8 99.7 99.8 
L-Pipecolic acid  5.1 2.6 5.7  100.0 100.1 100.0 
L-Glutamic acid  8.6 8.3 7.1  100.0 99.9 99.9 
L-Glutamine  15.1 11.7 8.8  99.9 99.7 99.9 
Pyridoxal phosphate  8.4 7.1 6.4  104.0 100.0 100.1 
Piperideine-6-carboxylic acid  5.6 7.8 7.9  99.3 100.6 99.9 
 
 
3.4.2 Time-course analysis of lysine metabolites in mouse plasma  
We performed a time-course experiment using 5 week old C57BL/6/J mice, with 5 
animals used per experiment. A PBS solution containing 20 mg of L-lysine, pH 7, was IP 
injected into each animal and small aliquots of venous blood were taken at one hour intervals 
for 6 hours. Samples were processed for metabolite extraction from plasma and analyzed 
using the developed LC-MS/MS method. 
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Figure 3 - Time-course analysis of lysine metabolites in mouse plasma after IP injection of 
20 mg lysine. Fc means Fold Change as compared to concentration obtained in the 0h time. 
Asterisk represents statistic difference compared to 0h concentration with p<0.05 from T 
Test.  
 The main metabolite of lysine degradation detected was AAA, which reached a peak 
of approximately 70 μM in the plasma one hour after IP lysine injection (Fig. 3A). This value 
represents a 24-fold increase compared to the basal values seen in mice injected with PBS. 
The basal levels of AAA at 0 hours time point was approximately 3 μM, which is similar to 
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basal 4μM AAA concentrations found in normal mouse plasma, as reported in the mouse 
multiple tissue metabolome database (MMMDB) (Sugimoto et al. 2012). This value is also 
similar to that reported in the human metabolome database (HMDB 2.0) (Wishart et al. 2013; 
Vallat et al. 1996). These results show that lysine is rapidly oxidized to AAA reaching a 
maximum within the first two hours after lysine administration. Four to six hours following 
IP lysine injection, AAA returned to concentrations that were not statistically significant 
different from baseline levels (P=X and Y, respectively).  
The levels of SAC and PIP (Figs. 3B and 3C, respectively) followed the same pattern 
of AAA with increased levels within the first two hours after IP lysine injection although the 
concentrations and fold changes reached were lower than that of AAA. The basal levels of 
SAC are not listed in the MMMDB or HMDB and thus we could not compare these to the 
present values. The basal levels of PIP found in the MMMDB (~4.6 μM) (Sugimoto et al. 
2012) and the HMDB [(~3.5 μM) (Baas et al. 2002) and 3.75 – 10.8 μM (Kok, et al., 1987)] 
were similar to the PIP 4.9 μM basal plasma values found in this study. 
The P6C levels showed a tendency to follow the pattern observed for these three 
metabolites but the increased signal detected at the two hour time point was not statistically 
significant (Fig. 3D). The basal levels found in mouse plasma ranged from 0.1 to 0.38 μM, 
similar to the expected basal levels in human plasma (Sadilkova et al. 2009). 
These findings suggest that the AASADH enzyme rapidly convert P6C and only the 
reaction product AAA is detected. It is also possible that the downstream stages of lysine 
degradation are slower than the initial steps favoring the accumulation of AAA in the blood 
within the first two hours. Taken together, these results suggest that experiments aiming to 
investigate lysine metabolism in vivo should be performed within the first two hours after IP 
lysine administration for optimum signal detection and quantification. Therefore, the 
reported results obtained using longer time points for tracking and detection of lysine 
metabolites may not reflect the best signal and reaction dynamics of the saccharopine 
pathway (Posset et al. 2015). 
We also measured GLU in this study (Fig. 3E) as it is a direct product of saccharopine 
pathway. GLU is produced as a transamination reaction product in wich the ε nitrogen of 
lysine is transferred to α-ketoglutarate during the saccharopine hydrolysis performed by the 
 90 
 
SDH enzyme. It may be expected that GLU levels would increase after IP lysine injection, 
but this was not observed in the current study, indicating that the fraction of GLU derived 
from LYS is very small. In addition, GLN levels remained high and no significant change 
was observed during the time-course analysis (Fig. 3F). The observed average basal levels 
of GLU (~55 μM) and GLN (~610 μM) were also within the basal concentration ranges 
observed in the MMMDB (GLU ~25 μM, GLN ~400 μM) and the HMDB (GLU ~20-100 
μM, GLN ~490-650 μM). 
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Figure 4 - Time-course analysis of pyridoxal-5’ phosphate after IP injection of 10 mg 
pyridoxine hydrochloride. 
Absorption of vitamin B6 occurs mainly in the form of pyridoxine, pyridoxal and 
pyridoxamine and then these compounds are converted by the enzyme pyridoxal kinase into 
5’-phosphate derivatives in the liver. Pyridoxamine-5-phosphate and pyridoxine-5-
phosphate are then converted to PLP by the enzyme pyridoxamine phosphate oxidase 
(PNPO) (Mills et al. 2011). We also tested IP injection of pyridoxine hydrochloride into mice 
to determine if increased levels of free PLP are seen at the same time that AAA is produced 
from lysine catabolism. If this indeed occurs, it may be suggested that the accumulating P6C 
in PDE may react with PLP immediately after the dietary intake of lysine and pyridoxine. 
Although it is well known that most of PLP is found bound to Albumin, we could measure 
its small free proportion. The levels of free PLP detected during the time-course experiment 
(Fig. 4) showed that this metabolite was also increased during the first hour after injection, 
similar to the observed pattern for lysine degradation metabolites. 
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3.5. Conclusions 
We developed a single LC-MS/MS method capable of simultaneous detection of the 
relevant metabolites of lysine catabolism via aminoadipate with high sensitivity, precision 
and accuracy. Other reported methods normally require three distinct approaches to detect 
these analytes: GC-MS for pipecolic acid, LC-MS/MS without derivatization for P6C 
detection, and finally LC-MS/MS with derivatization for AASA, SAC and AAA.  Our 
method did not detect AASA but since this compound is in equilibrium with its cyclic form 
P6C, the detection of the latter can be used as a surrogate marker to follow lysine catabolism 
(Struys et al. 2012). The quantifications from mouse plasma at baseline were consistent with 
the basal plasma values listed in the MMMDB and HMDB. Time-course experiments for the 
detection of lysine degradation metabolites in mouse blood indicate that lysine degradation 
to AAA is a fast process, with a maximum occurring within the first and second hours after 
IP lysine injection. Therefore, we suggest that future experiments investigating lysine 
catabolism should adopt shorter time points as at longer time points (from 4-6 hours) most 
of the metabolites tested in this study had returned to basal levels. Our finding of an increased 
peak for free PLP one hour after injection of pyridoxine may indicate that the synthesis of 
PLP and degradation of lysine are roughly simultaneous processes. This may be important 
since accumulated P6C may react with PLP just after dietary intake of lysine and pyridoxine 
in PDE patients. Finally, we suggest that the method developed here which allows 
simultaneous analysis of lysine degradation metabolites would be useful in investigations of 
diseases such as PDE, in which this pathway is perturbed. Obtaining multiplex data from a 
single experimental run increases accuracy of cross-comparisons. 
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3.7. Supporting Information  
Supplemental Table 1: MS/MS conditions for analytes and internal standards used for 
Multiple Reaction Monitoring (MRM). This was the method used for quantitation of 
metabolites. Q1, precursor ion; Q3, fragment product ion; DP, dispersion potential; CE, 
collision energy; CXP, collision cell exit potential. 
Analyte Abbreviation Q1 Q3 DP CE CXP 
Retention 
Time (min) 
L-Glutamine Gln 
147.1 130 41 13 8 
2,1 
147.1 84 46 21 14 
L-2-Aminoadipic acid  AAA 
162 98 46 21 14 
2,37 
162 55 46 35 8 
DL-2-Aminoadipic-d3 acid  d3-AAA 165 101 56 21 16 2,37 
DL-Pipecolic-d9 acid d9-PIP 139.1 93.1 71 23 12 2,85 
∆-1-Piperideine-6-carboxylate P6C 128 
82 101 17 10 2,39 
55 101 27 8 2,39 
L-Pipecolic Acid PIP 130 
84.1 51 21 12 
2,87 
56 51 39 8 
Pyridoxal 5'-phosphate PLP 248.1 
150 66 21 10 
4,85 
67 66 41 10 
L-Saccharopine SAC 277.1 
84 71 29 14 
2,08 
1130 71 21 14 
L-Aspartic acid-13C4 C13-ASP 138 76 56 19 10 2,15 
L-Glutamic Acid GLU 
148 84.1 61 19 14 
2,16 
148 56 61 37 8 
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Supplemental Table 2: ηg/ml to nanomolar (ηM) conversion table 
  Nanomolar concentration equivalent to each ng/ml solution 
Analytes/solution 
 
300 
ng/ml 
150 
ng/ml 
75 
ng/ml 
37.5 
ng/ml 
18.75 
ng/ml 
9.38 
ng/ml 
4.69 
ng/ml 
2.34 
ng/ml 
1.17 
ng/ml 
L-Aminoadipic 
acid 1861.55 930.78 465.39 232.69 116.35 58.17 29.09 14.54 7.27 
Saccharopine 1085.82 542.91 271.45 135.73 67.86 33.93 16.97 8.48 4.24 
L-Pipecolic Acid 2322.75 1161.38 580.69 290.34 145.17 72.59 36.29 18.15 9.07 
L-Glutamic acid 2359.59 1179.79 589.90 294.95 147.47 73.74 36.87 18.43 9.22 
L-Glutamine 2052.83 1026.41 513.21 256.60 128.30 64.15 32.08 16.04 8.02 
L-Aspartic acid 2253.78 1126.89 563.44 281.72 140.86 70.43 35.22 17.61 8.80 
Pyridoxal-5' 
Phosphate (PLP) 1213.88 606.94 303.47 151.73 75.87 37.93 18.97 9.48 4.74 
Piperideine-6 
Carboxylate (P6C) 2359.59 1179.79 589.90 294.95 147.47 73.74 36.87 18.43 9.22 
D9-Pipecolic Acid 2322.75 1161.38 580.69 290.34 145.17 72.59 36.29 18.15 9.07 
D3-Aminoadipic 
acid 1827.26 913.63 456.82 228.41 114.20 57.10 28.55 14.28 7.14 
L-Aspartic acid-
13C4 2188.66 1094.33 547.17 273.58 136.79 68.40 34.20 17.10 8.55 
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Supplemental Figure S1 Calibration curves obtained for each analyte in artificial plasma extracts 
showing the linear correlation between signal (area ratio shown in y axis) and concentration (ng/ml 
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shown in x axis). The curve equation and r squared are also shown. The compounds are abbreviated 
as shown in Table 1. 
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Chapter 4 – “Aminoadipate-semialdehyde synthase (AASS) as a novel 
therapeutic target for pyridoxine dependent epilepsy.” 
4.1 Abstract 
The Saccharopine pathway is considered the main route for lysine catabolism in mammals in 
which aminoadipate-semialdehyde synthase (AASS) catalyzes the oxidation of lysine into 
aminoadipic semialdehyde (AASA). The latter is immediately oxidized to aminoadipic acid 
(AAA) by AASA-dehydrogenase (AASADH, encoded by ALDH7A1 gene). In humans, 
mutations in AASS gene lead to hyperlysinemia, a benign inborn error of metabolism. In 
contrast, mutations in ALDH7A1 cause pyridoxine dependent epilepsy (PDE). The 
accumulation of AASA and its cyclic form, piperideine-6-carboxylate (P6C) are considered 
the main pathogenic drivers of this disease chiefly through the depletion of pyridoxal 5′-
phosphate (PLP) by formation of Knoevenagel condensation products.  Although there exist 
alternative lysine catabolic pathways, we hypothesize that the elevated plasma and urine 
levels of AASA/P6C observed in PDE patients arises predominantly from the saccharopine 
pathway. Our quantitative LC-MS/MS analysis of mouse plasma and tissues suggests the 
primary site of lysine degradation, and thus primary source of pathogenic compounds is the 
liver and kidney. In addition, we reinforce the hypothesis of Pipecolate Pathway playing only 
a minor role in the overall figure of lysine oxidation. We hypothesize that, by targeting AASS 
inhibition by small molecules or Aass down-regulation at transcriptional level, one would 
observe reduced levels of these toxic compounds. We detected that primary skin fibroblasts 
from PDE patients display increased death in the presence of high Lysine levels. As proof-
of-concept, we observed recovery of normal survival when knocking-down Aass expression. 
In addition we solved the crystallographic structure of the Saccharopine Dehydrogenase 
(SDH) domain of human AASS at 2.6Å, which may provide basis to facilitate structure-based 
inhibitor design. We therefore suggest AASS a new target for substrate reduction strategy 
against lysine degradation disorders, especially PDE. 
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4.2. Introduction 
Pyridoxine Dependent Epilepsy (PDE) is a rare autosomal recessive disease caused 
by mutations in the gene ALDH7A1, which encodes the enzyme α-aminoadipic-
semialdehyde-dehydrogenase (AASADH), a central component of the L-lysine (Lys) 
degradation pathway (Mills, et al., 2006). PDE patients display neonatal onset of intractable 
and recurrent seizures which are only responsive to administration of high doses of 
pyridoxine (Baxter, 2001). The pyridoxine dependence is believed to derive from the toxic 
accumulation of the AASADH substrates α-aminoadipic-semialdehyde (AASA) and its 
cyclic form, piperideine-6-carboxylate (P6C). Recently it has been shown that P6C reacts 
with pyridoxal-5-phosphate (PLP) causing the depletion of this essential coenzyme from the 
organism (Mills, et al., 2006).  AASA and P6C in plasma, urine or cerebrospinal fluid (CSF), 
are the most reliable biomarkers of this disease; L-pipecolic acid elevations in body fluids 
can also occur (Plecko, et al., 2005) although it is not considered a reliable biomarker 
(Mercimek-Mahmutoglua, et al., 2013). Pyridoxine treatment although effective against 
seizures is not sufficient to reduce the levels of AASA and P6C. In keeping with this, despite 
effective seizure control with pyridoxine treatment, most PDE patients display significant 
postnatal developmental delay (Baxter et al, 2001); the therapy does not ensure normal 
neurodevelopment. Elevated levels of P6C and AASA thus appear to result in neurotoxicity 
through other avenues in addition to pyridoxine deficiency. This observation underlines the 
need for adjuvant therapies, like lysine restricted diet, an approach that has resulted in 
improved biochemical and neurodevelopmental outcomes (van Karnebeek, et al., 2012). 
However a recent study demonstrated that lysine restriction can reduce but not normalize 
AASA levels and that patients can develop serotonin deficiency as a side effect of the diet 
(Mercimek-Mahmutoglu, et al., 2014). L-arginine (ARG), a competitor of lysine transport, 
supplementation in the diet has arisen as another alternative therapeutically-based 
intervention. It has been shown that this diet approach can partially reduce AASA levels, 
similar to that observed for lysine restriction diet (Mercimek-Mahmutoglu, et al., 2014). Both 
strategies have improved neuropsychological assessments although only partial; this fact plus 
the onerous nature of these interventions make it clear that alternative more efficacious 
therapeutic approaches are needed.  
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It has been shown that two pathways for lysine degradation exists in humans (Figure 
1). Both pathways converge to the synthesis of AASA and its equilibrium form P6C both of 
which are substrates of AASADH. The final product of this step, formed by a fast reaction, 
is amino adipic acid (AAA) (Fig 1). Although there is a general consensus that saccharopine 
pathway plays a major role in the overall lysine metabolism especially in liver and kidney 
(Higashino, et al., 1971) (Blemings, et al., 1994) (Papes, et al., 1999) (Papes, et al., 2001) 
recent reports have shown that this pathway is almost absent in the brain and that the 
pipecolate pathway plays a major role in cerebral tissues and thus may be connected to lysine 
degradation disorders (Hallen, et al., 2013) (Sauer, et al., 2011) (Posset, et al., 2015). On the 
other hand, individuals with hyperlysinemia present mutations of aass gene and this leads to 
accumulation of high levels of lysine in body fluids (Markovitz, et al., 1984 ), which is in 
accordance with the hypothesis of AASS enzyme as the main catabolic route for lysine. This 
condition is considered a benign variation of metabolism (Houten, et al., 2013). 
In the present study, mouse tissues collected after itraperitoneal lysine injection were 
analyzed to investigate the relative contribution of liver, kidney and brain for lysine 
degradation using a recently validated quantitative method to access the concentrations of 
lysine metabolites by LC-MS/MS . In addition, we used mice IP injected with 15N-lysine 
differentially labelled  at alpha or epsilon nitrogen to further identify if the pipecolate or the 
saccharopine pathway are the main responsible for lysine degradation in the whole organism 
(accessed in blood) and in a tissue-based analysis. From this analysis we suggest AASS as 
the main producer of AASA/P6C and AAA. Thus, one can consider AASS as a potential 
target for the development of new PDE therapies and other lysine-degradation diseases such 
as Glutaric Aciduria. We observed that dermal skin fibroblasts derived from five PDE 
patients display high sensitivity to Lysine when compared to normal control lines. As a proof-
of-concept of AASS as a new target, we used shRNA to knockdown its mRNA levels and this 
was sufficient to revert to normal survival levels in the presence of lysine. In addition, we 
describe the biochemistry and structural biology of this new potential target. 
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Figure 1: In mammals, L-lysine can be degraded via two pathways. The first which uses L-
pipecolic acid as an intermediate (left) and is believed to operate mostly in brain, leading to 
the oxidative deamination of the alpha nitrogen of lysine. The second pathway (right) is 
suggested as the main player in liver, kidney and other tissues and proceeds via deamination 
of the epsilon nitrogen of lysine by condensation with a-ketoglutarate to form saccharopine 
as an intermediate. The enzyme AASS plays a principal role in the saccharopine pathway 
and possess two domains, LKR and SDH, which act independently as two separate enzymes 
catalysing the first two steps of the oxidative pathway. AASADH activity is absent in PDE 
patients. GCDH activity is absent in glutaric aciduria type 1 patients. 
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4.3. METHODOLOGY 
4.3.1. Chemicals and reagents 
The restriction endonucleases and T4 DNA ligase were obtained from New England 
Biolabs (Ipswich, MA, USA). Formic acid was obtained from Sigma–Aldrich (São Paulo, 
Brazil). Acetonitrile (ACN) was purchased from J.T.Baker (São Paulo, Brazil). All solvents 
used were HPLC grade. Mili-Q water was obtained from a Milli-Q purification system 
(Millipore, São Paulo, Brazil). All chemicals and reagents were of the highest purity and 
were stored at appropriate temperatures and conditions. All aminoacid reagents and standards 
were obtained from Sigma-Aldrich (St Louis, USA). Deutered compounds (d3-aminoadipic 
acid and d9-ipecolic acid) were purchased from CDN Isotopes (Pointe-Claire, Canada) The 
15N-α-lysine, 15N-ε-lysine, L-aspartic acid-13C4 were purchased from Sigma-Aldrich (St 
Louis, USA). Plasmids pNIC28 and pFBLIC were obtained from Dr Opher Gileadi (SGC-
University of Oxford). AASA/P6C was synthesized according to Mills et al. (2006). Briefly, 
10 mg of L-allysine ethylene acetal (Sigma-Aldrich) was dissolved in 1 mL of Milli-Q water 
and then incubated with 40 mg of Amberlyst 15 resin (Sigma, USA) for 20 minutes with 
stirring. The mixture was loaded onto a glass column (I.D. 10 mm × L 10 cm), and the liquid 
phase was collected. The resin was rinsed with 0.5 mL of 25% NH4OH and then washed 3 
times with 1 mL of Milli-Q water. The collected fractions were pooled and dried under a 
nitrogen stream. 
4.3.2. Animals and tissue sampling 
Five weeks old C57BL/6/JUnib female mice were obtained from CEMIB, University 
of Campinas. Experiments were approved by the Ethics Committee (CEUA) of the 
University of Campinas under the protocol number 3625-1. The experiments were done using 
overnight-starved mice and intraperitoneal (IP) injection of a solution of 20 mg of lysine, 
15N-α-lysine, 15N-ε-lysine or a phosphate buffered saline (PBS). For the targeted metabolite 
quantification in liver, kidney and brain, a 20 mg lysine solution or 10 mg pyridoxine 
hydrochloride or PBS as control was IP given for a group of five individuals each. For the 
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15N tracking experiments, five mice per group were used to IP injection of 20 mg of unlabeled 
lysine, 15N-α-lysine or 15N-ε-lysine. All injected solutions were adjusted to pH 7.4 and filter-
sterilized.  After two hours, mice were sacrificed by cervical dislocation and fresh organs 
(liver, kidney and brain) were collected and immediately stored at -80°C. For metabolite 
extractions from tissues, 60 mg of liver left lateral lobe, 60 mg of cerebral cortex and 60 mg 
of kidney were used for tissue homogenization. 
4.3.3. Metabolite extraction 
For plasma and serum, 100μL samples was precipitated with 200μL of acetonitrile 
(ACN), vortexed and centrifuged at 20.000 x g for 15 minutes at 4°C. The supernatants 
containing the polar metabolites were collected and used either immediately for LC-MS/MS 
or stored at -80°C. The polar metabolites from tissue samples were extracted from 60mg of 
tissues in an Eppendorf tube with 300 μl of methanol and 150 μL of chloroform. Silica beads 
were added to the samples, which were lysed in a cold homogenizer mixer by 3 rounds of 20 
seconds each. After homogenization 225μL of chloroform and 225μL of ddH2O were added 
to the lysate, vortexed vigorously and then centrifuged at 20.000 x g for 20 minutes at 4° to 
allow phase separation. The polar metabolites, in the aqueous phase, were collected and 
analyzed immediately or stored at -80°C. The LC-MS/MS run was performed by diluting ten 
or twenty times the metabolite extracts from plasma and ten or hundred times the tissue 
extracts in ddH2O containing 0.1% formic acid.  
4.3.4 Analysis of saccharopine pathway metabolites by LC-MS/MS 
The chromatographic system consisted of an Agilent 1260 series HPLC with a binary 
gradient pump and all the conditions used for the chromatographic separation of the analytes 
is described in the Chapter 3 (Pena, et al., Submitted 2). The analytes were loaded and 
quantified using an ABSciex 5,500 Qtrap mass spectrometer coupled with TurboV source 
(Concord, Ontario,CA) and the software MultiQuant, following the same method developed 
in the Chapter 3 (Pena, et al., Submitted 2).  
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4.3.5. Detection of 15N labeled compounds in plasma and tissue extracts 
 For the 15N tracking experiments, metabolite extracts were obtained from plasma, 
liver, kidney and brain of mice injected with PBS, 20 mg of unlabeled lysine, 15N-α-lysine 
or 15N-ε-lysine for two hours. The LC-MS/MS method (Pena, et al., Submitted 2) was 
adapted to detect 15N-pipecolic acid, 15N-aminoadipic acid, 15N-saccharopine and 15N-
glutamic acid. The MRM conditions used to detect the 14N and 15N analytes are shown in 
Table 1. 15N enrichment was estimated by using a qualitative approach. The isotopic content 
or isotopic pattern as atom percent excess (APE) were estimated as described in (Hellerstein, 
2014). To determine APE, the fractional abundance of the isotope of interest in the molecule 
of interest was determined regarding all the isotopes of the given molecule. This was then 
calculated from abundance data, such as the peak areas of N15 and N14 compounds detected 
through LC-MS/MS. So the fractional abundance of a given isotope (N15 containing) is 
calculated as: 
  
where 0 to n is the range of possible isotopes of the chosen atom in which abundances are 
measured (as peak areas). 
 Once the fractional abundance is determined, it is compared to the baseline. In this 
case the baseline was considered the fractional abundance of 15N isotope in the extracts of 
mice treated with unlabeled lysine. Thus, the atom percent excess (APE) was defined as the 
fractional abundance of 15N compounds in the enriched sample (from mice treated with 15N-
α-lysine or 15N-ε-lysine) minus the baseline sample, as the following: 
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where subscript e refers to enriched and b refers to baseline or natural abundance. 
4.3.6. Cell culture and shRNA inhibition of human AASS expression 
HEK293 cells were obtained from ATCC (www.atcc.org) and maintained in 
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal 
bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 1% glutamine and 5 mM 
Hepes pH 7.5. Human AASS was silenced by transduction of short hairpin RNA (shRNA) 
targeting AASS. Mission lentiviral shRNA vectors were purchased from Sigma and included 
control vector (SHC002, MISSION® pLKO.1-puro Non-Mammalian shRNA) and AASS 
specific shRNA (pLKO.1-puro-AASS, TRCN0000045677). A third generation lentiviral 
system (Tiscornia, et al., 2006) was used to generate knockdown cell lines in HEK293T. The 
packaging plasmids pMDL, pRev and pVSVG were transfected together with pLKO.1-puro-
AASS or control to generate lentiviral particles carrying the shRNA of interest and used to 
infect HEK293 cells with polybrene as described elsewhere (Kutner, et al., 2009). Given that 
pLKO.1-puro plasmids contain a puromycin resistance gene expressed constitutively, the 
transduced cells were submitted to Puromycin selection. Two days after infection the medium 
was replaced by DMEM containing 2ug/ml Puromycin and cells were under selection for 4 
days. The knockdown validation was performed two days after antibiotic removal. 
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Table 1: MS/MS conditions for analytes and internal standards used for Multiple Reaction 
Monitoring (MRM) detection of N14 and N15 metabolites.   
Analyte Abbreviation Q1 Q3 DP CE 
CX
P 
Retention 
Time 
(min) 
DL-Pipecolic-d9 acid D9 PIP  139.082 93.1 71 23 12 2.8 
L-Glutamic Acid 
Glu  
148 84.1 61 19 14 2.16 
148 56 61 37 8 2.16 
Glu 15N 149 85 61 19 14 2.16 
L-Saccharopine 
SAC  
277.1 84 71 29 14 2.08 
277.1 130 71 21 14 2.08 
SAC 15N 
278 85 71 29 14 2.08 
278.1 84 71 29 14 2.08 
L-2-Aminoadipic acid  
AAA  
162.048 98 46 21 14 2.37 
162.048 55 46 35 8 2.37 
AAA 15N 
163.048 99 46 21 14 2.37 
163.048 55 46 35 8 2.37 
DL-2-Aminoadipic-d3 
acid  
D3 AAA 1 165.08 101 56 21 16 2.37 
∆-1-Piperideine-6-
carboxylate 
P6C  
128.003 82 101 17 10 2.3 
128.003 55 101 27 8 2.3 
P6C 15N 129.003 83 101 17 10 2.3 
L-Pipecolic Acid 
PIP  
130.053 84.1 51 21 12 2.8 
130.053 56 51 39 8 2.8 
PIP 15N 131.053 85.1 51 21 12 2.8 
L-Aspartic acid-13C4 ASP C13 1 138.026 76 56 19 10 2.15 
 
4.3.7. shRNA knockdown validation of human AASS 
Total RNA was extracted with the illustra RNAspin Mini RNA Isolation Kit (GE 
Healthcare, Little Chalfont, UK) from up to 1x106 cells. The RNA quality and integrity was 
verified by gel electrophoresis. First-strand-complementary DNA was synthesized from 1 μg 
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total RNA using the RevertAid H Minus First Strand complementary DNA Synthesis Kit 
(Fermentas, Vilnius, LT, USA). Quantitative real-time PCR was conducted using defined 
primers (Table 2) and the SYBR GREEN PCR master mix (Applied Biosystems, Warrington, 
UK). Relative mRNA levels were normalized to glyceraldehyde-3-phosphate dehydrogenase 
mRNA levels using the ΔΔCT method. The PCR amplification was performed in triplicate. 
The Student’s t-test was used to evaluate the significance of the differential mRNA levels. In 
addition to validation by qRT-PCR, immunoblot analysis was also used to test knockdown 
for AASS. Total soluble proteins were extracted from HEK293 cells transduced with shRNA 
control scrambled and shRNA-AASS using a RIPA-like solution. Protein were quantified by 
BCA assay and ~30ug of protein of each sample was separated by SDS-PAGE (10%). 
Antibodies raised in rabbit against human AASS were obtained from Sigma (codes 
HPA020734 and HPA020728) and an anti-human beta-actin (Immuny) also produced in 
rabbit was used for endogenous control of Immunoblot analysis.  
Table 2: Primer pairs used for Real-Time PCR. 
Primer Sequence Primer Sequence 
1.GAPDH_FW_hs cagcctcaagatcatcagca 6.AASS_lkr_RV cgtactcctctatgatccac 
2.GAPDH_RV_hs catgagtccttccacgatac 7.AASS_sdh_FW tttcaccctcctctgagcat 
3.AASADH_ FW aacccatgggaccctaatgt 8..AASS_sdh_RV ccaagtaagcccaaccattc 
4.AASADH_RV accactgtgccaccttcttt   
5.AASS_lkr_FW aagctcaggaggccaatatg   
 
4.3.8. MTT assays for cell viability 
HEK293T control (shRNA scrambled) and AASS knocked-down (KD) were seeded 
onto 96 well plates at ~30,000 cells per well. 12 hours after seeding, cells were treated with 
0–500 mm NaCl for 12 h. MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assays were then performed as described elsewhere (Mosmann, 1983 ). 
 108 
 
4.3.9. Cell cycle analysis 
For the cell cycle analysis, cells were fixed in Ethanol 80% at 1 × 106 cells/ml for at 
least 2 hours in -20°C. Then, cells were centrifuged at 1,250 rpm and ethanol was discarded. 
Cells were ressuspended in PBS and an equal volume of detergent buffer containing 50 μg/ml 
of propidium iodide (Sigma) and 50 μg/ml of RNase (Puregene) was added. Cells were 
analyzed by flow cytometry. Cell cycle distribution was determined using ModFit LT 
software (Verity).  
4.3.9. Oxidative stress and mitochondrial analysis 
Oxidative stress parameters were evaluetd using the fluorescent dyes CellRox Deep 
Red and Mitotracker Green (Molecular Probes, Inc, Eugene, USA) used accordingly to 
manufacturer’s protocol for Flow Cytometry. 
4.3.10. Transcriptome sequencing, assembly, and mapping for HEK293 control versus 
AASS KD 
Total RNA isolated from five biological replicates of control and KD AASS were 
used to create pair-end RNASeq libraries using the Illumina TruSeq RNA Sample Prep Kit 
(Illumina, San Diego, CA, USA) according to the manufacturer’s instructions. The libraries 
were sequenced in two lanes of an Illumina HiSeq 2000 for 100 cycles which resulted in a 
total of 628,231,158 reads. The Illumina reads were filtered to remove adapters and low-
quality reads (reads <70% bases with quality ≥ Q20) using AdapterRemoval, the FASTX-
Toolkit (http://hannonlab.cshl.edu/fastx_toolki) and Perl scripts. The differential gene 
expression was analyzed using the Tuxedo protocol as described in (Trapnell, et al., 2012) 
which uses TopHat, Cufflinks and Cuffdiff programs and the expression levels are defined 
as FPKM (fragments per kilobase of exon per million reads mapped). The software 
Genevestigator (genevestigator.com) was used to further analyse the differentially expressed 
groups of genes. 
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4.3.11. Sample preparation for NMR analysis 
 Metabolite extraction was performed as described in the item 2.3 but using sonication 
in three cycles of 20 seconds each at 30% amplitude. The final polar extracts were dried in a 
vacuum concentrator (Speedvac) and the remaining solid phase was rehydrated in 600 µL of 
deuterium oxide (D2O, 99.9%; Cambridge Isotope Laboratories Inc., Tewksbury, MA, 
USA), containing phosphate buffer (0.1 M, pH 7.4) and 0.5 mM of TSP (3-
(Trimethylsilyl)propanoic acid; Sigma-Aldrich) for internal reference. Samples were added 
to a 5 mm NMR tube for immediate acquisition. 
4.3.12. NMR data acquisition and metabolite identification 
 1H-NMR spectra of samples were acquired using an Agilent Inova NMR 
spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA) equipped with a 5 mm triple 
resonance cold probe and operating at a 1H resonance frequency of 600 MHz and constant 
temperature of 298 K (25 °C). A total of 128 free induction decays (FIDs) were collected 
with 32 K data points over a spectral width of 16 ppm. A 1.5 s relaxation delay was 
incorporated between FIDs, during which a continual water pre-saturation radio frequency 
(RF) field was applied. Spectral phase and baseline corrections, as well as the identification 
and quantification of the metabolites present in the samples, were performed using the 
Chenomx NMR Suite 7.6 software (Chenomx Inc., Edmonton, AB, Canada). 
4.3.13. Cell culture of primary skin fibroblasts from PDE and control individuals 
 All assays were carried out using cell cultures between passages 5 and 15, with a 
matched number of passages in each assay. Primary dermal fibroblasts from normal infant 
controls were obtained from Coriell Cell Repositories (Camden, NJ): GM00038 and 
GM00969. An additional control skin fibroblast line from adult was also used. PDE 
Fibroblast cells were obtained as part of collaboration with the Care 4 Rare project, and were 
cultured from superficial skin biopsies of five different patients (here coded as CH3121, 
CH3122, CH3110, CH3111 and CH3139) (Table 3). All of these are cells from children were 
genetically proven for homozygous E399Q mutation on aldh7a1 gene and had also clinical 
and biochemical diagnostic as PDE patients prior to this study. This is the most prevalent 
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causative mutation of PDE, accounting for about 30% of the cases (Stockler, et al., 2011). 
This mutation is suggested to abolish NAD binding to the enzyme (Brocker, et al., 2010). 
Cells were maintained in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich, St Louis, 
MO, USA) containing 2 mM L-glutamine, 100 U/mL penicillin, 100 lg/mL streptomycin and 
10 % (vol/vol) heat-inactivated fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA) in 
a humidified 37 C incubator with 5 % CO2. 
 
Table 3: Primary skin fibroblast cells used in this study. 
Cell code Genotype - ALDH7A1 mutation 
AASADH 
change 
Age when biopsy 
was done 
CH3121 c.[1195 G>C]+[1195G>C] (Exon 14) E399Q 6 months old 
CH3122 c.[1195 G>C]+[1195G>C] (Exon 14) E399Q 1 year old 
CH3110 c.[1195 G>C]+[1195G>C] (Exon 14) E399Q 13 years old 
CH3111 c.[1195 G>C]+[1195G>C] (Exon 14) E399Q 6 years old 
CH3139 c.[1195 G>C]+[1195G>C] (Exon 14) E399Q 7 years old 
GM00038, Infant 
control 1 
normal no 9 years old 
GM00969, Infant 
control 1 
normal no 2 years old 
Adult control normal no mid-age woman 
 
4.3.14. Testing differential phenotypes comparing survival using the Alamar Blue assay 
The Alamar Blue (AB) assay was performed to measure cell survival following the 
description of the method in the literature (Page, et al., 1993). Briefly, the skin fibroblasts 
cells were trypsinized and seeded as 7.000 cels per well of a 96 well plate. After 36-48 hours, 
when cells were confluent, media was changed and cells were challenged with stress 
solutions. Complete DMEM containing additional 100-500 mM NaCl was used to test for 
survival in salt stress; 50-1 μM of H2O2 to test for survival in oxidative stress; and Lysine 
ranging from 100 to 2.5 mM to test for Lysine sensitivity. After incubation with the stress 
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solutions for 24 hr, the medium was removed and to each well 100μL AB solution was added 
(1:20 dilution in Hanks' balanced salt solution). The plate was returned to the incubator for 
another 3 hr to allow for the optimal oxidation-reduction of AB reagent. The reduction of AB 
in the cell cultures was determined by fluorescence reading using Synergy H1 Multi-Mode 
Reader, where a fluorescence excitation wavelength of 570 nm was used and fluorescence 
emission was read at 585 nm. The fluorescence values were normalized by the blanks (wells 
with only diluted AB solution) and survival was determined as the ratio between the 
fluorescence reading in the test well and a control well (confluent cells, without stress test) 
multiplied by 100. 
 
4.3.15. Knockdown of AASS in PDE skin fibroblasts using lentiviral delivery of shRNA 
and puromycin selection of transduced cells 
The same lentivirus generated in HEK293T as described in the topic 4.3.6 were used 
to infect skin fibroblasts. Two days after removal of the lentiviral supernatant, cells were put 
under puromycin selection. In order to establish what is the minimal concentration of 
puromycin able to kill all the cells in a given well for 48 hours of exposition we performed a 
killing curve in 96 well plates by Alamar Blue assay as described previously in 4.3.14 (see 
Figure 2). We conclude that 4μg/ml is the optimal puromycin concentration to select correctly 
transduced cells. Selection was performed for 4 days, medium was replaced by complete 
DMEM and after two days of recovery RNA was extracted and knockdown was validated as 
described in 4.3.7. Survival assays in the presence of Lysine were performed as described in 
4.3.14. 
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Figure 2: Puromycin killing curve for two distinct patient cells and one control cells to 
evaluate the minimal concentration that kills most of the cells after 48 hours of exposure. 
Survival was evaluated by AB assay and expressed as a percentage of fluorescence as 
compared with controls cell wells without addition of puromycin.  
 
4.3.16. Cloning human AASS in pNIC28 and pFBLIC for heterologous expression in 
bacterial and insect cell expression systems 
Sixteen constructs (Figure 3) covering the full length and each individual domain of 
AASS were produced, containing or not the initial signal peptide and avoiding or not putative 
unfolded regions. All the constructs were cloned using the ligation Independent cloning (LIC) 
technique into pNIC28 and pFBLIC, which are pET-based vectors designed for expression 
in bacteria and insect cells, respectively. Restriction enzymes and T4 DNA Polymerase were 
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bought from New England Biolabs. Insert amplifications were made using Pfx platinum 
DNA polymerase (Life). Cloning and expression of the constructs for a small-scale screening 
of soluble proteins in E. coli was done as described elsewhere (Strain-Damerell, et al., 2014) 
(Burgess-Brown, et al., 2014).  
Figure 3: Schema of the constructs designed for the expression of recombinant human AASS 
in E. coli (cloned in pNIC28) and in Sf9 cells (cloned in pFBLIC-Bse). 
 
4.3.17. Expression and purification of AASS constructs in E. coli 
Briefly, the chosen strain for expression of the constructs was the E. coli BL21(DE3)- 
R3-pRARE2 and small-scale tests were performed to test the best expression conditions, such 
as growth temperature (37 and 30ºC), induction temperature and time (37ºC and 30 ºC for 4 
hours or 18ºC overnight), culture medium (LB or TB) and IPTG concentration (100μM or 
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500 μM). In almost all tests, the produced proteins were shown to be mostly 
insoluble/unfolded. The only constructs that were seen to be promising were AASS-c013 and 
AASS-c015, which correspond to the SDH domain. AASS-c015 was selected for a scale up 
expression in which the growth was carried out in 3L of culture in TB medium at 37°C until 
OD600 reached 0.8, then the temperature was decreased to 18°C and induction was made 
with 100μM IPTG overnight.  
The extraction and purification steps were basically the same followed to purify 
AASS-c013 from insect cells (Sf9 cells) and will be described below in details in the section 
4.3.19, with the only additional step as the ion exchange chromatography. This additional 
step was done using HiTrap Q column (Anion Exchanger) pre-equilibrated with a pH 7.5 
buffer. The procedure followed was to change the protein buffer to a non-salt buffer (Tris 
HCl pH 7.5 50 mM, Glycerol 5%, TCEP 0.5 mM), by using Amicon centrifugal filter units. 
The run consisted of loading the protein into the column, performing a wash with 5 column 
volumes with the non-salt buffer, and then performing a gradient wash from the non-salt 
buffer to a 1M NaCl buffer (same buffer, but with added salt) in 10 column volumes. After 
obtaining 2.4 mg of purified potein from AASS-c015 harboring SDH activity, we proceeded 
with crystallization trials. Since no promising crystals appeared from AASS-c015, we 
changed to eukaryotic cell expression systems. The expected protein product weigth, 
isoelectrical point and other features of the constructs are shown in Table 4. 
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Table 4: Features of the expected protein products of each AASS construct. The human AASS 
RefSeq identifier is NP_005754. 
Construct ID 
Expected 
Mass (Da) 
Estimated 
Extinction 
Coefficient 
(M-1 cm-1) 
Protein pI 
Mass 
(no tag) 
(Da) 
Extinction 
Coefficient 
(no tag) (M-
1 cm-1) 
Protein 
pI (no 
tag) 
RefSeq 
Protein 
Start 
Position 
RefSeq 
Protein 
Stop 
Position 
AASSA-c001 104728 88130 6.15 102205 86640 6.15 M1 P926 
AASSA-c002 103595 86640 6.15 101072 85150 6.05 M1 I916 
AASSA-c003 52855.6 41830 6.25 50332.9 40340 6.25 M1 N452 
AASSA-c004 51139.7 41830 6.25 48617 40340 6.25 M1 E436 
AASSA-c005 103053 88130 6.05 100530 86640 6.05 K18 P926 
AASSA-c006 101920 86640 6.05 99396.9 85150 5.95 K18 I916 
AASSA-c007 51180.7 41830 6.15 48657.9 40340 6.05 K18 N452 
AASSA-c008 49464.8 41830 6.15 46942.1 40340 6.05 K18 E436 
AASSA-c009 102480 88130 5.95 99957.5 86640 5.95 K23 P926 
AASSA-c010 101347 86640 5.95 98824.2 85150 5.85 K23 I916 
AASSA-c011 50608 41830 6.05 48085.3 40340 5.95 K23 N452 
AASSA-c012 48892.1 41830 6.05 46369.4 40340 5.95 K23 E436 
AASSA-c013 54543.9 47790 5.95 52021.2 46300 5.85 L455 P926 
AASSA-c014 53440.9 46300 5.85 50918.1 44810 5.75 T454 I916 
AASSA-c015 51207.3 44810 5.65 48684.6 43320 5.35 K482 P926 
AASSA-c016 50074 43320 5.55 47551.3 41830 5.25 K482 I916 
 
4.3.18. Expression of construct AASS-c013 in insect cell system 
In order to obtain high amounts of pure protein for crystallography trials, the AASS-
c013 construct harbouring the human AASS SDH domain was chosen to be expressed in 
high scale in insect cell system. The methods for high-throughput cloning in pFBLIC-Bse, 
production of the baculovirus and expression testing are described elsewhere (Shrestha, et 
al., 2008). 12 mL of P2 virus was used to infect 4 L of Sf9 insect cells at 2x106 cels/ml. 
Protein expression was induced from the strong polyhedrin promoter, highly active at the 
very late stage of infection. Thus, cells were harvested 72 hours post infection by 
centrigugation 15 min at 900xg at 4°C. The cell pellet was resuspended in 50 mL binding 
buffer (500mM NaCl, 5% Glycerol, 50mM HEPES (pH 7.5), TCEP 0.5 mM and 20mM 
Imidazol). The cell suspension was transferred to 50mL falcon tubes and frozen at -80°C. 
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For protein extraction tubes were thawed and EDTA-free protease inhibitor was added. Cells 
were lysed by sonication (20 min at 35% power, 5 sec on, 10 sec off). The lysate was 
centrifuged twice at 35.000 xg, for 30 min at 4°C and the supernatants containing soluble 
protein were collected. 
4.3.19. Purification of construct AASS-c013 expressed in Sf9 cells 
The first purification step was done using nickel affinity column, since the expressed 
protein contained an N-terminal histidine tag, which has high affinity to divalent metal ions 
such as Ni+2. The supernatant was then equilibrated with 2mL of Ni-NTA agarose resin 
(Qiagen) for one hour at 4°C. A chromatographic column was assembled and the suspension 
containing the soluble lysate fraction and Ni-NTA beads were run through the column, 
allowing the resin to pack in the bottom of the column placed in a vertical position. The flow-
through was collected and only the proteins that have affinity with Ni+2 should be bound. A 
series of two washes with 25mL of binding buffer and wash buffer (500mM NaCl, 5% 
Glycerol, 50mM HEPES (pH7.5), TCEP 0.5 mM and 40mM Imidazole) was done, and the 
fractions were collected. Elution was performed in 5 x 5mL of a buffer containing 250mM 
Imidazole. SDS-PAGE was used to analyse all the fractions to identify the band 
corresponding to the protein expressed from the AASS-c013 construct. The molecular weight 
of the protein product of this construct is 54.517 kDa and the protein cut with TEV (without 
His-tag) is 52.051 kDa. An activity test was also performed to detect SDH activity in all 
fractions. The SDH activity assay consisted of the measurement of NADH formation 
monitored by the absorbance at 340 nm using a spectrophotometer (plate reader) and the 
reaction was composed of 100mM Tris pH 8.5m 2mM NAD+, 2mM saccharopine in 100μL, 
in duplicates. As negative controls we used the same mixture without the enzyme solution 
and the mixture with enzyme solution but without the substrate saccharopine. High activity 
was detected in the eluted fraction. 
The fractions containing highest SDH activity were used for a second step 
purification by size exclusion chromatography (“Gel Filtration”, GF) in a Superdex S200 Hi 
load 16/60 column using an AKTA Express. The GF buffer used was 500mM NaCl, 5% 
Glycerol, TCEP 0.5 mM and 50mM HEPES (pH 7.5). The fractions with high absorbance at 
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280ηm were analysed in a SDS-PAGE and the fractions containing the protein (54kDa band) 
were pooled and run in the GF Chromatography. This experiment also indicate the molecular 
weight of a given protein in solution by comparing its elution volume with a standard curve 
prepared by running through the same column proteins with known molecular weight. This 
curve was prepared using the Bio-Rad’s gel filtration standards, which correspond to 
Thyroglobulin (670 kDa), γ-globulin (158 kDa), Ovalbumin (44 kDa) and Myoglobin (17 
kDa). The standard curve was calculated and used to infer the molecular weight of proteins 
eluted in a given retention volume (ml). 
The protein concentration was measured using a Nanodrop 2000 spectophotometer. 
The concentration values were used to calculate the required amount of TEV protease to add 
(1/20 times the amount of protein to cut, in milligrams) to perform an overnight cleavage at 
4°C. In the next day, the occurrence of cleavage would allow a separation of the cut protein 
and TEV by another purification using Ni-NTA column, where only TEV and uncut protein 
(and also contaminants which bind Ni in the first step) will bind again to the column. In the 
end, SDS-PAGE was performed to check the presence of the 52 kDa band (cut protein) in 
the flowthrough and washes. The fractions containing the cut band are then concentrated 
using Amicon Centrifugal Filter Units until reaching about 10 mg/ml concentration. The 
purified protein had an experimental mass of 52.051 kDa as expected. Masses were 
determined by LC-MS, using an Agilent LC/MSD TOF system with reversed-phase HPLC 
coupled to electrospray ionisation and an orthogonal time-of-flight mass analyser. Proteins 
were desalted prior to mass spectrometry by rapid elution off a C3 column with a gradient of 
5-95 % acetonitrile in water with 0.1 % formic acid. 
4.3.20. Enzyme properties 
The enzyme kinetics for the NAD cofactor was estimated at NAD concentrations 
ranging from 0.01 to 2 mΜ. For saccharopine, the substrate concentrations used were the 
same as that for the NAD kinetics determination. Km and Vmax were calculated by fiting 
the data to the Michaelis-Menten equations. Activity was calculated by measuring NAD+ 
reduction as described above (Serrano, et al., 2012) and one unit of enzyme activity was 
defined as 1 ηmol NAD+ reduced per min at 25°C per mg of enzyme.  
 118 
 
Enzyme Inhibition assays were performed to test if a given compound (the same 
tested in the DSF experiment described above) could cause inhibition of the SDH activity. 
To test this, we used the abovementioned method to assay the SDH activity in buffer pH 8.5 
using 2mM of saccharopine and 2mM of NAD+ and testing if the presence of 5mM of a 
given aminoacid could affect the activity. The activity in the default conditions was 
considered 100% of activity, and the values obtained for each ligand would be compared as 
a ratio to the default condition. As controls, we used reactions without saccharopine but in 
the presence of the given ligand.  
The ligands tested were: α-ketoglutaric acid, L-lysine, L-methionine, L-glutamic 
acid, L-ornithine, L-aminoadipic acid, L-triptophan, L-cysteine, L-glycine, L-proline, L-
serine, L-arginine, L-leucine, L-isoleucine, L-tyrosine, L-aspartic acid, L-threonine and L-
glutamine. 
4.3.21. Buffer screenings and ligand binding screening by differential scanning 
fluorimetry (DSF) 
Thermal shift assay (or Differential Scanning Fluorimetry experiments) was carried 
out using an Mx3005p Real Time PCR machine (Stratagene). Proteins were buffered in 10 
mM HEPES pH 7.5, 500 mM NaCl and assayed in a 96-well plate at a final concentration of 
2 µM in 20 µl volume. SYPRO Orange (Molecular Probes) was added as a fluorescence 
probe at a dilution of 1:1000. Excitation and emission filters for the SYPRO-Orange dye 
were set to 465 nm and 590 nm, respectively. The temperature was raised with a step of 3°C 
per minute from 25°C to 96°C and fluorescence readings were taken at each interval. The 
temperature dependence of the fluorescence during the protein denaturation process was fit 
to the Boltzmann equation. This method was used to identify optimal stabilizing buffer 
conditions to be employed in crystallography trials. The tested buffer conditions are shown 
in Table 5, where 17 μL of buffer solution was added to 1 μL of protein solution at 2mg/ml 
and 2 μL of Sypro Orange dye diluted 1:1000, in duplicates. The best buffers were used in 
further crystallography screenings. 
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Similarly to the buffer screening approach, DSF assay was performed to test if the 
addition of a given ligand would cause Tm shifts. This would be expected because normally 
the binding of a ligand causes additional stability of the target protein, which is reflected in 
an increased melting temperature (Tm). This means that when a ligand stabilize the protein 
structure, more heat would be required to unfold the protein, and this would reflect in a higher 
Tm. In order to test if the substrate, cofactor amino acids and saccharopine pathway related 
molecules can increase Tm of SDH protein, we selected one buffer to use (150 mM NaCl, 
Tris-HCl pH 8.5 50 mM) which has the pH in which the enzyme is most active and we added 
several aminoacids and combinations of the amino acids in the presence of absence of the 
cofactor nicotinamide adenine dinucleotide (NAD+). 
 
Table 5: Conditions tested in buffer screening experiments by DSF. 
        
4.3.22. Crystallography screenings and crystal optimization 
The sitting drop vapour diffusion method was applied to obtain crystals of the purified 
SDH domain. The first tests were made using a concentrated protein solution (10mg/ml) 
mixed with precipitant solutions contained in commercial crystallography screen kits from 
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Hampton Research. The drops contained 150 ηl final volume in three proportions of protein 
and mother liquor solution (2:1, 1:1 and 1:2) and plates were incubated either at 20°C or 4°C. 
Further optimizations were performed to obtain best-diffracting crystals, using the same 
screens with addition of NAD 2mM, Saccharopine 2-4 mM and both. Additionally, follow-
up screens were made based on the starting conditions that produced crystals. In the end, the 
best diffracting crystal was obtained in 25% PEG3350, Tris-HCl 100mM pH 8.5, NAD 2mM 
and Saccharopine 2mM. 
4.3.23. Crystal mounting, diffraction screening and data collection 
Crystals were cryo-protected with reservoir solution supplemented with 25% (v/v) 
glycerol or ethylene glycol, mounted in cryogenic loops and flash-cooled in liquid nitrogen. 
Several crystals were tested to check if they are diffractable, to visualize if the diffraction 
pattern resembles protein diffraction (and not salt) and what is the maximum resolution. This 
initial screen was performed using the in-house diffractometer Bruker AXS x-ray diffraction 
system. The most promising crystals regarding resolution and quality of the spots were 
selected for further screening and data collection at the Diamond Light Source beamline IO4. 
The best crystal diffracted at 2.6 Å and a dataset was collected, from which the parameters 
are shown in table 6. 
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Table 6: Data collection parameters for human AASS-c013 crystal diffracted at Diamond 
Light Source I04. 
Parameter Values Parameter Values 
Wavelength 0.9796 Å  Rmerge(%) 6.9 (53.4) 
Unit cell parameters (Å) 71.28, 86.69, 149.9 CC* 0.996 (0.462) 
(°) 90, 90, 90 I/sig(I) 10.2 (2.0) 
Space group P212121 Completeness 98.9 (94.5) 
Resolution range (Å) 74.729 - 2.600 (2.72-
2.60) 
Multiplicity 3.2 (2.8) 
Observed/Unique 
reflections 
91974/28602 
(9303/3269) 
 
4.3.24. Structure solution and refinement 
The homodimeric structure of SDH domain of human AASS bound to NAD was 
solved by molecular replacement using the PHASER program (McCoy, 2007) employing the 
fungi saccharopine reductase (SR) structure (PDB code 2AXQ) as search model, which is 
39% identical to the human SDH. Two molecules were found in the asymmetric unit (a.s.u.). 
The initial model was rebuilt using phenix.autobuild (Adams, et al., 2010). A bound 
nicotinamide adenine dinucleotide (NAD) molecule in the active site was identified by 
difference Fourier method and manually placed into the electron density using the software 
Coot (Emsley & Cowtan, 2004). To complete the model, iterative cycles of phenix.refine 
(Adams, et al., 2010) including TLS refinement followed by manual model building for 
missing residues using Coot were performed alternated with refinement cycles in REFMAC5 
(Murshudov, et al., 2011). No NCS restraints were applied due to conformational differences 
in domain III (res 278-376) of the two copies in the a.s.u. 
 The Rfactor and Rfree values obtained for the moment after several refinement cycles 
were 0.20318 and 0.26706, respectively. 97.2%, 2.8% and 0% of the residues are in the 
favoured, allowed and outlier regions of Ramachandran plot from a total of 887 residues (442 
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and NAD at chain A and 443 and NAD at chain B). Model validation was performed by 
Molprobity (Chen, et al., 2010) and What Check (Hooft, et al., 1996). The model and map 
quality were improved through refinements using Coot and Refmac5. 
4.3.25. Computational biology analysis 
Java Protein Dossier (G, et al., 2004) was used to perform physico-chemical 
properties analysis of the human SDH structure. Data regarding contact type identification, 
atoms and the residues involved was obtained from STING, stored and analyzed in a local 
MySQL database. The secondary structure elements was defined by STING module 
SS_Stride. Loop positions and extensions as well as the positions of the secondary structure 
elements at human SDH was defined based on the position of the first residue after a defined 
helix or strand and up to the last residue before a new helix or strand. The definition of ligand 
surrounding residues and interactions was performed by LigPlot (Wallace, et al., 1995) and 
Molegro Virtual Docker (MVD) (Thomsen & Christensen, 2006). Saccharopine position was 
determined by molecular docking using MVD and the algorithm MolDock Optimizer with 
10 runs, each with 3000 iterations in a population size of 100. Energy minimization was 
performed at the end of each run. Protein structure images were created using the PyMOL 
Molecular Graphics System, Version 1.5.0.4 (Schrödinger, LLC). 
4.3.26 Structure based ligand design 
The structure of human SDH was used to help guiding the rational design of ligands 
which are tested for the probability of binding to the enzyme by computational dockings 
simulations. By using the knowledge about the ligand target site it was possible to identify 
the binding interactions within the site and also the size and shape of the ligand that fits into 
the pocket (Patrick, 2013). Preliminary ligand designing and 3D optimization was performed 
using the software ChemSketch (ACD/Labs) using the saccharopine structure as a starting 
point in an iterative procedure of design and computational docking. Modifications were 
added mainly replacing the charged groups of L-saccharopine, with the goal to improve the 
shape, charge complementarity, hydrogen bond network and aromatic interactions. The 3D 
structure of the ligands were evaluated based on docking procedures with MVD as described 
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above. The ligands were ranked by MolDock Score and the positive control for the docking 
runs is the molecule of saccharopine, the SDH substrate and negative control were the 
compounds L-lysine-p-nitroanilide and yL-glutamyl-glutamate which were experimentally 
found to not act as inhibitors for SDH (Fjellstedt & Robinson, 175). Chemical synthesis of 
selected ligands was performed by collaborators in the Institute of Chemistry, Unicamp. 
Ligands were evaluated in vitro by inhibition assay of SDH activity as described in 4.3.20.  
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4.4. RESULTS 
 
LC-MS/MS studies of lysine degradation using mouse model 
4.1.1 LC-MS/MS analysis of lysine catabolism suggest its predominance in liver and 
kidney 
A new LC-MS/MS method was established to detect with high precision most of the 
relevant metabolites of lysine degradation via aminoadipate, as described previously in 
Chapter 3. The time course analysis performed by analysing blood samples in mice showed 
that lysine degradation occurs within the first two hours after IP lysine administration (see 
Chapter 3 (Pena, et al., Submitted 2)). Thus we have chosen the time point of two hours to 
perform subsequent experiments. The treatments consisted of IP injection of a PBS solution 
containing 20mg lysine or 10 mg pyridoxine IP. PBS was also injected in a third group of 
animals as a control. Five individuals were used for each experimental group. Two hours 
post-injection, the mice were sacrificed and the liver, kidney and brain were collected and 
dissected. Metabolite extracts were prepared using 60 mg for each tissue.  
High levels of AAA were found in the liver and kidney (~80 and ~45 ug/ml of tissue 
extract, respectively), while the concentration in the brain was much lower (~1ug/ml of tissue 
extract). These results suggest that the level of lysine oxidation in the brain is insignificant 
when compared to the liver and kidney (Fig. 4A). If we use these results to predict what 
occurs with AASA/P6C in PDE patients, it is possible that these toxic compounds accumulate 
largely in the liver and kidney. The observation that the liver is the main tissue for lysine 
catabolism is in agreement with previous data showing that AASS enzyme is mainly found 
in the liver (Papes et al, 1999). Although the genes encoding the enzyme of lysine catabolism 
have been reported in the literature, the data from the present work represent the first 
quantitative assay for the relevant metabolites of lysine catabolism that provides a reliable 
comparison among tissues after lysine injection.  
Similar to AAA, sacharopine and pipecolic acid were also found mainly in the liver 
and kidney (Fig. 4B and 4C). Saccharopine was found at concentrations that were 10-fold 
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that of pipecolic acid. If the observed pipecolic acid was derived from the pipecolate pathway 
(Fig 1), the notion that this pathway is more active in the brain compared to the liver and 
kidney (Sauer et al, 2011) may not be precise. Lysine injection did not produce significant 
effects on the tissue levels of glutamic acid (Fig. 4D) and glutamine (data not shown).  
PLP was mainly found in the liver and increased 1.4-fold 2h after IP injection of 
pyridoxine (Fig 5). This result might support the hypothesis that PLP synthesis and lysine 
degradation occurs in the same tissues and at the same time. It is possible that PLP depletion 
by the reaction with P6C in PDE patients occurs predominantly in the liver a few hours after 
dietary intake. 
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Figure 4: Metabolite quantification per tissue (Liver, Kidney and Brain) in mice injected 
with a PBS solution (PBS 2h) or 20 mg L-lysine solution (Lys 2h). Fc means Fold Change as 
compared to concentration obtained in the 0h time. Asterisk represents statistically 
difference with p<0.05 when PBS 2h and Lys 2h are compared using T Test. 
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Figure 5: Quantification of free PLP levels in Liver, Kidney and Brain after IP injection of 
PBS or 10 mg/ml Pyridoxine (Pyr) solution.  
4.4.2. Mass spectrometry analysis suggest saccharopine pathway as the source of toxic 
accumulation of P6C in PDE patients 
In this section of the project, differential labelling of the amine nitrogen in lysine was 
used to determine the preferential pathway (pipecolate or Saccharopine) for lysine 
degradation in mouse by detection of 15N labelled metabolites in the blood, liver and brain. 
A distinctive feature of the pipecolate and saccharopine pathway is the differential 
deamination of lysine. In the saccharopine pathway, the epsilon (ε) nitrogen is removed and 
incorporated into glutamate, whereas the alpha (α) nitrogen remains in the metabolites P6C, 
AASA and AAA (Fig 6A). Pipecolic acid can be produced from P6C by the enzyme P5CR 
and thus this compound would have its nitrogen derived from the α group of lysine. The 
opposite occurs in the pipecolate pathway, where pipecolate would have its nitrogen derived 
from ε N of lysine, and therefore this nitrogen would be found in P6C, AASA and AAA. 
Since we defined that the main lysine metabolite in normal mice is aminoadipic acid, we 
could determine the pathway of its synthesis by tracking the lysine nitrogen. By using IP 
injection of 20 mg of either one of the two forms of stable isotope labelled L-lysine, i.e. L-
[α-15N]lysine and L-[ε-15N]lysine in mice we detected the heavy isotopes (Table 1) of lysine 
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metabolites. Two possible scenarios could be expected in this differential labelling 
experiment, with saccharopine (Fig. 6A) or pipecolate (Fig. 6B) being the main lysine 
catabolism pathways. Mice injected with unlabelled lysine were used as a control for APE 
calculations as discussed. Each group contained five individuals and blood and tissues were 
collected 2 hours post lysine injection. 
The first analysis aimed to assess the overall metabolite content in the blood. We 
detected 15N-aminoadipic acid mainly in the blood extracted from mice injected with L-[α-
15N]lysine (Fig. 7A), which strongly support the hypothesis that the saccharopine pathway is 
the main pathway used for lysine degradation in mammals. It is possible to infer that in the 
absence of AASADH as seen in PDE patients, the accumulated P6C/AASA would primarily 
be derived from AASS activity. 
15N-saccharopine was found in mice injected with both α-15N and ε-15N lysine (Fig. 
7B). This indicates that the saccharopine pathway is active and the result is plausible since 
L-saccharopine contains both lysine nitrogens in its structure. 15N-pipecolic acid was also 
found in mice injected with both α-15N and ε-15N lysine, which suggests that both pathways 
exist to produce this compound (Fig. 7C). The incorporation of α-15N into pipecolate 
indicates activity of the P5CR enzyme (see Fig. 1). It is possible that this enzyme serves as a 
metabolite repair route to avoid AASA/P6C toxicity in the presence of high lysine 
degradation. The existence of ε-15N incorporation into pipecolic acid confirms that the α-
deamination pathway of lysine exists but pipecolic acid does not significantly contribute to 
the formation of the aminoadipic acid pool as seen from the low APE(%) of AAA found in 
ε-15N lysine injected mice (Fig. 7A). Pipecolic acid may be used in other cellular processes, 
which have not yet been described. It is possible that low activity of the enzyme pipecolic 
acid oxidase in the liver and kidney may have contributed to this scenario (Mihalik & Rhead, 
1989). 
 We further assessed whether the saccharopine pathway is the main pathway 
responsible for AAA production in the liver and brain by analysing extracts obtained 2 hours 
post-injection of differentially labelled and unlabelled lysine. The results were consistent 
with the pattern observed in blood. In both tissues 15N aminoadipic acid was detected mainly 
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in the mice injected with α15N-lysine, confirming the saccharopine pathway as the main 
lysine degradation pathway in mice (Fig. 8A). The low APE found for 15N-AAA detected in 
mice injected with ε15N-lysine was not statistically different from the endogenous 15N-AAA 
levels found in mice injected with unlabelled lysine. Although not statistically significant, 
average values of 4-5% APE were found for 15N-AAA after ε15N-Lys IP injection, which is 
less than the enrichment values found for 15N-AAA after α15N-Lys treatment (35 and 47% 
APE, respectively, for liver and brain). 
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Figure 6: Tracking of labelled lysine nitrogen. If saccharopine pathway is used (A) or if 
pipecolate pathway is used (B). In case of lysine being oxidized by saccharopine pathway, 
N15 aminoadipic acid would be found in mice injected with L-[α-15N] lysine whereas if 
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pipecolate pathway is used, N15-aminoadipic acid would be found in mice injected with L-
[ε-15N] lysine. 
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Figure 7. Formation of 15N metabolites shown as Atom Percent Excess (APE) in mice 
injected with unlabeled L-lysine (Lys 2h), L-[α-15N] lysine (α15N-Lys 2h) and L-[ε-15N]lysine 
(ε15N-Lys 2h). Detection of 15N isotopes of aminoadipic acid (A), saccharopine (B) and 
pipecolic acid (C) are shown. 15N-glutamate was not detected in blood. 
Labelled saccharopine with high enrichment (APE ~36%) was found in liver samples 
obtained from both α15N-lysine and ε15N-lysine treated mice (Fig. 8B). A lower enrichment 
(APE ~18%) was found in the brain, which may suggest that the pathway does exist in this 
tissue. Another possible explanation could be that labelled saccharopine in the blood crosses 
the Blood-Brain Barrier. Similar to what was observed in the blood, labelled pipecolic acid 
was also found in both α15N-lysine and ε15N-lysine treated mice (Fig. 8C). 15N-glutamic acid 
was not detected in blood samples but was found in liver and brain extracts, with low APE 
(~5%) (Fig 8D). This reinforces the hypothesis that the saccharopine pathway does occur in 
the brain and that saccharopine was not merely transported from the blood. This data suggests 
that the saccharopine pathway is the main pathway for conversion of lysine to aminoadipic 
acid in mammals and although lysine is converted to pipecolic acid by α deamination, this 
pipecolic acid is not further converted to aminoadipic acid. Therefore, we suggest that the 
inhibition of AASS could be an alternative therapy against PDE by preventing AASA/P6C 
accumulation. We subsequently evaluated the effects of inhibiting AASS in a cellular model. 
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Figure 8: Formation of 15N metabolites shown as Atom Percent Excess (APE) in liver and 
brain of mice injected with unlabelled L-lysine (Lys 2h), L-[α-15N] lysine (α15N-Lys 2h) and 
L-[ε-15N]lysine (ε15N-Lys 2h). Detection of 15N isotopes of aminoadipic acid (A), 
saccharopine (B), pipecolic acid (C) and glutamic acid (D) are shown. Each bar represents 
an average of n=5. 
 
4.4.3. Knockdown of aass gene in HEK293 cell line does not have implication in 
detrimental phenotypes 
 We investigated the changes in cell physiology and metabolism upon the down 
regulation of AASS and ALDH7A1 transcription. We used lentivirus carrying a control 
shRNA or shRNA targeting either AASS or ALDH7A1 to generate knockdowns in HEK293 
and tested if cell morphology, viability, ROS accumulation, cell cycle and metabolite content 
was affected. Cells were infected with lentivirus and subjected to puromycin selection for 
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five days. Cells displaying puromycin resistance were selected. Cell knockdown for aass 
showed 80-85% reduction of aass mRNA while the knockdown for ALDH7A1 showed only 
62% reduction of the ALDH7A1 mRNA (Fig. 9) After cell expansion, 15 days after infection, 
the knockdown for AASS still showed 75% mRNA reduction while the knockdown for 
ALDH7A1 showed only 30% reduction in mRNA levels. Thus we decided to proceed only 
with the AASS knockdown. AASS protein levels were also reduced in the knockdown cells 
(Fig. 10A). Protein levels of the AASS enzyme were still lower in the knocked down cells 
eighteen days after infection (Fig 10 B).  
 
 
Figure 9: Knockdown for aass and aldh7a1 expression by real time PCR eight days after 
lentiviral infection. The mRNA levels were calculated by using the delta Ct differences 
between KDs and control. Bars represent SD for three replicates. Two primers for aass gene 
were used (targeting LKR or SDH region, AASS-LKR and AASS-SDH respectively). Asterisk 
represent statistically difference with p<0.05 compared to control sample using T Test. 
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Figure 10: Knockdown validation of AASS protein as detected by Western Blot using anti-
AASS antibody and anti-βActin antibody ten days after infection (A) and eighteen days after 
infection (B). 
 We have shown in previous work studying the saccharopine pathway in marine 
bacterium that lysine degradation is associated with salt stress adaptation (Neshich, et al., 
2013) (Pena, et al., Submitted 1). In plants, studies have shown that lkrsdh and aasadh are 
upregulated in salt stress (Buchanan, et al., 2005) (Kiyota, et al., 2015). Thus, we tested the 
viability of control versus AASS KD cells in the presence of increasing NaCl concentrations. 
However, we found no difference in viability as determined by the MTT assay (Fig. 11).  
 
Figure 11: Assay for cell viability in the presence of salt stress. The indicated concentration 
of NaCl is the amount added to DMEM medium, not the final concentration. MTT test was 
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performed in HEK293 transduced with lentivirus carrying shRNA scrambled control and 
shRNA AASS. 
We also tested if the KD cells changed ROS production using flow cytometry analysis 
and the fluorescent probe CellRox. We did not observe differences in control conditions or 
in the presence of oxidative stress (Fig. 12A). MitoTracker Green was also used in FACS to 
test if changes in AASS levels would affect mitochondrial signal but no difference was 
observed (Fig 12B). We also observed that there was no change in cell size and granularity 
(not shown). Cell cycle analysis also demonstrated that there was no difference in apoptosis 
occurrence and the percentages of cells in each phase of the cell cycle are roughly the same 
both in the control and AASS KD (Fig. 13). 
 
Figure 12: FACS analysis using CellRox Deep Red (A) and MitoTracker Green (B) of 
HEK293 infected with scrambled shRNA (control) or AASS shRNA (KD AASS).   
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Figure 13: Cell-cycle does in not altered upon KD AASS as detectedusing propidium iodide 
(PI) staining in ethanol fixed cells. Control cells infected with shRNA scrambled control (A) 
and AASS shRNA (B). 
We also analysed the metabolomics of control and AASS KD cells by NMR 
spectroscopy. This technique allows for the detection of the metabolites that exist at high 
intracellular concentrations (e.g.>100 μM range). The analysis was done with cells grown 
under normal conditions. The major difference observed was in glutamate content, which 
was higher in the control than in AASS KD (Fig. 14). Based on the fact that AASS activity 
results in the production of glutamate this may contribute to intracellular levels of this amino 
acid. However, this may not be relevant to the overall glutamate pool of the organism, since 
the mass spectrometry results demonstrated that on a tissue-based level the glutamate content 
did not change significantly when mice were injected with IP Lysine (see Fig. 4D). In 
addition our labelled lysine analysis showed that the glutamate APE levels were low, near 
5%. Interestingly, proline displayed lower levels in AASS KD than in the control. This may 
also be related to lower glutamate levels observed in this in vitro model, since this amino 
acid is the direct substrate for proline synthesis. Threonine levels were also reduced in the 
AASS KD cell. Of note, high levels of threonine are found in the plasma and CSF of PDE 
patients. Further experiments will be conducted to elucidate the effects of AASS inhibition 
in in vitro experiments. Unfortunately, we could not access any of the other lysine 
degradation metabolites by this technique likely due to their low levels in the cell extract. 
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Figure 14: Metabolomics of AASS knockdown versus control HEK293 cells, showing the 
main metabolites detected by NMR spectroscopy. Black and blue asterisk represent 
statistically difference with p<0.05 and p<0.1, respectively, compared to control sample 
using T Test. 
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4.4.4. Pipecolate pathway is not induced when AASS expression is inhibited in HEK293T  
We used five biological replicates for control shRNA and AASS KD cells to extract 
total RNA and perform a transcriptome analysis by RNA-seq. The quality of the RNA 
extracted was assessed by Nanodrop and Electrophoresis (Fig. 15). RNA integrity as assessed 
by Agilent Bioanalyser showed RIN scores higher than 8.8 for all samples. Prior to library 
preparation and sequencing, the knockdown of AASS as analysed by Real-Time PCR 
showed an average reduction of 74% of AASS mRNA. The sequencing and analysis of reads 
were done as described in the 4.3.10 section. Bioinformatics analyses indicated that genes of 
the pipecolate pathway were not significantly changed. FPKM levels of pipecolate oxidase, 
for example, which is considered the central enzyme of pipecolate pathway, were around 0.4, 
which indicates that this enzyme is not significantly expressed in this cell line (Table 7). 
Although direct evidence for the first steps of lysine oxidation via pipecolate pathway is still 
lacking (Sauer, et al., 2011) (Mercimek-Mahmutoglu, et al., 2014), it has been suggested that 
they are catalysed by the enzymes encoded by genes CCBL2 and CRYM (Hallen, et al., 2013). 
Although the expression of ccbl2 is shown with high FPKM values in both samples, crym is 
not significantly expressed with low FPKMs.  
The AASS mRNA levels as detected by FPKM also suggest that the knockdown has 
occurred and from FPKM the aass levels were reduced ~60% (Table 7). The FPKM of 
ALDH7A1 had a slight reduction of 1.25 fold in when AASS is knocked down. All of the 
downstream lysine catabolism genes displayed no significant change. GAPDH, which is the 
endogenous control of qPCR, had no change in its FPKM values comparing the control to 
KD cells. We did not observe also significant expression changes in lysine transporters. We 
observed that 318 genes were downregulated and 386 were upregulated in the KD AASS 
with changes greater than 1.5-fold, a statistically significant difference (p < 0.05). However, 
using the software Panther v 10.0 (Mi, et al., 2013) and the PANTHER Overrepresentation 
Test, no enrichment was observed for the set of controls or the KD upregulated genes for the 
following datasets: GO biological process, Panther Pathway, PANTHER GO-Slim 
Biological Process and Cellular Component. Following analysis of the “Panther GO-Slim 
Molecular Function” dataset, we identified a small set of seven genes associated with TGF-
B signalling, which were found to be upregulated 1.5 times on average in the KD cells. 
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According to the literature, TGF-B is involved in the expression of AASS gene in PANC-1 
cells (Jazag, et al., 2005), with a 5.4 fold increase in the expression of this gene observed in 
the presence of TGF-B. Except for this small subset of genes, most of the variations do not 
represent specific pathway disruptions.  
 
Figure 15: Quality assessment of mRNA extracted from control shRNA and KD AASS for 
five biological replicates showing the quality of the samples as analysed from Nanodrop 
2000 (A, A260/A280 and A260/A230 ratios close or over than 2) and agarose gel 
electrophoresis (B, showing the rRNA bands and no evidences of RNA degradation or 
genomic DNA contamination). 
Table 7: Lysine metabolism genes as accessed by transcriptome analysis of KD AASS in 
HEK293 cells. FPKM levels for cells infected with control scrambled shRNA (FPKM Cont) 
or shRNA targeting aass mRNA (FPKM KD) are shown, as well as the fold change (FPKM 
Cont/FPKM KD) and the p value resulted by T test comparison among the average of FPKM 
between the two groups. 
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Together, these results suggest that knocking down AASS expression does not cause 
a detrimental phenotype in the cells. Most of the alterations seen in the transcriptome analysis 
appear to be random and not representing any specific stress or great changes in any 
biological process. The only set of genes with significant change are associated with the TGF-
beta family. It was also observed that pipecolate pathway genes were not induced upon AASS 
KD.  
 
4.4.5. Using patient skin fibroblasts as models for PDE: finding a differential phenotype 
Skin fibroblasts from five different clinically proven PDE patients were used to 
search for differential phenotypes associated with the aldh7a1 loss of function mutations. 
This part of the current work was developed in the Research Institute of the Children’s 
Hospital of Eastern Ontario (CHEO), University of Ottawa, as part of the Care 4 Rare project.  
Our first observation was that the PDE cells displayed normal growth characteristics 
and no evident morphological change was observed. We then decided to test for any 
differences in the survival of such cells in the presence of a given stress. Given that a 
connection between the AASADH enzyme (deficient in PDE cells) with osmotic and 
oxidative stress in mammalian cells has been suggested in the literature (Brocker, et al., 2010) 
ENSEMBL_ID GENE FPKM Cont FPKM KD fold_change P value
ENSG00000008311 AASS 10.00 4.22 2.37 0.00
ENSG00000251400 ALDH7A1P1 63.99 51.29 1.25 0.00
ENSG00000164904 ALDH7A1 118.50 94.80 1.25 0.00
ENSG00000137944 CCBL2 30.16 30.66 0.98 0.22
ENSG00000103316 CRYM 0.82 1.44 0.57 0.01
ENSG00000179761 PIPOX 0.32 0.46 0.69 0.71
ENSG00000109576 AADAT 10.03 10.21 0.98 0.25
ENSG00000183010 PYCR1 135.98 145.69 0.93 0.05
ENSG00000181192 DHTKD1 16.84 18.90 0.89 0.00
ENSG00000105607 GCDH 29.39 28.53 1.03 0.26
ENSG00000127884 ECHS1 110.88 102.21 1.08 0.03
ENSG00000138796 HADH 50.66 49.18 1.03 0.94
ENSG00000167315 ACAA2 22.66 22.77 1.00 0.98
ENSG00000111640 GAPDH 1271.39 1282.91 0.99 0.86
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(Brocker, et al., 2011), PDE and control cells were exposed to media containing several 
concentrations of NaCl and H2O2. No significant change was observed for cell survival in 
the presence of salt (Figure 16) or oxidative stress (data not shown). 
We then hypothesized that PDE cells may display higher sensitivity in the presence 
of Lysine, since it has been shown in the literature (Struys & Jakobs, 2010) that these skin 
cells accumulate AASA/P6C in Lysine supplemented medium. If these compounds were 
toxic to the cells, the presence of high lysine in the medium would result in high levels of 
these toxins. This may result in the depletion of crucial compounds (such as PLP) or even 
oxidation of proteins and DNA as a side effect of the accumulation of AASA/P6C. In order 
to test this hypothesis a survival assay was carried out using Alamar Blue and concentrations 
of Lysine ranging from 2.5 to 100 mM were tested for 24 hours. We observed a clear 
differential phenotype when comparing control cells and PDE cells (Figure 17) in the 
presence of lysine-supplemented medium for 24 hours. In high concentrations of lysine 
(higher than 40 mM) PDE cells displayed significantly reduced survival compared to normal 
controls. Cell death in the presence of high lysine concentrations was observed for cells 
derived from all five PDE patients (Figure 18). The calculated IC50 for Lysine was ~80 mM 
for the control skin fibroblast and ~ 40 mM for the PDE cells, representing a significant 
difference in lysine sensitivity among these two cell types. 
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Figure 16: Survival assay using Alamar Blue to test the effect of salt stress in skin fibroblast of control 
individuals and PDE patients. 
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Figure 17: PDE skin fibroblasts display a differential phenotype when compared to control cells: 
lysine sensitivity.  
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Figure 18: Average of survival rates using all cell lines of this study ((3 control cells: GM00038, 
GM00969 and KB) (5 PDE patients: CH3121, CH3122, CH3110, CH3111 and CH3139)) assessed 
by Alamar Blue assay, showing the distinctive phenotype of lysine sensitivity. 
 
4.4.6. Lysine sensitivity phenotype is reverted in PDE cells when AASS expression is 
knocked-down 
The discovery of this differential phenotype allowed us to test if the lysine sensitivity 
in PDE cells could be reversed when knocking down AASS expression. If the reduction of 
enzyme expression could further reduce AASA/P6C levels, we could thus alleviate the 
pathogenic effect of aldh7a1 mutation associated with lysine toxicity in these cells. As 
demonstrated by Struys et al (2010), cell cultures derived from primary skin fibroblasts 
isolated from PDE patient accumulate intracellular AASA/P6C and can therefore be used as 
a model to study this disease. We used the same virus produced in HEK293 cells harbouring 
shRNA targeting AASS gene or a control shRNA as described previously. Cells were infected 
and then selected by four days in puromycin treatment (4 μg/ml) and resistant cells could be 
successfully obtained (Figure 19). The knockdown levels were validated as described in 
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4.3.15. A variable range from 68% to 94% KD was observed for AASS in the skin fibroblast 
cells of control and PDE individuals (Figure 20). These values are shown here as an average 
of the values found for two different primers.  
To further support the use of AASS as a new target for PDE treatment, we observed 
that AASS knockdown was sufficient to revert PDE cells to normal survival levels in the 
presence of lysine stress (Figure 21). For example, as demonstrated in Figure 21, the control 
PDE cells displayed very low survival in the presence of high levels of lysine (e.g.: 8.3% for 
CH3121 at 80 mM Lys). When knocked down for AASS, CH3121 displays a survival of 
41.6%, which is similar to the value observed for the control cell lines GM00038 and 
GM00969, 40% and 49% respectively. This increased survival in the presence of Lysine 
when knocking down AASS was observed for all the PDE cells obtained from the five 
patients, which suggests that the result is robust and reproducible. Taken together, these 
findings may be the first evidence for suggesting the use of Antisense oligonucleotides 
targeting AASS or chemical probes that inhibit the expression/activity of this enzyme to treat 
PDE. 
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Figure 19: Cells were successfully transduced and display puromycin resistance, which 
indicate they would also contain the shRNA of interest.  
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Figure 20: Validation of AASS knockdown in the cell lines used in this study by Real Time 
PCR as described previously. “CNT” cells are the cells transduced with control shRNA and 
“KD AASS” represent the cells transduced with shRNA-AASS. Values of Fold Change 
represent average of relative expression values obtained from delta Ct calculation based on 
two different primers targeting AASS expression. 
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Figure 21: Recovery of survival levels in PDE cells (CH3110, CH3111, CH3121, CH3122 
and CH3139) close to the levels found in the normal skin fibroblasts cells (GM00038 and 
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GM00969) when AASS expression is knocked down (KD AASS). “Control” cells are the cells 
transduced with control shRNA. Survival was measured by Alamar Blue assay. 
 Figure 22: Proposed mechanism for reversion of 
lysine sensitivity phenotype. PDE cells have 
mutations in aldh7a1 gene resulting in abolished 
AASADH activity which means that the toxic 
compounds AASA and P6C will exist in high levels 
when cells are fed with Lysine (red arrow) and this 
would probably be the cause of the observed 
sensitivity phenotype. We propose that by 
knocking-down or blocking the activity of AASS 
(green crosses) the levels of Lysine would be 
higher (green arrow) because no metabolic flow of 
this aminoacid would occur towards its 
degradation via AASS, the main enzyme for its 
catabolism as suggested in this doctoral thesis. 
Therefore, with reduced turnover, reduced synthesis of the products AASA and P6C would 
occur and probably their levels would be significantly reduced or even normalyzed (green 
bars). Basically this idea would be to convert PDE into hyperlysinemia, which is considered 
benign and which we have also suggested that does not cause detrimental effects in cellular 
models. 
All of the aforementioned concepts rely on the importance of the saccharopine 
pathway as the major source of the AASA/P6C accumulating in PDE cells. Our experiments 
using mice IP injected with stable lysine isotopes support the hypothesis that the saccharopine 
pathway (via AASS) is the main player. As indicated in recent studies (Mercimek-
Mahmutoglu, et al., 2014), the pipecolate pathway (specifically the first steps) has not been 
proven to exist in humans. It is likely that the levels in the brain might have a significant 
contribution from the conversion of AASA/P6C to pipecolate via P5CR. This reaction was 
first suggested by Struys (2010) and we also have observed this reaction in bacteria ( 
(Neshich, et al., 2013) and (Pena, et al., Submitted 1)) and in the current mouse experiments 
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(section 4.4.2). The Mercimek-Mahmutoglu (2014) paper showed that the Lysine Restriction 
Diet is partially efficient to reduce AASA levels but can result in cerebral serotonin 
deficiency. We believe that by transcriptional or post-translational inhibition of the enzyme 
AASS, we could reduce the levels of AASA/P6C without causing detrimental side effects 
(figure 22).  
The next step of the project was to study the biochemistry and structural biology of 
AASS in order to identify an appropriate inhibitor using computational biology by structural 
based drug design. 
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4.4.7. Biochemistry and structural biology of saccharopine dehydrogenase (SDH) domain 
of AASS 
This part of the project was executed as part of the FAPESP’s BEPE program. The 
submitted project was named “Expression, purification and structural characterization of 
human lysine-ketoglutarate reductase/Saccharopine dehydrogenase (LKR/SDH)”, FAPESP 
process number 13/12271-9. The experiments on AASS structural biology were executed 
from September 2nd, 2013 to March 1st, 2014 at the Structural Genomics Consortium (SGC) 
laboratories, University of Oxford, UK. It was possible to solve the crystal structures of the 
SDH domain of human AASS enzyme and also the bacterial enzyme LysDH (the latter is not 
described in the current thesis).  
  
4.4.7.1. Bacterial expression, purification and crystallization trials of human AASS 
The first attempts to purify AASS constructs were made using a bacterial expression 
system as described in the 4.3.16 and 4.3.17 section. Although all the constructs were highly 
expressed, most of them were found at the insoluble fraction, which might indicate that the 
recombinant proteins were probably unfolded and non-functional (Fig. 17). There were faint 
bands in the elution fractions for the constructs AASS-c001, c003, c005 and c011 and strong 
bands in the elution fractions for the AASS-c013 and AASS-c015 (Fig. 17). Other expression 
tests were performed varying growth temperature, expression induction, culture media (LB 
versus TB) and IPTG concentration. None of the tested conditions improved the solubility of 
the recombinant proteins. The inserts of AASS-c001, c003, c005 and c011 were subcloned 
into pGTVL1 and pGTVL2 vectors, which contain GST-tag at the N-terminal. Although GST 
tag was partially sufficient to improve the solubility of some of these constructs, no activity 
was observed neither in the lysates nor the soluble fractions. Protein precipitation occurred 
after GST cleavage.  
The AASS-c015 construct (Fig. 17) that corresponds to the AASS SDH domain was 
chosen for a scale-up expression in 3L TB medium. Protein was extracted and purified as is 
shown in Fig. 18. The first SDS-PAGE of Ni-NTA purification revealed that, although a high 
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level of expression was obtained, very low amounts of protein were found in the soluble 
fraction. The protein was purified by Nickel column binding (Fig. 18A) followed by size 
exclusion chromatography (Fig. 18B). A significant void peak was observed (which might 
be an indicative of protein aggregation) followed by a high peak at elution volume of 83.49 
mL that, according to a standard curve, corresponds to a mass of about 89 kDa. This value is 
close to the mass of the dimeric form of human SDH, which is predicted to be 102.3 kDa. A 
small scale TEV digestion test was performed and the digested protein was analysed by mass 
spectrometry. This approach was performed in order to check if TEV could cut the protein 
and change its intact mass. Specifically for this case, a peak of lower mass was not observed 
by MS suggesting that the digestion failed, which might indicate that the tag is buried and 
not accessible to TEV. The pooled sample (Fig. 18B) was then concentrated and purified 
using ion exchange HiTrapQ column and the protein was found in the first peak (Fig. 18C). 
The fractions were pooled, concentrated to 12 mg/ml, with a final yield of 2.4 mg of protein. 
Mass spectrometry was used to check the intact mass of the pure protein and it matched the 
predicted mass of the tagged construct (Fig. 18D). Activity test confirmed SDH activity. 
Crystallography screenings were set up but no protein crystals appeared. Since it seems that 
the protein purified from bacterial expression does not produce crystals, a second approach 
was tested: heterologous expression in a eukaryotic system. 
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Figure 17: Bacterial expression experiments in 50 mL of TB medium of the sixteen constructs 
of human AASS showing that most of the recombinant proteins were found in the insoluble 
fraction (orange arrows) while only two constructs (AASS-c013 and AASS-c015) were found 
in the elution fraction in a significant amount.  
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Figure 18: Purification steps of AASS-c015 expressed in bacteria. (A) SDS-PAGE for Ni-
NTA purification where the elution fractions E1 to E4 were pooled for further purification 
using Gel Filtration at Superdex S200 column (B) and the protein eluted in a peak at 83.49 
ml of elution volume. SDS-PAGE confirmed that this peak corresponded to the protein of 
interest. Then ion exchange using the column HiTrap Q was performed (C) and the protein 
eluted in the first peak. (D) Intact mass analysis determined by LC-MS suggest a mass 
(51,151.68Da) closely related to the expected mass (51,150.3 Da). 
4.4.7.2. Insect cell expression, purification and crystallization trials of human SDH   
 The sixteen constructs were cloned in pFB-LIC and expressed using the baculovirus 
system as described. The most promising construct based on small scale expression in Sf9 
cells was AASS-c013, which correspond to the SDH domain of the human AASS. The other 
constructs did not show significant expression/soluble proteins. For the first step of 
purification a nickel affinity column was used. In contrast to what was observed in the 
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attempts using bacterial expression system, large ammounts of the SDH protein was obtained 
(Fig. 19A). Most of the protein was soluble and bound to the Ni-NTA agarose and eluted in 
the first two elutions (E1 and E2). The fractions were pooled for further purification steps 
(Pool 1). There were still great quantity of protein in the washes (WB1 and WB2) and later 
elutions (E3-E4), and these fractions were also pooled, concentrated and stored as Pool 2. 
Gel filtration was carried out for E1 and E2 (Pool 1) and it was possible to see that all SDH 
domain appeared in a single peak in the elution volume of 78.56 mL (Fig. 19B). From the 
calculated standard curves, this elution volume correspond to 100.6 kDa, which is close to 
the predicted mass of a dimer of this construct (monomer: 54.45 kDa, dimer: 108.9 kDa). 
There was no evident void peak in this chromatogram, which indicate low aggregation levels 
(in contrast to what was seen for AASS-015). Fractions C3 to C8 were pooled as Pool 1.1. A 
small scale digestion test with TEV protease using Pool 1 (E1 and E2) and, as shown in the 
first two lanes of Fig. 5B and 5E, there was a size shift in the cut protein. This was confirmed 
by intact mass analysis where the uncut protein was shown as a peak with 54,457.0 Da (Fig. 
19C) and cut protein with a mass of 52,024.2 Da (Fig. 19D), which is close to the expected 
mass of the SDH domain: 52,021.2 Da. The pooled samples Pool 1.1 were used to perform 
TEV cleavage overnight. Then, another nickel column purification was done to separate the 
cut proteins from uncutted ones and TEV (Fig. 19E). Fractions FT, GF1 and 2, BB 1 and 2 
were pooled, concentrated to 10 mg/ml, with a final yield of 35 mg of pure protein. 
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Figure 19: Purification steps followed for AASS-c013 expressed in 4L of Sf9 cells. (A) SDS-
PAGE for Ni-NTA purification where lanes are labled as “Lysate”, which corresponds to 
cells just after sonication, “Soluble” is the supernatant after centrifugation of the Lysate, 
“FT” is the set of proteins that didn’t bind to the Ni+2 resin, “BB” and “WB” are washes 
with 25mL binding buffer and wash buffer, respectively and “E”1 to 5 correspond to five 
elutions with 5 mL of elution buffer. After elution a sample of the resin was also run. One 
first purification was done with the pooled E1 and E2 (blue), which contain most of the 
expressed SDH and then another purification was performed with WB1, WB2, E3 and E4 
(green). (B)  Chromatogram of a Gel Filtration using Superdex 200 column, showing the 
peak of SDH enzyme from fractions C3 to C11 at 78.56 ml. (B) SDS-PAGE of the fractions 
separated by Gel Filtration. The first two lanes correspond to a small scale overnight TEV 
digestion test of the E1 and E2 samples. Fractions C3 to C8 were pooled to carry out TEV 
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digestion. (C) Intact mass determined by LC-MS show that the highest peak in the pooled 
sample E1-E2 correspond to 54,457.0 Da (upper image) and after digestion the mass is 
52,024.2 Da very close to the expected mass of the cut product, 52,021.2 Da. (D) Nickel 
rebind purification: P.1.1 uncut is the pooled samples after Gel Filtration, P1.1 cut is the 
same sample after overnight incubation with TEV protease, FT-cut is the flow-through, GF, 
BB and WB are washes with 1 ml with Gel Filtration Buffer, Binding Buffer and Wash Buffer, 
respectively. E1 and E2 are elutions with 250 mM imidazole. The pooled sample containing 
the pure protein is highlighted in blue.  
4.4.7.3. Biochemical assays to determine enzyme kinetics for recombinant SDH domain 
The purified recombinant protein produced by the AASS-c013 construct displayed 
high SDH activity. This protein was used to determine kinetic parameters that could possibly 
help in the crystallography trials. From assays varying the concentration of NAD+ (cofactor) 
and saccharopine (substrate) it was possible to calculate their Kms: 0.114 mM and 2.01 mM, 
respectively (Fig. 20). NADP+ was not accepted as cofactor. Other biochemical properties 
such as optimum temperature and pH and possibility to perform the reverse reactions and 
other characteristics will be calculated in the future. From inhibition assays using 2mM of 
substrate we could see that none of the tested ligands inhibited significantly the activity of 
the enzyme. 5mM Lysine and 5mM α-ketoglutarate inhibited about 22% of the activity, 
probably by competing with saccharopine in the active site. 5mM methionine inhibited about 
22% of the activity. 
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Figure 20: Michaelis-Menten kinetics graphics showing the Km determination for the 
cofactor NAD+ and for the substrate Saccharopine. 
4.4.7.4. Buffer screenings and ligand screenings by differential scanning fluorimetry 
(DSF) 
The identification of stabilizing components for a protein solution might lower the 
tendency for unfolding and aggregation and improve the success rate of crystallization 
(Vedadi et al, 2006). Some characteristics of the human SDH domain can also be inferred by 
a buffer screening where the concentration of NaCl, pH, presence of additives such as 
glycerol, glycine, sucrose and several ions can indicate whether these components can affect 
protein stability measured by changing thermal melting (Tm) values. A clear increase in Tm 
was observed when NaCl concentration is increased from 25 mM to 500 mM, in all pHs 
tested, except for pH 5.5 where the protein can be considered unfolded (Fig. 21). In this case, 
the protein is assumed to be unfolded based on the extremely high initial fluorescence found 
which indicates that the protein was complete or partially unfolded at that condition. Another 
condition that caused complete unfolding of the protein was the addition of 10 mM ZnSO4 
as compared to GF buffer pH 7.5 and also the addition of the detergent n-Dodecyl-β-D-
maltoside (DDM) to a pH 8.5 buffer. It seems that the addition of Glycerol also increases 
stability compared to other buffers in the same pH. Interestingly, imidazole seems to affect 
negatively protein Tm (shift of -4 degrees when binding buffer is compared to elution buffer). 
As it can be seen, the gel filtration buffer can be considered among the best buffers for this 
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enzyme and we decided to set up the first crystallography screens with the protein in this 
buffer containing glycerol 5%. 
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Figure 21: Gel Filtration (GF) buffer (red arrow) is among the best buffer condition for 
AASS-c013 as shown by this screen made with DSF method. The melting temperatures (Tm) 
are shown as points, in duplicate, for each condition.  
In addition to finding a buffer in which the protein is stable, the identification of 
stabilizing compounds can also be applied in terms of improving the chances of obtaining a 
protein crystal (Vedadi, et al., 2006). Ligands that interact with the native state of the protein 
can increase the thermal stability, mostly if the ligand concentration exceeds its KD value 
(Matulis et al, 2005). One can suggest, initially, that putative stabilizing compounds are the 
cofactors and substrates that the enzyme uses. Thus, the first compounds tested were NAD+ 
and saccharopine in Tris HCl 50 mM pH 8.5 and 100 mM NaCl. A great Tm shift was 
observed when NAD+ was added (about 4.5°C) but only a small shift occurred when 
saccharopine was added (about 1°C) (Fig. 22). It seems that simultaneous addition of both 
2mM saccharopine and 2mM NAD+ caused a synergistic effect, since the Tm shift compared 
to control condition was about 6.5°C. When doubled the concentration of saccharopine 
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(4mM) and maintaining NAD+ 2mM, this shift is even greater: 9.5°C. It is possible that the 
shift will be even greater if higher concentrations of saccharopine were tested, but due to low 
solubility of this compound, the maximum concentration it was possible to test was 4 mM. 
The presence of NAD+ or saccharopine might favour one state of the protein that provides 
better binding conditions and higher affinity for the other substance. Other ligands were 
tested (Fig. 23). At 5mM concentration, the ligands α-ketoglutarate, L-lysine, L-glutamic 
acid and L-methionine caused a shift of 1°C, similar to the substrate shift, but none could 
increase the NAD+ Tm shift when added together with the cofactor. Interestingly, 5mM of 
aminoadipic acid produced a shift of 2°C, which is greater than saccharopine 2mM shift. 
Another interesting observation is that 5mM ornithine somehow antagonizes the positive 
effect produced by NAD+ (Fig. 23). Together with NAD+ 2mM ornithine change 2°C than 
with NAD+ alone. Thus, in conclusion, no ligands could be identified as better to NAD+ and 
Saccharopine in terms of SDH thermal stabilization. Therefore, these ligands were chosen to 
be used in crystallization trials. 
Figure 22: Melting curves of AASS-c013 determined by DSF suggest that NAD+ (2mM) 
binding causes a Tm shift of about 4.5 °C in SDH domain whereas Saccharopine (2mM) only 
causes a shift of 1 °C. When both are combined, the shift is higher: ~6.5 °C. Using more 
saccharopine (4mM) the observed shift is about 9.5 °C.  
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Figure 23: Ligand screening using DSF method to determine if addition of a given ligand 
can cause Tm shifts. No ligands were found to cause higher Tm shift than Saccharopine and 
NAD+. 
4.4.7.5. Crystallography screenings and crystal optimization 
The first crystalization screenings were carried out using the protein at 10 mg/ml in 
GF buffer  without addition of ligands. The first crystals grew after 5 to 7 days in a Hampton 
Index (HIN) crystallography screen plate incubated at 20°C in a solution of 0.2 M ammonium 
acetate (also ammonium sulphate), 25% PEG3350 and 0.1M Tris HCl pH 8.5 (Fig. 24). These 
apo form crystals were mounted and used in diffraction screenings that demonstrated these 
crystals diffracted Xrays at minimum 7Å resolution at the Diamond Synchrotron facilities. 
Based on the DSF experiments, follow-up screens were prepared  in the presence of NAD+ 
or 2 mM NAD+ plus 2 or 4 mM saccharopine. Surprisingly, in some wells crystals appeared 
immediately (Fig. 25) and we could obtain best diffraction for most of the crystals at 2.6 Å 
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to 4 Å. The crystal that diffracted at 2.6 Å and allowed the solution of the tridimensional 
structure of AASS-SDH domain was grown in the presence of 2mM NAD+ and 2mM 
Saccharopine at 20°C and in a 2:1 proportion of protein to mother liquor solution containing 
0.2M NaCl, 25% PEG3350, 0.1M Tris HCl pH 8.5 (Fig. 25, upper part).  
 
 
 
 
Figure 24: First 
crystals obtained for 
the SDH domain of 
human AASS showing 
the first signs of 
nucleation at the 4th 
day after plating 
10mg/ml of protein and 
the HIN screen. These 
crystals diffracted at 
7Å at Diamond Light 
Source. 
 
Figure 25: Crystal 
optimization for the 
determination of SDH 
structure showing 
crystallization of the 
best diffracting 
crystals (upper part) 
and one of the 
observations that 
addition of NAD+ and 
Saccharopine allow 
immediate 
crystallization in 
several wells 
(bottom). 
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4.4.7.6. Structure solution and preliminary computational biology analysis  
  The SDH crystal structure was solved by the molecular replacement method, using as 
search model the fungi saccharopine reductase structure (PDB 2axq). The SDH protomer is 
bound with one molecule of NAD+ in each active site (Figure 26 A and B). Both active sites 
are accessible from the exterior and the interface region of the dimer is located in the opposite 
site of the ligand cleft (Fig. 26A). Each chain is composed by three structural domains: a 
variant of the Rossmann-fold domain (first domain) that binds NAD+, an α/β structure with 
seven β strands in the core (second domain) responsible for the substrate binding and the 
interface formation between the dimers and an all helical fold (third domain), that probably 
undergo large movements upon ligand binding domain, as it closes and opens upon cofactor 
and then substrate binding (Fig. 26A).  It can be seen that the NAD+ position is very similar 
in both fungi and human structures. By executing a superposition with the ternary complex 
of the fungi enzyme containing substrate and cofactor, it was possible to observe that the 
corresponding position of saccharopine matches the open pocket in the human SDH (Fig. 
26C). Similarly to the conformation observed for fungi ternary complex, the nicotinamide 
ring of NAD+ is less solvent accessible whereas the adenosine ribose moiety is more exposed 
in the entrance of the active site cleft (Johansson et al, 2000).  
The complex with NAD+ is maintained by several interactions, where residues Thr 
124, Ala 125, Pro 154, Glu 152 and Asp 153 bind strongly to carboxamide group of 
nicotinamide ring, mainly via hydrogen bonds (Fig. 27). The nicotinamide ring is placed by 
aromatic and hydrophobic interactions with Trp 201 and Val 423, respectively. Trp 201 also 
interacts with the substrate. Leu 102 and Ser 126 interact with the ribose moiety and the latter 
contacts one of the α-ketoglutarate-derived carboxyl groups from saccharopine by hydrogen 
bonding. Water molecules are found close to this ribose group and also to diphosphate 
moiety. Adenosine ribose group makes hydrogen bonds to Ser 37 and Gln 65 that, together 
with Asp 61 and Asp 81 place adenine ring at the entrance of the pocket. Other apolar residues 
also make hydrophobic contacts with this group. Surprisingly, there are no aromatic contacts 
with adenosine ring as oppose to what happens in the fungi homolog. Most of these residues 
are fully conserved among bacteria, fungi, plants and animals (Fig, 28). The residues that are 
not fully conserved are the ones responsible for binding to adenosine ring. 
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There is no electron density that could accommodate saccharopine or the products, 
despite the presence of saccharopine in the crystallization buffer. It is possible that all the 
saccharopine contained in the crystallization solution was hydrolysed to AASA and glutamic 
acid and dissociated from the enzyme active site. The presence of an excess of NAD+ might 
have induced the “open state” for Saccharopine, since computational modelling suggests a 
cavity that could accommodate saccharopine exactly surrounding the corresponding 
aminoacids that are predicted to bind the substrate in the fungi enzyme. By docking using the 
software Molegro Virtual Docker, the conformation of saccharopine in the active site that 
had the lower Docking Score was selected for further analysis. The best pose of the substrate 
exhibits -108.4 kcal/mol of interaction energies, as -83.7 kcal/mol with protein residues and 
-24.7 kcal/mol with the cofactor NAD+. The most favourable contacts of the docked 
Saccharopine with protein residues were predicted to be established with Arg 275, Tyr 127, 
Cys 182, Asp 153, Thr 273, Gly 184, Trp201 and Tyr 105 (-16.18, -10.28, -9.29, -8.76, -7.89, 
-5.43, -5.11 kcal/mol, respectively) (Fig. 26D, 26E and Fig. 27). All these residues are 
invariant except for Tyr105 (Fig. 28). The strongest interaction of the enzyme with the 
saccharopine best pose occurs between the ligand carboxyl group derived from lysine and 
the residue Asp153 where short range salt bridges (charged attractive interactions) take place. 
The α-amino group derived from lysine is important for hydrogen bonding with Thr 273 side 
chain and Cys 182 main chain and salt bridges with Asp 153. Interactions of saccharopine 
with NAD+ are suggested to be established mainly via the carboxyl groups derived from α-
ketoglutarate with the ribose and nicotinamide rings (Fig. 27). An important consideration to 
be made is that the saccharopine position and interactions were modelled using the solved 
structure of the human enzyme which we consider to be in an intermediate, semi-closed 
binary state. Saccharopine binding will likely close the enzyme further, and it is possible that 
other residues can be brought closely to the substrate and also more interactions might be 
formed. 
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             Figure 26: Structure of the human SDH domain solved by x-ray diffraction at 2.6 Å 
resolution. (A) Structure of the protomer highlighting the first, second and third structural 
domains in red, blue and yellow, respectively. Chains A and B are shown structurally aligned 
(RMSD 0.16), in green and blue, respectively, with their bound NAD molecules (yellow and 
orange, respectively) and the docked Saccharopine molecule (red). The assymetric unit is 
composed by a homodimer with electron density evidence for the presence of one molecule 
of NAD per chain (B). (C) Superimposition of the human SDH with fungi Saccharopine 
Reductase (SDR, PDB code 1E5Q) showing the human SDH electrostatic surfaces and the 
positions of NAD bound to human and fungi structures (cyan and orange, respectively) and 
the Saccharopine molecule as it binds to fungi protein. Model of Saccharopine binding sites 
shown in a 2D (D) and 3D schema (E). 
The assymetric unit of the solved structure of human SDH domain contained a dimer, 
which is consistent with the observed dimeric state in solution according to the elution profile 
of the gel filtration chromatography (Fig 19B). This is also evident from the predicted 
molecular weight of the SDH protein produced by the AASS-c015 construct expressed in E. 
coli which probably corresponds to a homodimeric state in solution (Fig. 18B). It has been 
proposed that the mammalian bifunctional AASS enzyme oligomerizes as a tetramer 
(Thorsten et al., 1975; Markovitz et al, 1984). It is possible that the isolated SDH domain 
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possesses only one dimerization interface and the tetramerization is dependent on a LKR 
domain interface region. Further studies should be carried out to check this hypothesis. 
 The dimer interface corresponds structurally to the position of the interface observed 
for Magnaporthe grisea SR (1E5Q) although the corresponding residues are different (Fig. 
29). The interface seen in fungi dimers at 1E5Q are smaller (825.14 Å2) compared to the 
human structure (1,155.93 Å2 and 1,183.66 Å2 respectively for chains A and B) as calculated 
using the program SurfV from STING suite (Neshich et al, 2006). This is probably because 
this fungi enzyme is in the closed state, in which fewer residues buried in the interface than 
the open state. The interface region comprises α-Helix 7, β-strand 12, 13, 14, the loop 
between β-strands 10 and 11 and the C-terminal loop. This description is very similar to the 
description of Johanson et al (2010) for fungi SR interfaces.  
The main difference observed by the authors when comparing the apo and the ternary 
complex with NADP and saccharopine was basically an increased interface by the helix 13 
and strand 16 of the third domain in the open state (apo). This domain probably moves 
towards the active site upon cofactor and substrate binding. Based on these observations it 
can be suggested that there are probably three states for the human SDH: open, in the apo 
form; intermediate: when the protein is bound to the cofactor and closed where both substrate 
and cofactor are bound (Fig. 29 A, B and C). The solved structure of the human enzyme 
might be in an intermediary form between the open (apo form, as in 1e5l) and closed forms 
(bound to saccharopine and NADP, as in 1e5q). This can be suggested by the intermediate 
active site pocket volume from MVD calculations: 1,026.56 Å³, 835.07 Å³ and 440.83 Å³ for 
1e5l (open), human SDH and 1e5q (closed), respectively. The observation of an intermediate 
state can also be seen by the superimposed structures in ribbon representation (Fig. 29 D and 
E). One possible hypothesis is that ligand binding induces a movement in the third domain 
helices (red arrow) and in the helix 8 (black arrow) that closes the active site pocket. 
Interestingly, Trp201 interacts with both with the co-crystallized NAD and the docked 
Saccharopine at human SDH, and it is located in helix 8. It is possible that the interaction 
with this residue can play an important role in the dynamics of the protein. Further 
mutagenesis and computational simulation studies should be performed to access this 
hypothesis. 
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Table 8: Areas calculated by the program SurfV for the human SDH structure. Residues 
AVLIMFP were defined as Hydrophobic, STYNQWG were defined as Polar, RKH were 
defined as positively charged and ED as negatively charged. 
  #of residues 
Accessible 
Surface area 
in isolation 
(Å²) 
Accessible 
Surface area 
in complex 
(Å²) 
Interface 
area (Å²) 
C
H
A
IN
 A
 
Negatively 
Charged 
53 (12%) 
3889.16 
(20%) 
3713.83 
(20%) 
175.33 
(15%) 
Positively 
Charged 
52 (12%) 
4596.88 
(24%) 
4492.56 
(25%) 
104.32 (9%) 
Polar 143 (32%) 
5874.04 
(30%) 
5416.29 
(30%) 
457.75 
(40%) 
Hydrophobic 195 (44%) 
4982.49 
(26%) 
4563.97 
(25%) 
418.52 
(36%) 
Sum 443 19342.57 18186.64 1155.93 
C
H
A
IN
 B
 
Negatively 
Charged 
54 (12%) 
3898.28 
(20%) 
3739.57 
(21%) 
158.71 
(13%) 
Positively 
Charged 
52 (12%) 
4230.55 
(22%) 
4111.16 
(23%) 
119.40 
(10%) 
Polar 143 (32%) 
6002.22 
(31%) 
5520.54 
(31%) 
481.69 
(41%) 
Hydrophobic 195 (44%) 
5048.11 
(26%) 
4624.24 
(26%) 
423.87 
(36%) 
Sum 444 19179.16 17995.50 1183.66 
 
From STING calculations, the total accessible surface is of chain A and chain B 
corresponds to 19,342.57 Å2 and 19,179.16 Å2 with the interface region covering 1,155.93 
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Å2 and 1,183.66 Å2 respectively. The proportions of charged, polar and hydrophobic residues 
exposed in the surface are about 44%, 30% and 26% at the surface of chain A whereas at the 
interface these values significantly change to 21%, 40% and 36% (Table 8). These 
proportions are very similar to what 
is found for fungi SR, although the 
residue identity is low at the 
interface. This means that less 
charged residues are hidden in the 
interface and exposed to solvent in 
the surface and that a great part of the 
hydrophobic surface residues are 
actually part of the interface. 
Regarding the aromatic residues (Trp 
and Tyr, which are counted as polar) 
and Phe (counted as hydrophobic), 
they correspond to 7% of the surface 
area and 15% of the interface region. 
 
Figure 27: Interactions of the co-
crystallized cofactor NAD+ and the 
model of substrate postition L-
saccharopine obtained from 
computational docking with protein 
residues at the active side of SDH. 
Dotted lines indicate hydrogen 
bonds, and red rays show 
hydrophobic interactions. 
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Figure 28: Alignment between several SDH sequences from animals, fungi and bacteria: 
mammals:Human_SDH (AASS-c013) and AASS_Human (from Q9UDR5), AASS_MOUSE 
(Q99K67.1) and AASS_BOVINE (A8E657.1); reptile:  AASS_TURTLE; birds:  (M7B5M4), 
AASS_AVES (R0M006); amphibian: AASS_FROG (F7ELD9); arthropoda: AASS_FLY, 
(Q9VLX0) and  AASS_ACARI (C9K2E7); worm: AASS_WORM(O44503); , Yeast: 
SR_FUNGI  (from PDB:2AXQ) and Bacteria: SDH_Bacteria (Q5LNA3)). Residues 
highlighted in red boxes are predicted to bind the substrate saccharopine, yellow boxes are 
the residues found in the interface between each chain of Human SDH structure and black 
boxes show the initial and final residues seen in the structure. Regions colored in blue are 
conserved and identical in a given position. The residues marked with circles were found to 
bind NAD molecule: orange, to adenosine group; blue: to ribose moiety bound to 
nicotinamide; black: to carboxamide group of nicotinamide; green: place nicotinamide ring. 
The secondary structure of both Human SDH and Fungi SR are shown. The consensus 
sequence is shown and the size of the boxes represents the conservation in each position. 
Figure 29: Structural comparison between fungi and human SDH proteins suggesting that 
the solved structure of human SDH is in an intermediary state. Surface Electrostatic potential 
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showing the apo form of fungi SR (A) in an open state, the human homolog bound to NAD 
(B) in an intermediary state and the fungi SR bound to NAD and Saccharopine (C) in its 
closed form. Structural alignment using the three structures (D) with a black arrow showing 
helix 8 and red arrow showing the big structural difference in the third domain. RMSDs are 
1.26 for alignment between the human SDH and fungi enzyme in the apo form (1e5l) and 3 
for human SDH and fungi 1e5q. (E) Zoomed view of the region that moves upon cofactor and 
substrate binding. 1e5l shown in pink, human SDH shown in cyan and 1e5q shown in green. 
 
4.4.8. Use of structure-based drug design to produce SDH competitive inhibitors 
One of the objectives of this project was obtaining the crystal structure of one of AASS 
domains to design substrate analogs that could possibly bind and act as inhibitors. From 
structural analysis of saccharopine binding to SDH, it is possible to see that there is a fraction 
of the pocket (adjacent to the carboxyl group of α-ketoglutarate part) unoccupied, possibly 
due to the use of the intermediate form of SDH. This region is surrounded by the aromatic 
residues Tyr127 and Tyr105. One of the several possible compound to be designed could be 
a molecule with a cyclic group attached to this carboxyl end. Another important consideration 
is that the alpha-amino and carboxyl groups of the lysine branch of saccharopine are very 
important for the interaction with the enzyme. Taken these informations into account, several 
compounds were in silico designed containing different radicals added or replacing the 
charged groups of saccharopine. MVD is being used iteratively to dock these compounds to 
the saccharopine site and compare with the substrate mode of binding through MolDock 
Score, Rerank Score, ligand efficiency (docking score divided by the number of non-
hydrogen atoms), interaction energy score and hydrogen bonds (Table 9). At the moment the 
best compounds according to the docking scores contained cyclic groups bound or replacing 
the α-ketoglutarate part of saccharopine. Several of these ligands are currently being 
synthesized by the collaborator group of Prof. Fernando Coelho at the Chemistry Institute of 
UNICAMP. Table 9 shows an example of docking simulations and some of the suggested 
ligands are shown in Fig. 30.  
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Preliminary assays were performed to test the inhibitory effect of three of such 
compounds regarding the SDH activity. At the moment three compounds could be 
synthesized: M21, M30 and M30a. The compound M21, which ranked as a low affinity 
binder, according to the docking simulation, does not inhibit the enzyme activity even at high 
concentrations (10mM) (Fig. 31). M30 was predicted to bind to SDH active site with affinity 
similar to that of saccharopine, since they displayed similar docking scores (Table 9). An 
isomer of M30, M30a, was also synthesized. Both are derivatives of the class of nicotinic 
acids fused with lysine. Both compounds were able to inhibit SDH activity but yet with low 
affinity (Fig. 31). Although they are weak SDH inhibitors, they can be considered good 
starting points for the development and improvement of saccharopine analogues and they 
might support the efficacy of computational simulations since they have similar binding 
affinities to Saccharopine. They displayed complete inhibition at high concentration (10mM). 
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Table 9: Docking simulations of several designed saccharopine analogues. The results are 
ranked by MolDock Score that is an indicative of the binding affinity of a given pose 
according to the computational simulation. The table shows Saccharopine as positive control 
(brown) displaying favourable docking score (-113 kcal/mol) and the negative controls Lys-
p-nitroanilide and yL-glutamyl-glutamate (not shown) with higher and unfavourable docking 
scores (-100 and -79 kcal/mol, respectively). The ligands already synthesized and tested are 
M30, M30a and M21. 
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Figure 30: Example of potential SDH ligands as suggested by computational docking 
simulations. 
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Figure 31: Preliminary analysis of designed and synthesized ligands by tests of SDH 
inhibition. Left panel: structure and chemical features of the synthesized ligands. Right 
panel: SDH inhibition assay using 2mM of Saccharopine and 1 to 10 mM of the compounds. 
M21 does not inhibit SDH in any concentration, as expected from the docking simulations. 
M30 and M30a are weak inhibitors, but at 10 mM can block completely SDH activity. 
 
 It was also tested if the presence of M30, M30a and M21 in the culture medium would 
restore the lysine sensitivity of PDE cells to normal survival levels as the KD AASS does. 
We used the same assay described in 4.4.6, testing cells in control DMEM medium, or in the 
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presence of 10 mM M30 and also in lysine stress medium (70mM) with or without 10 mM 
of M30. We did not observe any toxicity of M30 in control conditions. No recovery of 
survival was observed for the lysine stressed PDE cells in the presence of M30 (Figure 32). 
The same pattern was observed for M30a and M21. These results indicate that M30 and M30a 
have no effect in recovering PDE cells from lysine death and this might be due to their low 
inhibition properties.  
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Figure 32: Survival assay to test if lysine sensitivity phenotype observed more intensely in PDE cells 
can be reverted in the presence of M30.  
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4.5. Conclusions 
By using the newly developed LC-MS/MS methodology (Pena, et al., Submitted 2) 
to quantify all relevant lysine metabolites in mouse tissues, we suggest the saccharopine 
pathway as the main source of the AAA produced from lysine degradation. This can be 
extrapolated to P6C and AASA produced at high levels in PDE patients. Therefore, we 
suggest the human AASS enzyme as the main producer of AASA/P6C in mammals. The 
Liver and kidney may be responsible for high levels of circulating P6C in PDE, as seen from 
AAA levels. From the quantitative analysis of AAA in mouse tissues, we can infer that less 
than 1% of AAA is derived from brain, 65% from liver and 34% from kidney. Therefore, it 
is possible to suggest that, in PDE patients, most of the pathogenic P6C will be derived from 
liver and kidney and attention should be given to these tissues. The recent literature is focused 
on the lysine metabolism in brain (Posset, et al., 2015) (Sauer, et al., 2011), but our data may 
indicate that the depletion of PLP observed in PDE patients may occur in liver and kidney 
instead of in brain.  
There is evidence for the pipecolate pathway, however it does not produce 
aminoadipic acid. We found no or little 15N-AAA in mice injected with ε15N-lysine, although 
15N-pipecolic acid is present in these samples. An experiment carried out by Posset et al 
(2015) was published while our experiments were been carried out. The Posset experiment 
used IP injection of α15N-lysine and ε15N-lysine and measured aminoadipic acid, 
saccharopiene and pipecolic acid in liver and brain sampled 4 hours after injection. In their 
experiment, they observed very low 15N enrichment for Saccharopine in mouse brain samples 
and therefore concluded that Saccharopine pathway is almost absent in the brain. However, 
in our experiments we could observe APE ranging from 16 to 20% in brain 2 hours after 
lysine was IP injected. In their experiments, Posset et al (2015) also observed no detection of 
labelled AAA in mice injected with ε15N-lysine. Although this fact was observed and 
mentioned, the authors did not explore further that the only pathway that is actively producing 
AAA is the saccharopine pathway. We believe this is the key takeaway of the experiment, 
and this is one of the main observations that further support the hypothesis of AASS as 
potential target against PDE. Inhibition of this enzyme would likely result in lower levels of 
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the toxic AASA/P6C compounds since saccharopine is the major pathway of lysine 
degradation in mice and possible in humans. 
The data generated for the AASS KD cells indicates that inhibition of AASS does not 
implicate in upregulation of pipecolate pathway enzymes and it is very likely that AASA/P6C 
would not be produced from pipecolate oxidase in the AASS blocked cells. This is important 
information that, if confirmed in further models (such as in a KO mouse for ALDH7A1), 
could support the idea of targeting AASS against PDE. In addition, no detrimental 
phenotypes were observed in control and oxidative stress situations in AASS KD cells.  
We detected that primary skin fibroblasts from five different PDE patients display 
increased death in the presence of high Lysine levels compared to cells derived in our control 
group. This can be considered a differential phenotype between control and PDE cells. As 
proof-of-concept, we observed recovery of normal survival in the presence of Lysine stress 
when knocking-down AASS expression, which can suggest the use of Antisense 
oligonucleotides or the small molecule inhibitors against AASS enzyme in order to treat 
PDE. This “substrate reduction” strategy is also supported by the non-detrimental effects 
seen in hyperlysinemia patients, where AASS activity is reduced or absent. 
As a first step to facilitate a structure-based ligand design process to create inhibitors 
against AASS, we have expressed, purified and crystallized human AASS-SDH domain. Its 
crystal structure revealed binding pockets and clear electron density for the cofactor NAD+ 
and we could dock the position of the substrate saccharopine, the latter of which could be 
targeted by small molecules. Ligand screenings, computational docking, chemical synthesis 
and inhibition experiments have yielded low affinity inhibitors that could serve as chemical 
starting points for drug design.  
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4.7. Future Perspectives  
We believe it is possible to adapt the lysine sensitivity experiment to a high 
throughput screening platform to detect chemical compounds that may restore survival in the 
presence of high lysine levels. This will be part of Izabella Pena’s post-doctoral studies under 
supervision of Prof. Dr. Alex Mackenzie in the Children’s Hospital of Eastern Ontario 
(CHEO) Research Institute, University of Ottawa. This project is expected to start in July 
2015, with the goal to detect drugs that are able to restore the normal phenotype on PDE cells 
for lysine stress survival in a dose-dependent manner, probably by down-regulating lysine 
degradation (and therefore reducing levels of SAC, P6C/AASA, PIP and AAA). In addition, 
aldh7a1 KO mouse models will be obtained in order to study the biochemistry of PDE and 
test ASO against AASS and the potential drugs found as hits in the drug screenings. If we are 
able to find chemicals that restore the normal phenotype of PDE patient cells, we aim to 
execute a translational medicine project with clinical trials and follow-ups in real PDE 
patients. 
Further studies will be carried out in order to understand substrate and NAD+ binding 
of human SDH enzyme. Another goal will be to study if there is a structural explanation for 
the fact that fungi use this enzyme for the reverse reaction towards biosynthesis of lysine 
instead of the catabolism. In addition, site-directed mutagenesis of the residues that displayed 
highest contact energies for saccharopine (such as D153, R275, Y127 and W201) are in 
course now as part of Lucas Vale Adjafre’s scientific initiation project (FAPESP number 
14/27019-6), supervised by prof. Paulo Arruda and co-supervised by Izabella Pena. We aim 
to test if Alanine mutants will display reduced catalytic properties and/or saccharopine 
binding, in order to understand the structural basis of sacharopine binding. This would further 
validate computational simulations and allow the better design of substrate analogue 
molecules capable of bind to the active site with high affinity. More ligands will be designed 
computationally and in silico docked to the active site and ranked by docking scores. The 
best designed ligands according to computational analysis are being synthesized by 
collaborators based on the feasibility of chemical synthesis. These ligands are being tested in 
vitro by DSF and inhibition of SDH activity experiments.  
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Summary of the main scientific achievements of each chapter: 
 
CHAPTER 1: “Genome-wide analysis of lysine catabolism in bacteria reveals new 
connections with osmotic stress resistance” 
 Lysine catabolism to Aminoadipic Acid occurs through four different ways in 
Prokaryotes: Saccharopine pathway, Lysine Dehydrogenase (LysDH), Lysine 
Aminotransferase (LAT) and Pipecolate pathway; 
 A new Bioinformatics algorithm was developed and allowed ortholog gene finding 
and description of the occurrence of genes for all four pathways; 
 LysDH and LAT are the most widely distributed pathways in the prokaryotic world; 
 LysDH, LAT or PIPOX are frequently found co-localized in operon-like structures 
with AASADH gene; 
 Only a restricted number of organisms possess more than one of the pathways, one 
of which is Silicibacter pomeroyi (now Ruegeria): saccharopine (LKR and SDH) and 
LysDH pathways; 
 Within S. pomeroyi there is a preferential pathway: LysDH, over 200-fold 
upregulated in the presence of Lysine (whereas LKR and SDH genes are induced two 
or three-fold only); 
 Both pathways are also upregulated in the presence of NaCl stress; 
 Lysine presence in the culture medium promotes increased growth; 
 Expression of lysdh, aasadh or both in Escherichia coli resulted in increased salt 
tolerance; 
 E. coli expressing lysdh accumulated high levels of Pipecolic Acid, which may play 
a role on osmotic stress resistance;  
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CHAPTER 2: “Knockout of lysine dehydrogenase and aminoadipic semialdehyde 
dehydrogenase genes induces the saccharopine pathway in Ruegeria pomeroyi DSS-3” 
 The absence of saccharopine in WT bacteria grown in MB medium supplemented 
with lysine further supports the hypothesis that, in R. pomeroyi, LysDH is the 
prefered enzyme for lysine catabolism; 
 In the absence of LysDH bacteria can quickly adapt and switch to use saccharopine 
pathway for lysine degradation;  
 KO bacteria lost the growth advantage in the presence of lysine, confirming that 
LysDH and AASADH are crucial enzymes for lysine catabolism; 
 The KO bacteria grown in the presence of lysine showed a small but significant 
detection of AAA (Fig. 4D).  
 There might be other aldehyde dehydrogenases in R.pomeroyi capable to use AASA 
as a low affinity/alternative substrate to produce AAA. 
 The accumulated AASA/P6C is probably converted to PIP in the KO bacteria by 
P5CR;  
 Similarly to what is seen in the disease PDE in humans, the KO bacterium had 
significant reduction in PLP levels suggesting that the molecular mechanisms and 
chemical reactions are basically the same across the different biological models; 
 
CHAPTER 3: “Simultaneous detection of lysine metabolites by a single LC-MS/MS 
method: monitoring the dynamics of lysine degradation in mouse plasma.” 
 A new LC-MS/MS methodology was developed for detection and quantification of 
L-saccharopine, L-aminoadipic acid, L-pipecolic acid, piperideine-6-carboxylate, L-
glutamic acid, L-glutamine and free pyridoxal-5-phosphate in plasma samples with 
low Limits of Quantification (nano-molar range) for all the mentioned metabolites, 
without the need of chemical derivatization; 
 The method showed high accuracy, selectivity and precision; 
 The use of a pentaflourophenyl column provided good chromatographic separation 
of the compounds; 
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 Measurements in mouse plasma pointed for a good accuracy of the method, with 
quantifications matching what is observed in metabolome databases; 
 Time-course experiments for the detection of lysine degradation metabolites in mouse 
blood indicate that lysine degradation to AAA achieves a maximum in the first 1-2 
hours after lysine injection; 
 We suggest that future experiments investigating lysine catabolism should adopt 
shorter time points; 
 
CHAPTER 4: “Aminoadipate-semialdehyde synthase (AASS) as a novel therapeutic target 
for pyridoxine dependent epilepsy.” 
 Quantification of SAC, PIP and AAA by mass spectrometry in plasma, liver, kidney and 
brain confirms that the lysine degradation is mainly hepatic and renal; 
 The use of differential labelled lysine with 15N indicated that lys is mainly degraded via 
Saccharopine pathway rather than the pipecolate pathway; 
 Great portion of circulating and also hepatic and cerebral Pipecolate come from 
saccharopine pathway and P5CR activity;  
 These results support the idea that pathogenic AASA/P6C accumulation is hepatic 
and renal and thus the proper depletion of PLP might occur mainly in liver;  
 shRNA targeting AASS expression in HEK293 cells do not induce any detrimental 
phenotype and also do not induce Pipecolate pathway genes;  
 Dermal skin fibroblasts derived from five PDE patients display high sensitivity to 
Lysine as compared to control lines; 
 As a proof-of-concept of AASS as a new target for PDE treatment, we observed that 
AASS knockdown was sufficient to revert PDE cells to nearly normal survival levels 
in the presence of lysine stress; 
 The structure of human AASS, Saccharopine Dehydrogenase (SDH) domain was 
solved by X-ray crystallography at 2.6 Å resolution;  
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ACADEMIC ACTIVITIES AND SCIENTIFIC PUBLICATIONS 
This work was selected to be presented at the Gordon Research Conference in 
Enzymes in Health and Disease (Waterville Valley, USA, July 2014). In addition, Izabella 
Pena received the Best Oral Presentation award for presenting part of this work (Chapters 3 
and 4) at the Advanced Topics in Genomics and Cell Biology (ATGC 2014) held in the 
University of Campinas (Campinas, Brazil, August 2014). In 2012 the student received the 
SBBq Award for Best Poster at the XL Annual Meeting of The Brazilian of Biochemistry 
and Molecular Biology Society (SBBq) for presenting the results of Chapter 1. The copy of 
the awards are shown in the attachments session (see attachments 5 and 6).  
The student was first author and co-authored several publications since the beginning of the 
PhD program, most of them related to lysine metabolism and structural biology: 
1. Kiyota, E; PENA, IA; Arruda, P. The saccharopine pathway in seed development and 
stress response of maize. Plant, Cell & Environment, 2015. DOI: 10.1111/pce.12563 
2. Barreto, Pedro; Okura, Vagner Katsumi; Neshich, Izabella Agostinho; Maia, Ivan De 
Godoy; Arruda, Paulo. Overexpression of UCP1 in tobacco induces mitochondrial 
biogenesis and amplifies a broad stress response. BMC Plant Biology (Online), v. 14, p. 
144, 2014. 
3. De Moraes, Fábio R.; Neshich, Izabella A. P.; Mazoni, Ivan; Yano, Inácio H.; Pereira, 
José G. C.; Salim, José A.; Jardine, José G.; Neshich, Goran. Improving Predictions of 
Protein-Protein Interfaces by Combining Amino Acid-Specific Classifiers Based on 
Structural and Physicochemical Descriptors with Their Weighted Neighbor Averages. Plos 
One, v. 9, p. e87107, 2014. 
4. Neshich, I.P.; Kyiota, E; Arruda, P. Genome-wide analysis of lysine catabolism in bacteria 
reveals new connections with osmotic stress resistance. The ISME Journal 7: 2400–2410.  
2013 (See attachment 2). 
5. Neshich, I.A.P.; Lopes, C.; Neshich, G; Granier, C.; Ortega, J.M.; Chavez-Olortegui, C.; 
Molina, F.; Felicori, L. Identification of New Sphingomyelinases D in Pathogenic Fungi 
and Other Pathogenic Organisms. Plos One, v. 8, p. e79240, 2013. 
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6. Braghini, Carolina Ayumi; Neshich, Izabella Agostinho Pena; Neshich, Goran; Soardi, 
Fernanda Caroline; De Mello, Maricilda Palandi; Costa, Vital Paulino; De Vasconcellos, 
José Paulo Cabral; De Melo, Mônica Barbosa. New mutation in the myocilin gene 
segregates with juvenile-onset open-angle glaucoma in a Brazilian family. Gene 
(Amsterdam), v. 523, p. 50-57, 2013. 
7. Arruda, P ; Neshich, I. P.. Nutritional-rich and stress-tolerant crops by saccharopine 
pathway manipulation. Food and Energy Security, v. 1, p. 141-147, 2012. (Attachment 1) 
We have recently submitted two manuscripts for the study of lysine metabolism in 
prokaryotes and the newly developed mass spectrometry method, described in chapters two 
and three:  
Pena, IA, Marques, L., Eberlin, M. & Arruda, P., Submitted 1. Knockout of lysine 
dehydrogenase and aminoadipic semialdehyde dehydrogenase genes induces the 
saccharopine pathway in Ruegeria pomeroyi DSS-3. FEBS Letters (See attachment 3).  
Pena, I. et al., Submitted 2. Simultaneous detection of lysine metabolites by a single LC-
MS/MS method: monitoring the dynamics of lysine degradation in mouse plasma.. 
Metabolomics (See attachment 4). 
We are in the process of writing an additional article describing the biochemistry and 
structural biology of LysDH enzyme from the marine bacterium Ruegeria pomeroyi which 
we intent to submit to JBC (“Structural biology of LysDH of Ruegeria pomeroyi”).  This 
work was not mentioned in the present thesis. 
We aim to write a publication to suggest AASS as a new target for development of therapies 
against PDE. 
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Arruda, P ; Neshich, I. P.. Nutritional-rich and stress-tolerant crops by saccharopine 
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